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Despite some evidence that the effectiveness of HIV/AIDS interventions depends 
on the context of their implementation, there is a paucity of evidence on the 
cost-effectiveness (CE) of these interventions in South Africa. The objective of 
this study is therefore to compare the CE of major HIV/AIDS interventions in 
epidemiological and socio-economic contexts in South Africa using a 
methodology which takes into account the effect of the interaction between the 
context and HIV/AIDS interventions on the costs and effectiveness of such 
interventions. In epidemiological contexts, the CE of HIV/AIDS interventions is 
compared across a low HIV prevalence context (LPC) and a high HIV prevalence 
context (HPC) while in socio-economic contexts the comparison is done across a 
rural context and an urban context.  
 
The comparison of the CE of HIV/AIDS interventions requires the follow-up of 
patients in HIV/AIDS progression states (non-infected, infected, AIDS, death) 
over time.  However because this follow-up is costly, the thesis models 
hypothetical populations of HIV/AIDS patients in each context, using two types 
of models, namely, Markov models and population projection models. These 
models simulate and project patients in the above-mentioned HIV/AIDS states 
over time and the cost and effectiveness data, systematically collected from 
South African literature, are applied to simulated and projected patients.  
    
The study finds that in epidemiological contexts, modelled HIV/AIDS 
interventions are generally more cost-effective in a LPC than they are in a HPC. 
In socio-economic contexts, the pattern of the CE of modelled HIV/AIDS 
interventions across a rural and an urban context is not specific and depends on 
the type of intervention. Prevention of mother-to-child transmission (PMTCT) is 
more cost-effective in the rural context than it is in the urban context while 
highly active antiretroviral treatment for adults and children is more cost-
effective in the urban context than it is in the rural context. The study also finds 
that the extent of CE varies across HIV/AIDS interventions in any context. 
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Chapter 1 : Introduction  
 
 
Few studies have analysed claims that the different ways in which HIV/AIDS 
interventions interact with epidemiological and socio-economic contexts might 
result in different cost and effectiveness for such interventions (Hogan et al., 
2005; Verguet & Wash, 2010). In South Africa, in particular, where the impact of 
HIV/AIDS varies according to prevalence and socio-economic milieu 
(HSRC/MRC/CADRE, 2005;  2009) there have not been many CE comparisons of 
major HIV/AIDS interventions across these contexts except for studies 
comparing South Africa and other countries (Verguet & Wash, 2010, Dowdy et 
al., 2006). The aim of this study is to compare the relative CE of several 
HIV/AIDS interventions in different epidemiological and socio-economic contexts 
in South Africa. This chapter outlines the background, problem statement, 
objectives, methods, and structure of the thesis.  
 
1.1 Background and context of the study  
 
The idea of comparing the relative CE of HIV/AIDS interventions in South Africa 
originated from my personal observation in 2010 that HIV-positive members of 
some households in Durban, South Africa, were not adhering to highly active 
antiretroviral (HAART) treatment because of stigma. They feared to be seen 
taking antiretroviral (ARV) pills. Today, stigma remains a concern in South Africa 
(DeKoker et al., 2010; Pitpitan et al., 2012).  
 
My observation led me to believe that there would be different levels of health 
outcomes and costs across households with different levels of adherence rates to 
HAART given the evidence that non-adherence leads to virus resistance which in 
turn raises the cost of treatment (Bangsberg et al., 2001). In the process of 
crystallising ideas by reviewing the literature, the fear of stigma on the part of 
HIV-positive patients in Duran households found explanation in social theories. 
According to these theories, social factors such as stigma affect health outcomes 
through their effect on individual behaviour and attitudes towards treatment and 
prevention interventions (Becker, 1974; Bandura, 1986; Glanz et al., 1990; 






Such household-related social factors and the resulting impact of HIV/AIDS are 
likely to depend on the contexts of households, making these contexts important 
determinants of the effectiveness of HIV/AIDS interventions. Furthermore, 
HIV/AIDs interventions influence the impact of HIV/AIDS by directing specific 
activities to that impact. Because the impact of HIV/AIDS depends on the 
contexts, so, too, do the activities of HIV/AIDs interventions and therefore their 
costs.   
 
These observations relating to the dependence of the costs and effectiveness of 
HIV/AIDS interventions on household contexts were extended from households 
to broader epidemiological and socio-economic contexts. By definition, a context 
is a circumstance with specific characteristics which differentiate it from another 
situation. In terms of this study, epidemiological contexts refer to two contexts, 
the low HIV prevalence context (LPC) or area, and the high HIV prevalence 
context (HPC) or area. Similarly, socio-economic contexts refer to two contexts, 
the rural context or area and the urban context or area.  While context and area 
are considered synonymous in this study, the term context is preferred and is 
mainly used in this thesis.   
   
Extending the dependence of the cost and effectiveness of HIV/AIDS 
interventions on household contexts to broader geographical contexts appeared 
to hold potential for greater efficiency in resource allocation. Because of the 
differences in the factors influencing the impact of HIV/AIDS in each context, 
differences in the effectiveness and costs of HIV/AIDS interventions were 
anticipated. The existence of lower (Western Cape, Northern Cape, Limpopo and 
Mpumalanga) and higher (KwaZulu-Natal, Gauteng, Free State, Eastern Cape 
and Northern Cape) HIV/AIDS prevalence provinces (Gouws, 2010:78) as well 
as the rural and urban contexts indicated that differences in the CE of HIV/AIDS 
interventions were possible.     
 
An early scan of the literature revealed that there has been little research on the 
CE of HIV/AIDS interventions across epidemiological and socio-economic 
contexts in South Africa. All these factors led to the idea of estimating and 





economic contexts in South Africa, so as to assist policy makers in resource 
allocation in such contexts.   
 
At the time of my observations, studies had shown the benefits of integrating 
HIV/AIDS interventions with  primary health care such as tuberculosis (TB) care, 
treatment of sexually transmitted infections and  reproductive health (Peck et 
al., 2003; Church & Mayhew, 2009). Some evidence on the benefits of 
integrating HIV services with other primary health care services also existed in 
South Africa but focused mainly on the integration of HIV services with TB 
services (Coetzee et al., 2004; Wallrauch et al., 2010). At the start of this study, 
pilot projects for integrating HIV/AIDS services with primary health care were 
carried out in the UMgungundlovu Municipality in Pietermaritzburg to assess the 
benefits of integration with a view to implementing such integration on a large 
scale. The Municipality included a number of different epidemiological and socio-
economic contexts.  
 
The study expected to use cost and HIV/AIDS outcome data from these pilot 
projects as baseline information. The intention was to compare the CE of 
integrating primary health care with major HIV/AIDS interventions versus not 
integrating. Comparison of the relative CE of HIV/AIDS interventions in rural, 
urban, low, and high HIV prevalence contexts in South Africa was to be 
conducted by supplementing data from the pilot projects with other cost and 
effectiveness evidence.  
 
Unfortunately, as is often the case in the South African public service, the early 
promise by municipal and provincial officials to facilitate access to the data did 
not materialise. Given my conviction of the importance of the study, I resolved 
to analyse the CE of HIV/AIDS interventions in different epidemiological and 
socio-economic contexts in the country, combining modelled data on costs and 
health outcomes and the evidence from the literature.  
 
1.2 Impact of HIV/AIDS 
    
Worldwide, the impact of HIV/AIDS has remained sufficiently significant to 





33.2 million people were living with HIV/AIDS worldwide (Joint United Nations 
Programme on HIV/AIDS, [UNAIDS], 2011b). The worrying pattern of HIV 
infection has been its differentiated impact. Sub-Saharan Africa bears the brunt 
of the epidemic’s burden, with 22.5 million of her population living with 
HIV/AIDS. Southern Africa has the highest HIV/AIDS prevalence on the African 
continent with countries such as South Africa, Botswana, Zimbabwe and 
Swaziland recording a prevalence rate of 15% to 30% (UNAIDS 2011 a). Women 
suffer the greatest burden of the epidemic, with 60% of all affected people 
worldwide being female, of whom 75% are in the age group 14-25 years 
(UNAIDS, 2011a).     
 
South Africa has more people living with HIV/AIDS than any other country in the 
world, with the number of people living with HIV/AIDS estimated at over 5 
million in 2013 (Statistics South Africa, 2013). Furthermore, the country has 
experienced rapid growth in new infections, increasing from 0.7%in 1990 to 
12% in 1996. Since the mid-2000s, the number of new infections has stabilised 
and currently, it is expected to decline. However, new infections are still 
unacceptably high. In 2011, new infections for 2012 were projected at 110,000 
(Actuarial Society of South Africa, 2011). While deaths from AIDS were 
alarmingly high in the late 1990s and early 2000s, amounting to hundreds of 
thousands per year, these cases have dropped significantly since 2007 due to 
the widespread rollout of antiretroviral drugs. Despite the decreasing death 
rates, the impact of HIV/AIDS remains significant, with about 100,000 AIDS-
related deaths projected for 2012 in 2011 (Actuarial Society of South Africa, 
2011).   
 
As in other parts of the world, the HIV/AIDS epidemic in South Africa presents a 
differentiated impact. HIV/AIDS affects segments of the South African population 
to varying degrees. People with a low socio-economic status are hardest hit by 
the epidemic, females suffer the burden more than males, and young people 
aged 15-25 are the most affected, while the province of KwaZulu-Natal suffers 
the highest burden of the epidemic (Gouws, 2010). Given the link between 
HIV/AIDS health outcomes and other socio-economic woes, the differentiated 
impact of HIV/AIDS in terms of health outcomes implies differentiated impact in 





socio-economic ramifications which are detrimental to current and future 
developmental prospects. The HIV/AIDS epidemic affects the survival of both 
households and firms and constitutes a barrier to human capital and economic 
development. Thus, the differentiated impact of HIV/AIDS requires a 
differentiated response. 
1.3 HIV/AIDS interventions, effectiveness and challenges 
 
HIV/AIDS interventions evolved over time and followed the changing response 
strategies. Prevention interventions progressed from the Department of Health’s 
measures applicable to the usual infectious diseases (Zwi & Bachmayer, 
1990:320), to more comprehensive measures involving many stakeholders 
beyond the Department (Department of Health, 2000). This evolution is marked 
by changes in the bodies that dealt with the response, each coming up with a 
strategic plan commensurate with the evolution of the epidemic to improve 
effectiveness. The bodies evolved from the Department of Health‘s AIDS 
Advisory Group in the 1980s (Zwi & Bachmayer, 1990:323), to the National 
AIDS Convention of South Africa (NACOSA) in the 1990s and the South African 
National AIDs Council (SANAC) in the 2000s (SANAC, 2012). Since 2000, 
SANAC’s 5-year national strategic plans have been upgraded to tackle HIV/AIDS 
in a more effective and comprehensive manner (Department of Health, 2000; 
2006; 2011).   
 
While political irresponsibility deterred the effectiveness of HIV/AIDS 
interventions in the mid-2000s (Schneider & Stein, 2001, Fassin & Schneider, 
2003; Johnson, 2004), the situation changed thereafter. Improved political and 
funding commitments after 2007 enhanced both prevention and treatment, and 
increased the number of people covered by both types of interventions. 
Furthermore, HIV/AIDS prevention interventions enhanced HIV/AIDS awareness 
and promoted changes in risky behaviours (Shisana & Simbayi, 2002; HSRC, 
2005; 2009; 2013). The increasing rollout of ARV treatment reduced the number 
of AIDS cases and deaths (Walensky et al., 2008). After 2007, the government  
adopted new guidelines that provided universal access to ARV services and more 





treatment (at CD4 count 350 rather than CD4 count 200)1. This policy resulted 
in a more than 20-fold increase in the number of people accessing treatment; 
from 50,000 people in 2004 to more than a million in 2012 (Meyer-Rath, 2010). 
Increased access to treatment has translated into better health outcomes.  
 
Despite the progress in responding to HIV/AIDS and the effectiveness of the 
interventions, South Africa still confronts a heavy HIV/AIDS burden. As the 
government strives to respond to the epidemic, an emerging challenge is the 
limited capacity and resources to implement such efforts. While recent efforts 
embraced the most effective strategies such as starting treatment earlier and 
offering HAART on a universal basis, the country faces resource challenges 
amidst current local and international economic turmoil (Walensky et al., 2011: 
27).  
  
The problem is even more important in light of government’s recent efforts to 
increase coverage of both prevention and treatment in the face of resource 
constraints. While it has been suggested that effectiveness can be improved at 
the same or lower costs by targeting interventions to some contexts (Grassly et 
al., 2001), this has not been done in South Africa, where  epidemiological 
contexts (an LPC and a HPC) and socio-economic contexts (a rural context and 
an urban context) present efficiency opportunities for such targeting. In 
particular the question of whether or not the CE of an HIV/AIDS intervention 
depends on the contexts, and if so to what extent, has not received sufficient 
attention in the literature on the CE of HIV/AIDS interventions in South Africa.  
 
While recent literature in South Africa indicates that CE evidence can be used in 
different types of priority settings (Doherty, 2010), such evidence has not been 
sufficient to guide priority setting in different epidemiological and socio-economic 
contexts. The lack of contextual CE evidence may account for the limited 
contextual response in the country. Therefore, this study aims to contribute to 
this evidence.  
 
                                       
1 CD4 measures the strength of the immune system. The lower the CD4 count, the 





 1.4 Research objectives  
 
The overall aim of the study is to compare the CE of a set of HIV/AIDS 
interventions in epidemiological and socio-economic contexts in South Africa. 
The specific objectives are:   
 
 To provide an update on the nature, extent, trends and consequences of 
the HIV/AIDS epidemic in South Africa;  
 To evaluate HIV/AIDS interventions and their CE in South Africa; 
 To argue the case for the CE of HIV/AIDS interventions across HIV/AIDS 
epidemiological and socio-economic contexts in South Africa; 
 To estimate and compare the CE of HIV/AIDS interventions in  
epidemiological and socio-economic contexts in South Africa; and   
 To offer policy recommendations on how to conduct HIV/AIDS 
interventions in epidemiological and socio-economic contexts in the 
country in a cost-effective manner.  
1.5 Research methodology  
 
Comparing the CE of every modelled HIV/AIDS intervention across a rural 
context and an urban context or across an LPC and a HPC requires an estimation 
of the costs and effectiveness of that intervention in each of these contexts. 
Such estimation entails a follow-up of patients and a record of cost and 
effectiveness of that intervention. However, such follow-up is costly and provides 
cost and effectiveness estimates only up to the point of follow-up, while policy 
makers need such estimates beyond this point for planning purposes. In such a 
case, modelling is usually used to avoid the cost of a physical follow-up and to 
allow an estimation of future costs and effectiveness. To these end two 
approaches to modelling are used in this study.  
 
The first approach uses Markov modelling. This modelling uses a hypothetical 
cohort of patients whose size changes over time only as a result of deaths. The 
model tracks a cohort of patients in each context over their lifetime since 2007. 
In other words, the model tracks patients in HIV/AIDS stages until almost all 





account the time when the South African Government started to seriously 
commit to HIV/AIDS response. The estimation of the costs and effectiveness of 
HIV/AIDS interventions is expected to assess the costs and health benefits of 
such a commitment.  The Markov Model tracks the cohort of patients over time 
by assuming the initial distribution of the patients in HIV stages based on the 
estimates from the literature on South Africa and the current evidence on the 
transition of patients from one HIV stage to another in South Africa.  
 
The transition of patients in HIV/AIDS states over time in an LPC and a HPC are 
based on the projections of the AIDS model of the Actuarial Society of South 
Africa (ASSA) which depicts the dynamics of HIV/AIDS interventions in these 
contexts.  Similarly, the transition of patients in HIV/AIDS states over time in a 
rural context and an urban context is assumed on the basis of the projection 
estimates of Spectrum Policy Modelling System (SPMS). The ASSA AIDS model 
projects population over time per province. Provinces making up either an LPC 
or a HPC are determined through an arbitrary antenatal HIV prevalence rate 
threshold of 25%.  A province whose antenatal prevalence rates are below this 
threshold is designated an LPC and provinces whose prevalence is above the 
threshold are HPCs. Antenatal HIV prevalence in an LPC has been shown to be 
consistently lower than it has been in a HPC (Gouws, 2010).   
 
Following the distribution of patients in HIV stages over time, the costs 
determined from the evidence in the literature are applied. The data on costs in 
this model are derived from CE evidence in South Africa from which the base-
case values and their ranges are estimated. Health outcomes are measured 
based on patients’ distribution in HIV/AIDS stages over time. The study applies 
utility weights (percentage of perfect health in a given HIV/AIDS state in a year) 
data from the South African literature to estimate the number of life-years free 
of ailment, the quality adjusted life years (QALYs) in each intervention. Utility 
weights are estimated by quality of life researchers and in the case of this study, 
were drawn and adapted from the main studies on health-related quality of life 
(O’Keefe et al., 1996; Jelsma et al., 2005; Louwagie et al., 2007). Markov 
modelling estimates the total costs by summing up the costs in HIV/AIDS states 
over time. Similarly, the health outcomes are estimated by summing up the 






The second modelling approach uses population projection models. These 
models project estimates of a changing size of patients over time due to deaths, 
migration and new births and compare estimates across contexts. The models 
used in this respect are the ASSA AIDS model and SPMS model. These models 
project the effectiveness of HIV/AIDS interventions in terms of infections and 
death averted and the number of patients using interventions based on the 
interventions’ coverage rates. To produce cost-effectiveness estimates over 
time, particularly for the period 2007-2020, the study uses projected annual 
estimates of the number of patient-years using interventions from the ASSA 
AIDS and SPMS models. Annual costs per patient sourced from the South African 
and African literature are applied to the patient-years using interventions as 
projected by the models.  
 
In this analysis, the CE comparisons across a rural and an urban context are 
limited to HIV/AIDS interventions modelled by SPMS, while the comparisons 
across an LPC and a HPC are limited to HIV/AIDS interventions modelled by the 
ASSA AIDS model. HIV/AIDS interventions modelled by the ASSA AIDS model 
are prevention of mother-to-child transmission (PMTCT), the treatment of 
sexually transmitted diseases (STD), voluntary counselling and testing (VCT) 
and highly active antiretrovirals (HAART), while interventions modelled by SPMS 
are HAART FOR ADULTS, HAART FOR CHILDREN and PMTCT.   
 
The effectiveness of HIV/AIDS interventions in epidemiological contexts are 
compared on the basis of the infections averted for prevention interventions and 
deaths averted for treatment interventions. The costs are estimated based on 
the annual number of patient-years in each context and on the evidence of the 
annual estimates of costs per patient. The study uses the discount rate of 3% 
(Gold et al., 1996) and measures the costs in US$ dollars using the 2010 
exchange rate to facilitate comparison with other studies.  Sensitivity analysis is 
used on various uncertain parameters; details of this analysis are provided in 
specific chapters. The CE of an HIV/AIDS intervention is compared across an LPC 
and a HPC or across a rural and an urban context. In this analysis, an 





when the cost per health outcome in context one is lower than that of context 
two.      
   
 1.6 Structure of the thesis  
 
This thesis is organised into ten chapters to achieve the study’s objectives. Each 
chapter addresses a specific aspect of the study.   
 
Chapter one introduces the subject matter of the study. It provides the 
background, purpose, problem statement, objectives of the study, overview of 
the methodology and structure of the thesis. 
 
Chapter two provides an update on the impact of HIV/AIDS in South Africa. It 
highlights the nature of the impact of HIV/AIDS, explores HIV/AIDS impact 
studies, and examines the trends and extent of the impact of HIV/AIDS by 
means of the best AIDS models in South Africa.  
 
Chapter three examines the extent to which HIV/AIDS interventions have been 
conducted in South Africa. More precisely, it elaborates on the extent to which 
HIV/AIDS interventions have been targeted.  
 
Chapter four presents the CE evidence of HIV/AIDS interventions in South Africa 
with a view to justifying the need for such studies. It also scrutinises the 
evidence on the basis of the studies’ patterns, the extent to which they have 
covered important HIV/AIDS policy aspects and particularly the extent to which 
they have compared CE interventions across rural/urban and low/high 
prevalence contexts.  
 
Chapter five argues the case for CE comparisons of HIV/AIDS interventions in 
different contexts. It focuses on the case for the CE comparison of HIV/AIDS 
interventions across epidemiological and socio-economic contexts.   
 
Chapter six explains the general methodology used to compare HIV/AIDS 
interventions across contexts. It describes the modelling approach used, the 






Chapter seven compares the CE of intervening in an LPC and a HPC in South 
Africa. The comparison is carried out with Markov states transition models.  
 
Chapter eight compares the CE of HIV/AIDS interventions across a rural context 
and an urban context. It also uses the Markov states transition models.  
 
Chapter nine compares the CE of HIV/AIDS interventions in epidemiological and 
socio-economic contexts. In this case, projection models are used to conduct the 
analysis from a different point of view.  
 
Chapter ten provides the summary, conclusions and policy recommendations.  
The summary recapitulates the main aspects of the research process. The 
conclusions highlight the main findings, while the recommendations offer policy 

























Chapter 2 : Socio-economic and epidemiological impact 
of HIV/AIDS in South Africa: An update 
 
This chapter provides an update on the socio-economic and epidemiological 
impact of HIV/AIDS in South Africa. Following a discussion of the nature of the 
impact of HIV/AIDS in section one, an overview of HIV/AIDS impact studies is 
presented in section two. Section three presents the extent of the impact; and 
section four discusses the trends; while section five examines the distribution 
patterns of the impact. 
2.1 Nature of the impact of HIV/AIDS  
 
The impact of HIV/AIDS consists of a direct effect on the health status of the 
infected and an indirect effect on the society in which the infected person lives. 
The impact of HIV/AIDS begins with the acquisition of the HIV virus via blood 
contact through needle sharing or injury, unprotected sexual intercourse, during 
pregnancy, at birth or during breastfeeding. Once the HIV virus enters the body, 
it replicates and progressively destroys the body’s protective system. This 
eventually weakens the system and makes it vulnerable to diseases which at 
some point become serious (AIDS) and ultimately lead to the death of the 
infected person. 
 
While the impact of HIV/AIDS is first observed at an individual level, it has far 
reaching ramifications. HIV/AIDS primarily affects the most economically active 
population between 24 and 59 years old who in most cases are also heads of 
households (Booysen et al., 2004). By killing heads of households or causing 
their disability, HIV/AIDS not only imposes current impact but also attracts 
future socio-economic consequences for households and society at large.  
 
At the household level, the socio-economic impact of HIV/AIDS commences with 
the partial loss of income as a result of illness, estimated to be higher in affected 
households than non-affected ones (Bachmann &  Booysen, 2003). HIV/AIDS 
leads to the total loss of income when the infected person dies (Casale & 





households’ patterns of expenditure from investment (in education, for example) 
towards consumption. This pattern ultimately results in poverty. The mechanism 
through which HIV/AIDS impoverishes households is the simultaneous loss of 
income and the erosion of accumulated wealth as household members are 
obliged to draw on savings (Freire, 2004; Collins & Leibbrandt, 2007), other 
wealth and borrowings to provide treatment for the infected persons, to pay for 
their funerals or to cover other basic household needs. While some studies on 
the impact of HIV/AIDS have focused on the mechanism through which AIDS 
induces poverty, others note that the relationship is simultaneous (Tladi, 2006). 
Infected families’ unwillingness to save/invest in the future because of their 
focus on present realities has also been identified as a mechanism through which 
HIV/AIDS induces poverty (Booysen et al., 2004). 
 
Furthermore, studies have found that in most cases, these effects spread to the 
infected person’s community and to the broader society in the form of support 
from extended families and social assistance from government and non-
governmental organisations. At community level, the socio-economic burden of 
HIV/AIDS extends to relatives of the infected in the form of care provided by 
extended family members for the infected person or their children during 
sickness and after death. In many cases, this consists of sending members of 
extended families to affected households or taking the infected or their children 
into non-affected or least affected extended families. A study by Raniga & 
Simpson (2011) found that, in KwaZulu-Natal, some households which received 
old age state pension were more impoverished due to caring for grandchildren 
infected with HIV/AIDS.  
 
At societal level, the socio-economic impact is also diverse and includes an 
increase in morbidity, mortality and excessive demands on the public health 
system (Zelinick & O’Donnell, 2005). Illness and death among public servants 
lead to a shortage of essential services such as education and health care, and 
there is a reduction in productivity and economic growth (Arndt & Lewis, 2001), 







2.2 Overview of HIV/AIDS impact studies in South Africa 
  
The impact of HIV/AIDS in South Africa has been studied extensively. These 
studies can be categorised based on the scope of analysis: micro-level 
(households, firms, individuals) or macro-level (regional or nationwide) studies. 
Furthermore, the studies can be categorised on the basis of the direct health 
impact (new infections, morbidity and mortality) or the indirect health impact 
(socio-economic and demographic consequences). A summary of representative 
studies is provided in Table 2:1.  
 



















The level of study  
Micro studies  
 
These studies compared 
affected households in 
which one member was 
infected and non-affected 
households in the 
neighbourhood comparing a 
set of variables ranging 
from expenditure to 
financial response,  quality 
of life, and short and long-
term income. 
(Bachmann & Booysen, 
2003; Bachmann & 
Booysen, 2004; Booysen et 
al., 2004, O’Keefe & Wood, 
1996, Collins & Leibrandt, 
2007). 
Macro studies  
 
Analysed the impact on 
factors such as economic 
growth and unemployment 
using models that project 
over time, based on the 
effect of HIV/AIDS on 
different sectors of the 
economy and the link 
between supply and 
demand of factors of 
production over time.  
(Bollinger & Stover, 1999;  
Booysen et al., 2003; Arndt 
& Lewis ,2001;  Connolly et 







Types of impact  
Direct health impact  
 
These studies analysed the 
impact of HIV/AIDS on 
morbidity whether at 
household,  sector or macro 
levels, reporting morbidity, 
mortality, life expectancy 
etc. 
(Bachmann &  Booysen, 
2003; Johnson &  
Dorrington, 2006;  Rehle &  
Shisana, 2003). 
Indirect  socio- economic 
impact  
These studies reported the 
consequences in terms of 
poverty, social problems, 










Table 2:1 indicates that micro-impact studies compared the impact at the 
household and firm levels and typically compared affected with non-affected 
households or firms. Affected households were in most cases identified via HIV 
service providers and unaffected households in the vicinities of affected households 
were used as controls (Bachmann & Booysen, 2003; Naidu & Harris, 2006). These 
studies assessed the impact of HIV/AIDS by comparing patterns of spending, health 
status, use of health care services, and borrowing.  
 
Macro-impact studies used population and epidemiological projection models to 
estimate and simulate the impact on morbidity and mortality which in turn was 
used to estimate the loss in productivity and other socio-economic consequences. 
They measured the impact by comparing estimates of economic growth, 
unemployment, life expectancy and mortality in the absence and presence of 
HIV/AIDS or in the absence or presence of interventions (Johnson & Dorrington, 
2006). Some studies simulated the impact to take the interactions between 
different sectors of the economy into account and used computable general 
equilibrium models. Arndt & Lewis’s (2001) study is the most recent of these kinds 
of studies.    
 
In terms of the type of impact measured, some studies assessed the direct impact 
of HIV/AIDS on health status, whilst others studied the indirect consequences. The 
studies that measured the direct health impact reported the impact of HIV/AIDS on 
mortality and morbidity (Johnson & Dorrington, 2006).  Those that examined 
indirect effects reported the impact of HIV/AIDS on education, orphanhood, 
economic growth, and unemployment (Johnson & Dorrington, 2006).  
 
Since most of the studies that documented the impact of HIV/AIDS date back to 
2007 or earlier, there is a need for an update.  Given that time, space and data 
availability do not allow for an  update on the non-health impact of HIV/AIDS on 
households, changes in macro HIV/AIDS health variables such as new infections, 
AIDS cases and deaths can assist in making inferences about the impact of 





follows relies mainly on the projections of the ASSA AIDS model to provide an 
update on the extent, trends and patterns of HIV/AIDS in South Africa. The 
discussion begins with the extent of the impact of HIV/AIDS.  
 
2.3 Extent of the impact of HIV/AIDS in South Africa 
 
HIV/AIDS has thus far killed three million people in South Africa and currently 5.5 
million people are living with the disease (Statistics South Africa, 2011). While 
HIV/AIDS’s impact has been devastating in the past, the extent of its impact in 
more recent times is not well reported, except for anecdotal reports that the impact 
has decreased. In this section, the ASSA AIDS model is used to provide an update 
on the extent of the impact of HIV/AIDS in terms of new infections, prevalence, 
AIDS, and deaths. The data are presented in Figure 2:1. 
















Results extracted from the ASSA (2011)’s full AIDS and Demographic model of the Actuarial Society of South Africa 
as downloaded (10/01/2012) from www.assa.co.za. 
 
Figure 2:1 Change in new infections, death cases, prevalence and AIDS cases over time in South 
Africa 
 
Panel 1 of Figure 2:1 shows that the number of new infections in South Africa was 
insignificant in the period before 1990. However it increased rapidly in subsequent 
periods, reaching a peak in the period 1996-2000 before starting to decrease. The 
number of new infections increased from an annual average of 3,000 new infections 
in the period before 1990 to 100,000 new infections in the period 1991-1995 and to 
an average of 480,000 new infections in the period 1996-2000. The number of new 
infections decreased thereafter to 360,000 in the period 2001-2005 and to an 
average of 130,000 new infections in the period 2006-2010. According to 
projections, new infections are expected to continue decreasing to less than 





There were very few AIDS deaths before 1995.  Thereafter, the country started 
experiencing an increase in these deaths. In the period 1996-2000, AIDS deaths 
reached an annual average of 50,000. From 2001 to 2005, AIDS deaths increased 
to 210,000 per year, the highest since the advent of HIV/AIDS in South Africa. 
However, the number of deaths remained high  over the next period (2006-2010). 
The number of annual AIDS deaths is projected to decrease slightly to 200,000 for 
the period 2011-2015.   
 
Analysing the impact in terms of people living with HIV/AIDS in the same period, 
Figure 2:1, Panel 2 indicates an insignificant number of people living with HIV 
before 1990. In the period 1991-1995, however, the average number of people 
living with HIV/AIDS increased to about 20,000. In the period 1996-2000, the 
number was about 200,000; from 2001-2005 it was around 420,000; and from 
2006-2010 it was about 520,000; while it is estimated at 560,000 for 2011 - 2015. 
This continued increase in the number of people living with HIV/AIDS is expected 
because of the persistence of new infections, although at a decreasing rate. The 
increase in prevalence can also be explained on the one hand, by the widespread 
impact of HAART, which prolongs the lives of people living with HIV/AIDS, while on 
the other, it might reflect an increase in the natural survival of HIV/AIDS patients.  
While survival is a good thing, it comes at the cost of increased health care.   
 
It is worth noting, however, that the impact of HIV/AIDS has been significantly 
affected by the success of HIV/AIDS interventions, particularly HAART in terms of 
survival. This is observed in Figure 2:1 (both panels), which compares scenarios of 
absence of HIV/AIDS interventions with scenarios where such interventions are 
present.  
 
In the absence of HIV/AIDS interventions, additional new infections in the period 
2006-2010 would have been about 100,000; and additional new deaths would have 
been 250,000, while 250,000 additional people would have been living with 
HIV/AIDS. HAART in particular has reduced mortality; in 2009, 52% of all deaths in 





HIV/AIDS and life expectancy increased from 54 to 60 years (Abdool Karim, 2012). 
Figure 2:1 Panel 1 shows that even in the absence of HIV/AIDS interventions, the 
number of new HIV infections and AIDS deaths would eventually decrease after a 
long period. This evidence reflects the fact that the reduction in new infections 
could take place naturally over time, whilst people also tend to resist HIV/AIDS-
related deaths as time progresses.  
 
2.4 Trends in the impact of HIV/AIDS  
 
Analysed from the point of view of new infections, three periods mark the trends in 
the number of new infections. These periods consist of a period of almost no impact 
(1980-1990); the period of exponential increase in the impact (1991-1999) and the 
period of decrease in the impact (2000 onwards).  Figure 2:2 shows these data. 
 
 
Source: Results extracted from the ASSA (2011) full AIDS and Demographic model of the Actuarial Society of 
South Africa as downloaded (10/01/2012) from www.assa.co.za. 
 







As Figure 2:2 shows, in the first ten years (1980-1990) after the outbreak of HIV in 
South Africa, less than 1,000 new infections were reported annually. However, the 
number of new infections increased exponentially from 1,000 in 1991 to about 
580,000 in 2000.  Since 2000, there has been a decrease in new infections which 
can be partly explained by the impact of HIV/AIDS interventions and partly by the 
natural evolution of the epidemic. The natural evolution of the epidemic is depicted 
by the curve representing the projection of the number of new infections in the 
absence of HIV/AIDS interventions. This curve shows that the decrease in the 
number of new infections would have started after 2000 even in the absence of 
interventions (Figure 2:2). From 2000 to 2012, the number of new infections was 
projected to decrease from 580,000 to 80,000.  
 
The trend in the number of people living with HIV/AIDS (prevalence) is expected to 
follow the trend in the number of new infections since prevalence, the total number 
of people infected with HIV/AIDS at a given point in time, is the cumulative number 
of new infections before that time.  However, prevalence can be affected by the 
number of deaths. In the case of South Africa, the number of new infections has 
been always higher than the number of deaths and is projected to remain higher at 







Source: Results extracted from the ASSA (2011) full AIDS and Demographic model of the Actuarial Society of 
South Africa downloaded (10/01/2012) from www.assa.co.za 
 
Figure 2:3 New deaths and infections and prevalence in South Africa  
The higher number of new HIV infections relative to AIDS deaths over time shown 
in Panel 1 of Figure 2.3, explains why prevalence has been increasing. The period 
with the highest number of deaths, 1997-2005, coincided with an ever-increasing 
number of new infections, except for 2000-2005, when the number of new 
infections started decreasing, but remained significantly greater than the number of 
deaths (See Figure 2:3 Panel 1). Because the number of new infections has been 
significantly higher than the number of deaths, the trend in prevalence has followed 







period 1993-2003 from 200,000 people living with HIV/AIDS in 1993 to about 5 
million people living with HIV/AIDS in 2003. 
 
Likewise, three periods can be distinguished when analysing the trend of the impact 
in terms of deaths. Figure 2:3 Panel 1 shows that in the period 1980-1993, the 
number of AIDS deaths was almost zero. During 1995-2005, the number of deaths 
increased from 20,000 to 280,000, while from 2005, the number of AIDS deaths 
started decreasing. In 2011, the number of AIDS deaths stabilised at 200,000 
although the projections suggest a slight increase in the future. Since the time of 
death is very close to the time of onset of AIDS, especially in the absence of 
intervention (on average, death takes place one year after the onset of AIDS), 
these statistics indicate that suffering caused by AIDS is still significant in South 
Africa. Figure 2:3 Panel 2 shows that, prevalence, and thus new infections would 
have been higher in the absence of HIV/AIDS interventions.  
 
2.5 Distribution Patterns of the impact 
 
HIV/AIDS has affected different segments of the South African population, and 
epidemiological and socio-economic contexts to a different extent. The literature 
notes that HIV/AIDS has a greater impact on women; younger people aged 15-25, 
in a rural context, and in some provinces (Gouws, 2010). This section provides an 
update on the impacts to ascertain whether these patterns have persisted or 
changed.    
    
2.5.1 Gender and age  
 
HIV/AIDS has affected men and women to a different extent in South Africa. The 








Source: ASSA (2011). Note prevalence rate as percentage of total population and not as percentage of 
susceptible population because of lack of data  
 
Figure 2:4 Changes in proportions of people living with HIV/AIDS in the presence of HIV/AIDS 
interventions  
 
Figure 2:4 shows that, females aged 15-24 years have been the most affected. The 
prevalence rate of females in this age group increased from 2% in the period 1991-
1995, to 15% in the period 2001-2005 and 14% in the period 2011-2015. The 
respective prevalence rates among males in the same age group are 1%, 5% and 
3%. The data suggest that the patterns in the impact of HIV/AIDS in this age group 
have not changed (ASSA, 2011).  
 
However, the prevalence patterns have changed in younger people in the age 
groups 0-9 and 10-14 years. Figure 2:4 shows that in the period before 1995, HIV 
was not prevalent among these age groups. However, from 1996-2000, the 
proportion of children aged 0-9 living with HIV/AIDS reached around 1%. In the 
period 2006-2010, this increased to 3.5%. This proportion is projected to remain at 
this level in the period 2011-2015, although it is predicted to decrease thereafter. 
The data indicate that males and females in this age group, who may have acquired 
HIV mainly from their mothers, were equally affected (ASSA, 2011).   
 
While HIV/AIDS was expected to be absent in the age group 10-14 years, given the 





find that in the period 2006-2010, about 1% of children in this age group were 
living with HIV/AIDS (Figure 2:4). For the period 2011-2015, the proportion is 
projected at 2% with no difference in terms of gender, although it is projected to 
decrease in the future. Recent changes in the patterns of HIV/AIDS prevalence 
signify changes in risky sexual behaviours, with young people in South Africa 
engaging in sexual activities earlier than had been previously reported. 
Alternatively, this could be a result of antiretroviral therapy which is reported to 
prolong the lives of children infected by their mother from childhood to teenage and 
adulthood (World Health Organisation (WHO), 2007).   
 
With regard to prevalence across age and gender, it would have been preferable to 
analyse the patterns of the impact of HIV/AIDS in terms of deaths across age 
groups and gender. However, detailed data for this analysis were not available. 
Therefore, the patterns of AIDS and cases of death across gender are analysed by 
examining the impact across adult males and females, and the impact across age is 
analysed by comparing the impact across children (less than 15 years old) and 
adults. Figure 2:5 provides these data. 








Source: Results extracted from the ASSA (2011) full AIDS and Demographic model of the Actuarial Society of 
South Africa downloaded (10/01/2012) from www.assa.co.za 
 
Figure 2:5 Composition of AIDS cases  
 
The data in Figure 2:5 show that the proportion of AIDS cases has been 
consistently higher among females than males, with the gap in the proportion of 
AIDS cases across gender increasing over time. Panel 1 of Figure 2:5 shows that 
the proportion of AIDS cases was the same across the genders in 1996-2000, about 
20 cases in a population of 10,000 people. In 2001-2005, the number of AIDS 







10,000 people, while the corresponding estimate for females was 72. In the period 
2006-2010, there were 88 and 110 AIDS cases, respectively in a population of 
10,000 people. For the period 2011-2015, the projected figures are 82 and 110. 
AIDS cases are projected to decrease but with increasing gaps across gender 
(ASSA, 2011).  
 
AIDS death patterns across gender appear to generally follow the patterns of AIDS 
cases.  Panel 2 of  Figure 2:5 suggests that the number of AIDS deaths were similar 
across the genders in the periods 1991-1995, 1996-2000 and 2001-2005 with the 
number of deaths in a population of 10,000 people being 2.5, 15, and 45, 
respectively. AIDS deaths were higher among males (45 male deaths versus 42 
female deaths) in a population of 10,000 in the period 2006-2010, while for the 
period 2011-2015, the number of AIDS deaths in a population of 10,000 is 
projected to be higher among females than males (38 female deaths versus 35 
male deaths). The data indicate that the gap in AIDS deaths across gender is 
predicted to increase, with more females dying (ASSA, 2011). 
 
2.5.2 Provincial impact  
 
The impact of HIV/AIDS in terms of new infections and AIDS deaths has also been 
differentiated across South Africa’s nine provinces. Panel 1 of Figure 2:6 shows, 







Source: Results extracted from the ASSA (2011) full AIDS and Demographic model of the Actuarial Society of 
South Africa downloaded (10/01/2012) from www.assa.co.za 
 
Figure 2:6 Impact of HIV/AIDS across provinces  
 
The data in Panel 1 of Figure 2:6 indicate that in the period 1985-1990, the number 
of new infections was still insignificant but differences already existed across 
provinces. The top five provinces in terms of the proportion of infected people, with 
no clear ranking on the basis of the available information were: the Free State (FS), 
Gauteng (G), KwaZulu-Natal (KZN), Mpumalanga (M) and North West (NW). In the 
period 1991-1995, however, the statistics suggest some ranking. The top five, 







were: KZN, FS, NW, G, and the Eastern Cape (EC). In the period 1996-2000, the 
top five were: KZN, FS, NW, M, and EC.  
 
This ranking persisted in the following periods, suggesting that the burden of HIV 
infections has been disproportionately distributed across provinces with a specific 
set of provinces consistently emerging as the most affected over time. Not 
surprisingly, Panel 2 of Figure 2:6 show that, over time, these provinces have borne 
most of the burden of the HIV/AIDS epidemic in terms of deaths (ASSA, 2011).  
 
2.5.3 Urban and rural impact  
 
Finally, the differentiated impact of HIV/AIDS has been observed across rural and 
urban contexts. Although detailed differences in HIV infections, AIDS cases and 
deaths have not been modelled in urban and rural contexts in South Africa, the 
differentiated impact of HIV/AIDS across the two contexts has been documented. 
HIV/AIDS surveys in South Africa revealed that people in rural contexts were less 
aware of HIV/AIDS; knew less about how to avoid it; and practiced more risky 
sexual behaviours than their urban counterparts (Department of Health, 2003 c: 
88). National HIV/AIDS prevalence surveys showed that prevalence was higher in a 
rural context than in an urban context (Shisana & Simbayi, 2002). Furthermore, 
micro studies indicated that greater poverty in a rural context interacted with 




This chapter provided an overview of the impact of HIV/AIDS in South Africa with 
respect to the extent, trends and patterns of the impact of HIV/AIDS in terms of 
new HIV infections, AIDS cases and deaths. It revealed that although the impact is 
decreasing, it remains highly significant and is differentiated across age, gender, 
provinces and rural and urban areas. An increase in risky sexual behaviours among 
young people aged as young as 10-14 was noted as a new pattern of the epidemic. 





Chapter 3 : Analysis of HIV/AIDS interventions in South 
Africa 
 
This chapter examines the extent to which policies to improve the effectiveness of 
HIV/AIDS interventions accommodated context-specific responses. The chapter 
starts with an overview of the conduct of HIV/AIDS interventions in section one. 
Section two discusses the effectiveness of HIV/AIDS interventions in South Africa. 
Section three examines the extent to which policies to improve the effectiveness of 
HIV/AIDS interventions have been implemented, while section four focuses on the 
extent to which these policies were context-specific.  
 
3.1 Overview of HIV/AIDS interventions in South Africa 
 
The conduct of HIV/AIDS interventions in South Africa has been very influenced by 
political leadership. In this overview, the conduct of HIV/AIDS interventions as well 
as the role of political leadership is emphasized. 
  
3.1.1 Conduct of HIV/AIDS interventions  
 
HIV/AIDS interventions in South Africa are a result of policy strategies which 
evolved over time. In South Africa, HIV/AIDS was initially dealt with like any other 
infectious disease by the Department of Health. The department’s strategies 
included putting HIV patients in quarantine and only allowing immigrants who were 
HIV negative into South Africa (Zwi & Bachmayer, 1990). However, from the late 
1980s and early 1990s, proper strategies to deal with HIV/AIDS were placed on 
South Africa’s national agenda. The common feature of these strategies was that 
they took the multi-facet nature of the epidemic into account. This implied that the 
response was not limited to the activities of the Department of Health but to the 
concerted efforts of many stakeholders, both government and civil society. The 
strategies were refined over time through successive strategic five-year plans, 
2000-2005, 2007-2011 and 2012-2016 (Department of Health, 2000; 2006; 






The first official body to deal with HIV/AIDS in the country was the National AIDS 
Convention of South Africa (NACOSA) which was instituted in 1992 and chaired by 
non-politicians. The influence of political leadership in the response started with the 
involvement of a high level political body, the inter-ministerial committee in 1998, 
which was chaired by the then president of South Africa. In 2000, the inter-
ministerial committee was replaced by the South Africa National AIDS Council 
(SANAC), also chaired by a politician, the Deputy President of the country 
(Department of Health, 2006). 
 
A number of HIV/AIDS interventions emerged from the national strategic plans and 
political involvement in the HIV/AIDS response. Table 3:1 summarises these 






Table 3:1 Categorisation of HIV/AIDS interventions in South Africa 
target Prevention interventions Treatment  and care interventions 











provided at over 4000 testing centres  countrywide 





Started in 2000 and is 
provided at different 
antenatal clinics 
throughout the country  
(Department of Health, 
2000) 
 
Voluntary circumcision:  
Conducted at the request 
of clients 
VCT 
Treatment of STD   
-HAART: Started officially in 
2003 and is  provided at 
dedicated clinics 
(Department of Health, 
2003a) 
 
-Caring for TB and HIV and 
other infections  
 
-Caring For TB/AIDS co-
infection (trial) 2007 













-Pre-schoolers: Takalami sesame in 2000 
       (CADRE,2001) 
-Youth: TshaTsha  in  2003 
  Kincaid & Coleman (2006) 
 
-HIV positive: (Gazlam) 
-Stigma: Phamokate   
-High school learners: peer groups 
-Primary school learners: peer groups  
   
-General public: Khomanani, Love life and Soul City 
mass media campaigns started in 1999 (Tufte, 2002, 
Parker, 2003) 
 



















Table 3:1 shows that HIV/AIDS interventions can placed in two main categories: 
prevention interventions and treatment interventions. Prevention interventions 
consist of interventions aimed at reducing the number of new infections while 
treatment interventions seek primarily to reducing suffering and death.   
 
Prevention interventions can be categorised into behavioural interventions and 
biomedical interventions. Behavioural interventions consist of activities that seek to 
reduce infections through education about avoidance of risky behaviours. 
Biomedical interventions seek to reduce the occurrence of new infections by using 
biomedical practices.  
 
Treatment and care interventions can be categorised into biomedical interventions 
and psychosocial counselling. Biomedical treatment interventions consists of 
interventions seeking to reduce suffering among the infected by means of medical 
or clinical care. Psychosocial interventions consist of interventions aiming to 
decrease suffering through trauma counselling.  
 
In terms of the type of audience targeted by HIV/AIDS interventions, some 
interventions target individuals while others target groups of individuals. Most of 
the interventions targeting individuals are biomedical interventions. Biomedical 
prevention interventions offered at an individual level consists of PMTCT, pre-
exposure prophylaxis, voluntary circumcision and treatment of sexually transmitted 
infections. In South Africa, prevention of mother-to-child HIV transmission started 
in 2000. PMTCT services have since expanded to the extent that they are provided 
in almost 95% of all public health care facilities countrywide (Goga et al., 2010:x). 
Recently about 91% of all pregnant women who are HIV positive have been 
receiving antiretroviral prophylaxis and the rate of transmission decreased from 
about 15% in 2009 to 3.5% in 2011(Leach-Lemens, 2011). In 2009, SANAC put an 
accelerated plan in place to implement PMTCT in order to strengthen the supply and 
demand side of the programme (Department of Health, 2010 c). In contrast, the 
treatment of sexually transmitted diseases (STDs) among HIV/AIDS patients has 





strategy to reduce the risk of HIV transmission has been considered an important 
intervention both in South Africa (Johnson & Budlender, 2002; Johnson, 2008) and 
elsewhere (Sweat et al., 2000; Price et al., 2006). HAART started in 2003 and 
increased over time. In 2012, about 2 million people were on HAART across all 
2,552 approved facilities in the country (IRIN/Plus News, 2012). While other 
interventions have been conducted as fully fledged responses to the impact of 
HIV/AIDS, Microbicide (Abdool Karim et al., 2010), antiretroviral prophylaxis 
(Christofides et al., 2006; Pretorius et al., 2010) and voluntary circumcision (Kahn 
et al., 2006) have been mainly conducted in the form of trials thus far.  
  
Biomedical treatment interventions offered at individual level are HAART and 
treatment of TB and other opportunistic infections among HIV/AIDS patients. 
Another type of intervention offered at individual level is trauma counselling. 
Counselling is provided to patients to help them manage the shock experienced 
when they discover that they are HIV positive. Trauma counselling offers advice to 
patients on their behaviour and lifestyle and encourages them to adopt a positive 
attitude towards life while living with HIV/AIDS.   
 
While most biomedical interventions have been offered at individual level, the 
opposite is true for behavioural interventions which were educational interventions 
delivered to groups of patients. These interventions consisted mainly of use of mass 
media in the form of HIV/AIDS-related drama, targeting different groups of people 
at risk. These drama programmes included TshaTsha in 2003, which targeted the 
youth (Kincaid & Coleman, 2006); Gazlam in 2003, which targeted HIV positive 
people; Phamokate in 2002, which targeted people with stigma and Takalami 
Sesame in 2000, which targeted pre-schoolers (CADRE, 2001). Concurrently, mass 
education using multimedia social campaigns such as Soul City which started in 
1994 (Tufte, 2002: 2), Love Life which started in 1999 (Parker, 2003:1) and 
Khomanani which started in 2002 (National HIV/AIDS & Tuberculosis Programme, 
2003) were implemented to modify individual and environment-induced HIV/AIDS 





circumstances which facilitate risky behaviours such as poverty and violence 
against women even though they are still in their trial stages (Pronyk et al., 2008).  
 
Testing and counselling are interventions with educational and biomedical aspects. 
This HIV/AIDS intervention started in 2000, primarily to provide education at an 
individual level on how to avoid HIV infection, and secondarily to link infected 
patients to treatment. Testing and counselling services have expanded; there are 
currently more than 4,000 voluntary counselling and testing (VCT) centres in South 
Africa. In 2011, Walensky et al., (2011: 26) reported that VCT was offered at 96% 
of public health care facilities.  
3.1.2 HIV/AIDS interventions and political leadership 
 
Although a fair number of HIV/AIDS interventions have been put in place, South 
Africa’s political leadership failed to act on time (Chigwedere et al., 2008). The 
literature on the politics of HIV/AIDS in South Africa (Schneider & Stein, 2001; 
Fassin & Schneider, 2003; Johnson, 2004) indicates that both the apartheid and 
post-apartheid governments failed to act at relevant times to reduce the impact of 
HIV/AIDS. The apartheid regime failed to put proper HIV/AIDS policies in place 
when HIV was nascent, while the post-apartheid leadership, despite having proper 
HIV/AIDS policies in place, was plagued by competing political priorities and 
misinformation, which undermined the implementation of such policies on time.   
 
The literature notes that political leaders, in particular the then president, Thabo 
Mbeki, believed that AIDS was a disease of poverty and that there was no link 
between HIV and AIDS (Schneider & Stein, 2001:728). Consequently, his 
administration prioritised policies to alleviate poverty. This resulted in the rejection 
of antiretroviral drugs which had been scientifically proven effective. Instead, the 
administration implemented scandalous measures such as the adoption of chemical 
compound Viroden instead of antiretroviral therapy. The refusal to provide 
antiretroviral treatment to HIV–infected pregnant women and other adults was 





provision of antiretrovirals to patients who needed them was forced on government 
through pressure and court action on the part of activists and civil society. In 2003, 
the public sector started making antiretroviral drugs available to patients 
(Department of Health, 2003a).  
 
The unwillingness of the government to provide antiretroviral drugs meant that 
patients’ coverage was slower than planned (Nattrass & Geffen, 2005:65). The 
refusal to providing antiretrovirals and the slow pace of rollout resulted in an 
unprecedented burden of HIV/AIDS. It is documented that the government’s failure 
to act appropriately resulted in hundreds of thousands of deaths which could have 
been avoided during the period 2000-2005 (Chigwedere et al., 2008). The failure of 
the government to act on time also resulted in an exponential increase in the 
infection rate from 0.8% in 1990 to 30.2% in 2005 and an increase in the number 
of people infected with HIV from 50,000 in 1990 to 4 million in 2005 (Nyabadza et 
al., 2010).   
 
This situation changed in 2007. The Jacob Zuma administration committed itself to 
the implementation of SANAC’s five-year, 2007-2011, strategic plan. The 
government urged every South African to be responsible by testing freely at South 
African clinics on a regular basis in order to receive treatment. Furthermore, the 
government campaigned against stigma and discrimination through a door-to-door 
campaign, billboard messages and vox pops, and set a target to test 15 million 
people by June 2010 (Culliman & Bodibe, 2010). In 2009, President Zuma 
announced generous policies in favour of the most vulnerable sections of the 
population. These included the provision of antiretroviral treatment to children 
under the age of one who test HIV-positive and earlier ARV (at CD4 count 350) to 
pregnant women and patients with TB and AIDS co-infection (Govender, 2009). In 
2011, earlier treatment was expanded to everyone who qualifies. On the facility 
side, managerial and attitudinal deficiencies in district–level health care facilities 
were addressed.  In terms of funding, the HIV/AIDS budget was increased by 33% 






3.2 Extent of HIV/AIDS interventions’ effectiveness   
 
Despite the efforts of the South African Government to improve the response to 
HIV/AIDS and the resulting effectiveness in terms of reduced infections and deaths, 
the effectiveness in terms of patients reached remains limited. This limitation arises 
from a shortage of resources which do not grow on par with the growth in the 
number of patients. While progressive HIV/AIDS policies have been adopted since 
2007, the shortage of resources can compromise the future effectiveness of 
HIV/AIDS interventions in terms of coverage if the levels of risky behaviours do not 
change significantly.  
 
3.2.1 Past and recent past  
 
The government’s late response to HIV/AIDS resulted in a huge burden of the 
epidemic. This limited the effectiveness of HIV/AIDS interventions in terms of 
patients reached despite an increase in funding.   
 
HIV/AIDS funding in South Africa can be understood by examining trends in 
HIV/AIDS conditional grants to provincial and local government. These conditional 
grants, which increased over time, were channelled to HIV/AIDS through three 
social sector departments; the Department of Health which is mainly responsible for 
HIV/AIDS care, the Department of Social Development which is responsible for 
HIV/AIDS social programmes and the Department of Education which is  
responsible for HIV/AIDS life skills. Table 3:2 shows that HIV/AIDS funding has 





Table 3:2 Government HIV/AIDS funding in South Africa (in thousands of Rands, current prices) 
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Source:  Adapted from Ndlovu (2009:25).  





This increase in funding permitted an expansion of HIV/AIDS interventions and 
resulted in an increase in the effectiveness of these interventions in terms of 
patient coverage. Increased investment in mass education campaigns notably Soul 
City for adults, Soul Buddyz for children, Love Life for teenagers 
(HSRC/MRC/CADRE, 2009,) and more recently VCT campaigns (SANAC, 2010 b), 
resulted in increased exposure to these interventions. The HSRC/MRC/CADRE 
(2009) reported an increase in exposure to these programmes from 75% in 2005 to 
80% in 2008. In terms of treatment interventions, South Africa significantly 
increased access to HAART. In 2012, the country reached the target of universal 
treatment. It is reported that in 2012, 80% or 2 million patients out of 2.4 million in 
need of HAART were receiving it (IRIN/Plus News, 2012).     
 
For patients reached by HIV/AIDS interventions, effectiveness in terms of a 
reduction of suffering and death increased. The scale-up of the antiretroviral 
programme led to a significant decrease in morbidity and mortality (Dorrington, 
2011). Likewise, patients reached by prevention interventions decreased their risky 
behaviours. In 2008, a survey revealed that mass information campaigns had 
generally decreased risky sexual behaviours among adults (HSRC/MRC/CADRE, 
2009); Govender’s (2011) study on the impact of Soul City confirmed these results. 
It has also been widely documented that as a result of an increase in the coverage 
of prevention interventions, condom usage increased and the number of sexual 
partners decreased  (Shisana & Simbayi, 2002; HSRC 2005; 2009; Williams, 2003, 
Pettifor et al., 2004; Pronyk et al., 2008; Pronyk et al., 2006).  
 
However, an increase in funding does not imply effectiveness in terms of patients 
reached as demand-side factors may play a deleterious role. While the increase in 
funding increased access to HIV/AIDS interventions, other evidence indicates that 
many patients are still unable to access HIV/AIDS interventions. The limited extent 
of effectiveness in terms of how HIV/AIDS interventions reach prospective patients 
is illustrated by low exposure to one of the most important interventions in South 
Africa, VCT. In 2011, Walensky et al. (2011: 26) found that more than 3 out of 5 





South Africans and 34% of those infected reported that they had tested for HIV. 
Pitpitan et al. (2012) found that only 49% of South Africans have ever tested for 
HIV. As the effectiveness of HIV/AIDS interventions begins with reaching those in 
need, this evidence suggests that their effectiveness in South Africa is still limited.  
 
Another issue is the extent to which accessing HIV/AIDS interventions or 
decreasing risky behaviours translates into actual reduction in infection rates. Many 
other factors such as sexual partners’ biological conditions may influence the 
infection rate more than behaviour. The evidence indicates that females are more 
at risk than male because of the efficiency of the transmission of the virus from a 
male to female (Nicolosi et al., 1994).  Therefore, a woman who reduces her risky 
behaviour as a result of an intervention is still more likely to be infected than a man 
who did not reduce his risky behaviour. This has resulted in inconclusive research 
findings on the effectiveness of HIV/AIDS behavioural prevention interventions. 
Studies that have reviewed interventions in South Africa have hesitated to draw 
firm conclusions about which intervention works best in terms of reducing infections 
(Harrison, 2010; Harrison et al., 2010).  
 
While the effectiveness of HAART in changing health outcomes in South Africa has 
been acknowledged (Fairall, 2008; Dorrington, 2011), until the end of 2011 the 
intervention had not reached many patients in need. Even with a significant 
increase in patients accessing treatment in 2012, many patients (20%) do not 
access treatment. The difference between intervention services and patients in 
need can be grasped by examining the gap between eligible and treated patients; 







Sources: Data obtained from Adam & Johnson (2009) and Meyer-Rath (2010).  
Figure 3:1 Comparison of eligible and treated patients since the launch of ARV treatment 
 
Figure 3:1 shows that since 2009, the gap between eligible and treated patients has 
been almost the same as in previous years. The gap in 2009 persisted or increased 
when the number of eligible patients increased, suggesting that additional funding 
served less additional eligible patients.  
 
The funding shortfall highlighted above has also been documented with regard to 
treatment affordability in terms of the number of untreated but eligible patients 
(Mills, 2008), shortage of infrastructure, and human resources. A 2008 study 
estimated that about 900,000 eligible (on the basis of CD4 counts 200 threshold or 
the World Health Organisation stage 4) adults were not on treatment. The same 
study estimated that only 40.2% of all eligible patients were treated in 2008, 
although this was a huge increase from 4.9% in 2004 (Adam & Johnson, 
2009:661). Limited effectiveness also manifested in terms of the limited number of 
antiretroviral drugs provision facilities (Meyer-Rath, 2010), although this may also 
be a result of poor planning. The extent of effectiveness in terms of patients 
reached by HAART interventions is likely to be even more limited with more recent 






3.2.2 Future prospects   
 
The above limitations of the effectiveness of HIV/AIDS interventions in observed 
data are likely to persist in the future.  Indeed, government’s increased 
commitment to enrol patients on HAART on a universal basis raises the question of 
whether or not funding will be available in the future. A simplistic analysis would 
predict a funding shortfall, given an immediate increase in the number of eligible 
patients. A more realistic analysis, however, would take into account the longer 
term savings in terms of avoided opportunistic and new HIV infections and the 
likely decrease in the cost of ARV drugs (Bangsberg et al., 2001).   
 
The funding shortfall analysis in South Africa should take into account the increase 
in the number of patients as well as the cost savings emanating from early 
treatment in order to estimate the additional funding requirement. In this respect, 
one study projected that with early treatment, the number of patients over the 




Sources: adapted from Meyer-Rath (2010)  
Figure 3:2 Projected trends in patients who would be on ARV therapy at treatment thresholds of 200 







The results  depicted in Figure 3:2 show that  early treatment would increase the 
number of patients  from 900,000 in 2009 to 3,500,000  in 2016 (an increase of 
288%), 14% more than late treatment, which would increase the number of 
patients from 900,000 in 2009 to 3,000,000 in 2016 (233%) as shown in  Figure 
3:2. Over the same period, it is estimated that the costs of early treatment would 
be about R70 billion, 17% more than the cost of late treatment of R59 billion 
(Meyer-Rath, 2010), which would be exorbitant if one considers the available 
government funding in Table 3:2. A more recent study (Hontelez et al., 2011) that 
analysed universal early treatment (at CD4 counts of 350) projected significantly 
greater benefits with modestly higher costs, which would break even with the costs 
of late treatment by 2026. 
 
Whether or not this long-term prediction will turn out to be true, the limitations of 
the extent of HIV/AIDS interventions relate mainly to the short-term. In light of the 
situation in the recent past, it could be argued that government will likely suffer a 
shortage of funds. Indeed, following the announcement of the early treatment of 
pregnant women and children in 2009, the number of eligible patients increased 
more (50%) than the increase in funding (30%) over previous years (Adam & 
Johnson, 2009).  
 
While these studies suggest that long-term effectiveness might not be a concern, 
short-term funding prospects remain a challenge.  Increasing funding in order to 
provide early treatment to eligible patients would require a significant increase in 
revenue. However, the extent to which the country can increase its main source of 
revenue, tax revenue, to fund early HIV/AIDS treatment is limited in the context of 
2012 and subsequent years’ economic prospects. Increasing revenue will require an 
increase in tax rates and /or an increase in taxable income. While an increase in tax 
rates might have a deleterious effect on economic activity, an increase in taxable 
income will be difficult to achieve given the effects of the global economic slowdown 





economy has not created sufficient jobs or business opportunities and the chances 
of this situation changing in the near future are slim.  Slow economic growth leads 
to increasing poverty and the need for an increase in social security. HIV/AIDS 
interventions are therefore likely to compete for funds with poverty related social 
programmes such as social spending and education. The country needed about 
R104 billion (about US$13 billion) for the 2011/2012 fiscal year to cater for the 16 
million people in need of social grants (Hweshe, 2011).  
 
The current health care system in South Africa also contributes to the limitation of 
the effectiveness of HIV/AIDS interventions by only reaching a restricted number of 
patients. The system serves fewer people in need because most of those affected 
by HIV/AIDS are poor and rely on the services of the public sector. However, the 
public sector’s resources are not commensurate with the number of HIV/AIDS 
patients it is supposed to serve. A national health insurance system is expected to 
resolve this problem by allowing people access to HIV/AIDS services regardless of 
their ability to pay, but controversy still surrounds its affordability (Parker, 2010). 
Consequently the effectiveness of HIV/AIDS interventions will remain limited in 
terms of patients’ access to services.  
 
Non-economic factors such as stigma which remains persistent in South Africa 
(Mahajan et al., 2008, Campbell et al., 2005), also cast doubt on the future 
effectiveness of HIV/AIDS interventions with respect to the number of patients 
reached. Despite the widespread incidence of HIV/AIDS, stigma is still reported to 
be an important deterrent to accessing HIV/AIDS interventions or to adhering to 
treatment (Young et al., 2010). If stigma persists, it will limit the effectiveness in 
terms of the number of patients reached by interventions and their health status. 
Non-adherence as a result of stigma leads to an increase in opportunistic infections 
and the development of drug resistance, both of which aggravate health status 
(Bangsberg et al., 2001).  
 
Briefly, the discussion in this section indicates that the effectiveness of HIV/AIDS 





policy implementation. The next section discusses the extent to which these policies 
have been implemented in South Africa.  
3.3 Effectiveness-targeted policies 
 
Policies to increase the effectiveness of HIV/AIDS interventions in South Africa have 
failed to address both the supply-side and demand-side factors. This has reduced 
the effectiveness of HIV/AIDS interventions.   
3.3.1 Supply-side policies  
 
South Africa put supply-side policies in place to improve the effectiveness of 
HIV/AIDS interventions. Broadly, these policies consisted of strategies to supply 
HIV/AIDS services in the country. Formulated since 2000, the strategies were 
imbedded in successive five-year strategic plans which determined the priority of 
HIV/AIDS interventions and how they had to be conducted. An important aspect of 
these strategic plans was involving many stakeholders in the response to HIV/AIDS 
because of its multifaceted nature. The responses arising from the plans resulted in 
an improvement in resource allocation and effectiveness in terms of coverage. 
Supply-side policies focused on addressing factors that limit access to HIV/AIDS 
services, such as a shortage of resources, HIV/AIDS facilities, drugs and human 
resources (Ndlovu, 2009), political unwillingness (Roger, 2009) and inadequate 
linkage of prevention to care (Bhagwanjee et al., 2008)  
 
Since 2012, policies to improve the effectiveness of HIV/AIDS interventions through 
supply-side factors included negotiations to decrease drug prices (Lucchini et al., 
2007: 174)). Other policy options included successful implementation of plans to 
manufacture some of the antiretroviral drugs locally (Business Report, 2012). More 
effective interventions such as PMTCT and HAART have been prioritised and more 
resources have been earmarked for them. Services have been made more 






At the implementation stage however, failure to improve effectiveness has resulted 
from government’s inability to fulfil its coordinating role. For instance, the 
government did not sufficiently mobilise the community around HIV/AIDS; such 
mobilisation has been found to increase effectiveness elsewhere (Oster, 2007). 
Community mobilisation could have raised responsibility among community 
members to deal with the epidemic. In particular, community mobilisation would 
have shifted some HIV/AIDS tasks from medical staff to members of the 
community and taken advantage of the empirical benefits of such a shift (Schneider 
et al., 2008).  Inadequacy in mobilising the community resulted in fewer patients 
being reached.    
 
3.3.2 Demand-side policies  
 
Supply-side deficiencies in policy making deterred the demand for HIV/AIDS 
services. The political attitude in the early 2000s created negative perceptions 
among the population about the benefits of HIV/AIDS services.  A recent study 
cited political equivocation as one of the deterrents to the demand for antiretroviral 
services (Mills, 2008). This political equivocation left its mark on the mind-set of the 
population to the extent that many people still may not believe in the benefits of 
the HIV/AIDS interventions provided by the government.  
 
Supply management as a deterrent to demand for HIV/AIDS services was also 
manifested in the provision of services. The literature in Southern Africa indicates 
that the low morale of medical staff as a result of the burden of patients (Zelinick & 
O’Donnell, 2005) led to a deterioration of services, so that there was less patient 
demand for such  services (Pendukeni; 2004, USAID, 2005). Another study 
indicated that the negative attitude of health care personnel towards HIV/AIDS 
patients played a role in deterring demand for HIV/AIDS services (Yeap et al., 
2010). Policy to deal with this has been limited to regulations but the extent to 
which these regulations have been implemented has not been clarified.  
 
Virus resistance and drug side-effects have been reported as deterrents to demand 





(Yeap et al., 2010). It is not clear how South African policy has responded to virus 
resistance and side-effects. This also applies to the management of serious HIV and 
TB co-infections.  Some policies have been formulated to reduce the impact of co-
infections but the fact that high mortality as a result of HIV and TB co-infection 
persists (O’Donnell et al., 2013) implies that the policy has had little effect at the 
implementation stage.     
 
Poverty, one of the community level factors, is also likely to reduce the 
effectiveness of HIV/AIDS interventions. Poverty has been a deterrent to the use of 
HIV/AIDS services due to hopelessness. Policy to deal with poverty has mainly 
consisted of distributing social grants. However poverty is associated with many 
other factors such as health illiteracy, multiple relationships, gender violence, 
substance abuse, crime and stigma which have been shown to perpetuate infections 
(Gouws, 2010). A study by Kagee (2006) in Cape Town suggested that psychosocial 
factors such as stigma affect individual-level demand for HIV/AIDS services. 
Campaigns against stigma have been launched recently (Culliman, K. & Bodibe, 
2010), but their effectiveness has not yet been demonstrated.  
 
Briefly, the above analysis shows that official policy has focused more on supply-
side than demand-side factors. Furthermore, both supply-side and demand–side 
policies have not been implemented adequately and as a result the effectiveness of 
HIV/AIDS interventions has been limited. Another weakness in HIV/AIDS policy 
concerns the absence of context-specific policies to improve the effectiveness of 
HIV/AIDS interventions.  
   
3.4 Context-specific HIV/AIDS policies    
 
Since epidemiological and socio-economic contexts in South Africa abound with 
demand-side factors in different patterns and to different extents, some policy 
strategies could have worked better in some contexts than in others. This suggests 
that context-specific policies would have improved the effectiveness of HIV/AIDS 






Context-dependent HIV/AIDS response policy recommendations have been 
addressed in the literature for some time (Grassly et al., 2001:1121). The rationale 
is that an HIV/AIDS intervention can have different success rates, depending on 
where it is implemented. Indeed, the extent to which an intervention succeeds 
depends on its net effect, between the risk factors and its own effect in reducing 
the impact. Risk factors are diverse, and range from structural factors (Pronyk et 
al., 2006; Pronyk et al., 2008; Raogupta et al., 2008) to epidemiological factors 
(Geoffard & Phillipson, 1996), environmental factors (Bolton & Talman, 2010) and 
cultural factors (Airhihenbuwa, 2004).  Risk factors have been found to influence 
health theoretically and empirically through their influence on health-seeking 
behaviour and attitudes towards health interventions (Bandura, 1986; Becker, 
1974; Geoffard & Phillipson, 1996) and their linkage with culture (Airhihenbuwa, 
2004). They are consequently expected to be at the centre stage of the differences 
in new infections, sickness and deaths, even in the presence of HIV/AIDS 
interventions. Finding policy responses which deal most appropriately with the 
parameters of a given context would therefore contribute to greater effectiveness.   
 
South Africa is good terrain for context-specific policy in relation to HIV/AIDS 
interventions. The country has a relatively low HIV prevalence context and a 
relatively high prevalence context as defined in this study. South Africa is also 
characterised by stark differences in socio-economic contexts with a very poor rural 
context and a relatively well-off urban context. Policy response tailored to the 
realities in these contexts would improve effectiveness.   
 
Despite the country being good terrain for contextual response to HIV/AIDS, this 
has not been addressed by the policy process.  South Africa has adopted a uniform 
response to HIV/AIDS regardless of the differentiated impact across an LPC and a 
HPC and across a rural context and an urban context.  The response to HIV/AIDS in 
South Africa has taken no account of the fact that factors influencing the 
effectiveness of HIV/AIDS interventions may be specific to these contexts. It has 





differentials in the impact of HIV/AIDS which may persist if HIV/AIDS interventions 
are conducted uniformly regardless of contextualisation.  
 
Contextual HIV/AIDS policy responses in South Africa have addressed the context 
of patients such as gender and age rather than broad geographical contexts. For 
instance, pregnant mothers and children were considered the most vulnerable and 
contextually different from other groups of patients. The policy response to deal 
with such vulnerability and which improved effectiveness consisted of starting them 
on HAART earlier than other patients. In the same vein, patients co-infected with 
HIV and TB were seen as contextually different in terms of vulnerability and 
effectiveness in their treatment was improved by giving them  HAART regardless of 
their CD4 counts (Govender, 2009). Targeting the most vulnerable patients such 
the youth aged 14-24 to increase the effectiveness of interventions in the general 
population has been the norm in other countries. For instance, studies have found 
that it is important to stop infections in women (Laga et al., 2001; Sterling et al., 
2008; Gouws & Abdool Karim, 2010: 56) and youth aged 15-24 (Ross et al., 2010) 
to improve effectiveness in Africa.     
 
While it has commonly been argued that the effectiveness of HIV/AIDS 
interventions may depend on contexts, geographical context-specific policies have 
been absent in South Africa. This study argues that more effectiveness could have 
been achieved by designing more contextual responses. The rationale for this 
argument is that if HIV/AIDS policy responses are tailored to all contextual groups 
of patients, an appropriate policy response tailored to geographical and socio-
economic contexts would have been included to improved effectiveness. Both 
demand-side and supply-side policies have not been very effective because their 
implementation has not been context-specific, yet HIV/AIDS in South Africa has 








Chapter summary  
 
This chapter reviewed HIV/AIDS interventions in South Africa with the aim of 
establishing the extent to which these have been context-specific. It was noted that 
effectiveness in terms of coverage and health outcomes has improved over time but 
there appears to be much room for improvement. One way to improve effectiveness 
is to design geographical and socio-economic context-specific responses. However, 
as the review showed, the extent of such responses has been limited. Although the 
consideration of the effectiveness of HIV/AIDS interventions is one aspect of policy 
making, the joint consideration of cost and effectiveness is an even more important 
aspect of the policy process. The extent to which the joint evidence on cost and 


















Chapter 4 : Cost-effectiveness studies of HIV/AIDS 
interventions in South Africa   
  
This chapter reviews CE studies of HIV/AIDS interventions in South Africa in order 
to identify the gaps in contextual cost-effectiveness analysis. Section one presents 
an overview of CE studies. Section two analyses the extent of CE studies through 
their patterns. Section three assesses whether or not the most relevant CE 
evidence for the country has been made available to policy makers, while section 
four assesses the extent of CE studies of HIV/AIDS interventions across contexts.  
 
4.1 CE studies of HIV/AIDS interventions in South Africa: An overview   
  
Thirty distinct CE studies in the public domain were obtained through a search of 
databases for the period 1995-2012. This section discusses the evolution of CE 
studies as well as the conduct of these studies with a view to identifying gaps in 
relation to contextual cost-effectiveness analysis.  
     
4.1.1 Evolution of CE studies in South Africa  
 
CE studies evolved over time in line with the change in the response to HIV/AIDS. 
This evolution is discussed per category of intervention notably (1) treatment and 
care (2) biomedical prevention and (3) behavioural prevention2  and per date of the 
study.   
  
4.1.1.1 Treatment and care interventions  
 
The earliest CE studies of HIV/AIDS interventions in South Africa were in the 
category of treatment and care interventions, which consisted of non-HAART 
interventions and HAART interventions. The non-HAART studies are shown in Table 
4:1. 
 
                                       






Table 4:1 Summary of CE studies of non-HAART interventions in South Africa 
Evolution of CE 
studies   
 Methodological features  Citation, 
comparison 
number and study 
number3   
Study area  
 
Options compared  
Follow-up  Results  Recommendation   
Cape Town  
no-isoniazid among TB 
infected stratified by 
HIV/AIDS status (0) 






a spread sheet   
 
Isoniazid is cost 
saving, saving R40.6 





isoniazid is the 
better option than no 
isoniazid and does 
not require value 
judgment.  
 
Masobe  et al. 
(1995), (1),  (1)  
Cape town  
 
Pro-test package (0) no 
Pro-test package (1) 
The costs were 
estimated 
based on  
ingredient 
method for  
facility 
participating.  
The cost-per HIV 
infection averted by 
VCT range was 
US$67-US$112, the 
cost per TB case 
prevented by VCT 
range was  US$129-
US$215 for normal 
VCT and US$323-
US$664 for intensified 
case finding. 
Pro-test was cost 
saving. 
Hausler et al. 
(2006) 
  (2), (2)  
South Africa  
No isoniazid (0) 
late isoniazid(1) 
early isoniazid (2) 











Incremental costs per 
life year gained of (1) 





CE judged on basis 
of the national per 
capita income.  
Bachmann (2006)  
(3),     (3) 




the ASSA AIDS 
model   
Direct costs of 
combined intervention 
in 2015 would be R20 
billion  
Low  net cost to 
government  given 
orphanhood, and 
opportunistic 
infections  costs  
saved  
 
Geffen et al. 
(2003) 
(4), (4)  
Hillbrow, Johannesburg 
syndromic management 
with no periodic 
presumptive treatment, 
PPT (0), syndromic 
management with PPT (1) 
Used 
hypothetical 
cohort and a 
mathematical 
model  
CE was US$78/ DALY 
averted. ICER of PPT 
was US$31/DALY 
averted. Initiating PPT 
at 15% prevalence 
level would have 
improved CE by 35% 
Interventions 
targeted at HIV 
prevalence are CE at 
all HIV stages. PPT 
could improve the 
CE of targeted STI 
interventions.  
 





                                       
3 The first and second number of each study in the 5th column of the Table denotes the study comparison and the 
study count respectively. There are more comparisons than studies because some studies made comparisons which 
spanned different categories of interventions. The study comparisons and count are numbered consecutively from 






The table shows that the earliest CE study in this category was a study of non-
HAART interventions by Masobe et al. (1995). This study compared no provision of 
isoniazid (0) with provision of isoniazid (1) among TB patients stratified by 
HIV/AIDS status in Cape Town. The main result of the study was that isoniazid 
saved R40.8 million (about US$4.08 million) in costs over an eight-year period. This 
study was followed by Hausler et al.’s (2006) study in Cape Town which compared 
a no Pro-test package (0) with a Pro-test package (1). The Pro-test package, 
recommended by the World Health Organisation for countries with high HIV/AIDS 
and TB prevalence, included voluntary counselling and testing, screening for TB 
through intensified case findings and provision of isoniazid and cotrimoxazole to 
HIV/AIDS patients to prevent TB. The study’s results were that the cost per HIV 
and TB infection prevented by no Pro-test Package (0) ranged between US$67 and 
US$129 and that the cost per HIV and TB infection averted by Pro-test Package (1) 
ranged between US$112 and US$212. Bachmann (2006)’s study in this category 
compared options to prevent TB with the provision of isoniazid4 and cotrimoxazole 
to TB and HIV/AIDS patients even though the study included CE comparisons of 
HAART. The incremental cost per life-year gained for various options compared with 
no isoniazid (0) ranged from US$17 to US$1,104.   
 
Up to 2003, the CE of treating sexually transmitted infections had not been 
estimated. Geffen et al. (2003) was the first study to carry out such estimation. 
Evaluating the costs and health outcomes of the intervention alongside the costs 
and health outcomes of  VCT, PMTCT and HAART, the study estimated  that by the 
year 2015, these interventions would cost up to R20 billion(about US$2 billion). 
While this study evaluated the CE of the intervention alongside other interventions, 
specific CE evidence on treating sexually transmitted infections was provided by 
Vickerman et al. (2006 a). This study compared the CE of syndromic management 
with no periodic presumptive treatment (0) and syndromic management with 
periodic presumptive treatment (1). In this study, STIs were treated in one group 
of patients based on observed symptoms for every period of treatment, and on 
                                       
4 Isoniazid is an antibiotic used to treat tuberculosis by killing the bacteria which cause the 
disease while cotrimoxazole eliminates bacteria that cause various infections. In the context 





presumed symptoms in another group of patients. The study reported that the 
additional cost per DALY averted by syndromic management with periodic 
presumptive treatment (1) was US$31. It concluded that syndromic management 
with periodic presumptive treatment (1) was cost-effective. The study further 
observed that targeting syndromic management with periodic presumptive 
treatment (1) at higher HIV prevalence levels would improve the CE of the 
intervention. 
 
While the CE study of non-HAART dates back to 1995, the first CE study of HAART 



























Table 4:2 Summary of CE studies of HAART in South Africa up to 2005  
Evolution of CE 
studies   







Options compared  
Follow-up  Results  Recommendatio
n   
Baseline (generic 
medication, baseline 
testing and visit costs (1), 
Higher proportion of 
doctors’ visits (2),  
patent medicine pricing 
scenario (3),   second line 
treatment offered to 50% 
(4), combination of 
scenarios  2 and 3 (5) 
second line treatment to 
75% with  scenario 2, 3 
and 4 (6), scenario 2 and 










Sans Frontières  
cohort studies  
 
 
Cost per life year 
gained is R5,923 


















(6),  (6)  
South Africa  
 
No HAART(0)   
 
HAART (1) 
Used the AIDS 
model of the 
Actuarial 
Society of South 
Africa 
Direct costs of 
combined intervention 
in 2015 would be R20 
billion 












 (7)   (7) 
Cape Town  
 






similar to the 
population of 
patients in three 
dedicated clinics 
in  Khayelitsha  
modelled with 
Markov model  
HAART cost R13,754 
per QALY gained; no 
HAART cost R14,189 
per QALY gained The 
incremental cost per 
QALY gained on 
HAART was R13,621. 
Lifetime costs were 
however significant  














(8) ,  (7) 
South Africa:  
 
Prevention only (0) 
HAART  linked to 
prevention in the case  of 
reduced price (1)  
 
 
AIDS model of 
the Actuarial 
Society of South 
Africa  
Decrease in risk 
behaviours  and 
infectivity reduction 
for those on 
treatment  make 
















(10), (9)  
 
                                       
5 The first and second number of each study in the 5th column of the Table denotes the study comparison and the 
study count respectively. There are more comparisons than studies because some studies made comparisons which 
spanned different categories of interventions. The study comparisons and count are numbered consecutively from 







Table 4:2 shows that earlier studies on the CE of HAART focused on comparing 
HAART versus no HAART. Boulle et al. (2002) was the first study in this category. 
This study compared eight different scenarios of providing antiretroviral drugs to a 
limited segment (10%) of the adult HIV/AIDS population in South Africa. It 
examined the scenarios of changing the type of antiretroviral drugs, the number of 
doctors’ visits, proportion of patients receiving second line drugs, and some 
combination of these scenarios. The cost per life-year gained by each scenario over 
the others ranged from US$908 to US$1,814.  
 
Geffen et al. (2003) provided the next study which evaluated the costs and health 
benefits of HAART although the evaluation included other major HIV/AIDS 
interventions, notably VCT, STD, and PMTCT. The study projected the direct costs 
of HAART and other interventions at R20 billion (about US$2 billion) by the year 
2015. 
 
As cohort data on cost and effectiveness of HAART became available from pilot 
facilities in Cape Town, CE studies comparing HAART (1) versus no HAART (0) used 
such data (Cleary et al., 2004). The results of the study showed that the 
incremental cost per QALY gained on HAART was R13, 621 (about US$1,362). The 
study concluded that HAART was efficient in economic terms and should be pursued 
even though it observed that lifetime cost of HAART would be significant.  
 
In this category of studies, Nattrass & Geffen (2005) compared prevention alone 
(0) and prevention linked to HAART (1) and introduced the effect of the decrease in 
the price of antiretrovirals in this comparison. The study showed that prevention 
linked to HAART (1) was cost-effective and argued against prevention alone (0), 
which had been advocated for developing countries (Marseille et al., 2002).  
 
 
CE studies using pilot sites data and modelling to compare HAART (1) versus no 
HAART (0) continued after 2005 as shown in Table 4.3 (Cleary et al., 2006; Badri et 






Table 4:3  Summary of CE studies of HAART in South Africa after 2005 
 
Evolution of 
CE studies   







Options compared  
Follow-up  Results  Recommendation   
 
Cape Town:  
 









Cost per QALY gained 
of ARV over non ARV 
was  US$1,102 per 
QALY gained and 









Cape Town:  
 





patients in Cape 
Town AIDS cohort 
patients  
 
Incremental cost per 
life year gained from 
HAART over no 
HAART was US$1,342 
per patient year 
under current pricing 
scenario and US$793 
under reduced cost 
scenario. 
 
HAART was judged 
cost effective on 
the basis that each 
intervention which 
achieved less than 
twice per capita 
income (US$6,960 
at the time of the 











One of these studies (Badri et al., 2006) included sensitivity analysis results on 
pricing scenarios to take into account anticipated trends in the decrease in drug 
prices at the time. Cleary et al.’s (2006) study found that the incremental cost per 
QALY gained by  HAART intervention (1) compared with no HAART (0) was R13,624 
(about US$ 1,362) while  Badri et al. (2006) reported that the  incremental cost per 
life year gained by HAART intervention (1) compared with no HAART (0) was 
US$1,342.   
 
Another type of CE comparison, CE comparison of HAART timing, emerged in 2006 
as shown in Table 4.4.  
 
                                       
6 The first and second number of each study in the 5th column of the Table denotes the study comparison and the 
study count respectively. There are more comparisons than studies because some studies made comparisons which 
spanned different categories of interventions. The study comparisons and count are numbered consecutively from 







Table 4:4  Summary of CE studies of timing of HAART interventions in South Africa 
Evolution 
of CE 
studies   







Options compared  
Follow-up  Results  Recommendation   
South Africa:  
 
No intervention (0) 
Early ARV (1) 





Markov model  
 
ICER of (1) and (2) over (0) 
is US$2,817 and US$2,443 
per QALY gained  
 











No HAART(0),  
Initiating  
HAART at CD4 
count 200(1), 
initiating HAART at 
CD4 between 200-
50 (2),  and 
initiating  
HAART at CD4  








Markov model  
HAART at CD4 200 had 
ICER of US$54/QALY over 
no HAART; HAART at CD4 
200-350 had an ICER of US 
$616 over HAART at CD4 
count 200; HAART at CD4 
count >350 had an ICER of 
US$1,137 over HAART at 














Badri et al. 
(2006) 
(12), (10)  
 
One of these studies, Bachmann (2006), compared the CE of starting treatment 
early (1), that is, at a CD count threshold of 350 and starting treatment late (2), 
that is, at a CD4 count threshold of 200. The study found that, relative to no 
treatment (0), the incremental cost per QALY gained was US$2,817 for starting 
treatment early (1) and the incremental cost per QALY gained was US$2,443 for 
starting treatment late (2). The study argued that early timing and late timing of 
treatment were both cost-effective. Therefore, even late treatment is better than no 
treatment. 
 
Badri et al. (2006) was a related study which adopted a stratified approach. It 
analysed the CE of timing of HAART by comparing the CE in several strata of 
starting treatment. These strata were: starting treatment at a CD4 count threshold 
of 200 (1), at a CD4 count threshold between 200 and 350 (2), and at a CD4 count 
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threshold greater than 350 (3), while including no HAART (0) as a baseline 
intervention. Relative to no HAART (0), the ICER per QALY gained of starting 
treatment at a CD4 count threshold of 200 (1) was US$54. Relative to starting 
treatment at a CD4 count threshold of 200 (1) the ICER per QALY gained of starting 
treatment at a CD4 count threshold between 200 and 350 (2) was US$616. Relative 
to starting treatment at a CD4 count threshold between 200 and 350 (2), the ICER 
per QALY of starting treatment at a CD4 count threshold greater than 350 (3) was 
US$1,132. 
 
As HAART rollout evolved, so did studies to inform policy makers of CE options. 



















 Table 4:5 Summary of CE studies of HAART interventions in South Africa since 2008 
Evolution 
of CE 
studies   








Option compared  
Follow-up  Results  Recommendation   
Cape Town:  
 
 No HAART(0), 
HAART with first 
line only(1) 
HAART with first 
and second line 






from a cohort 
in Khayelitsha  
 
First line costs US$795 relative 
to no HAART, First and second 
line costs US$1,625 relative to 
first line. If the budget is S10 
billion only first line is 
efficient. If the budget is 10-
12 billion (3) is efficient  
Concluded that it is 
important to 
consider both 
efficiency and CE 
to better guide 














CD4 and viral 
load based 








Monitoring CD4 counts relative 
to monitoring symptoms 
resulted in lifetime cost 
savings of US $464 per person 
while increasing life 
expectancy by 4 months. 
Monitoring CD4 and viral load 
had an ICER of US$5,414 per 



















South Africa:  
 
Current screening 
practice (0),   
one time 
screening (1),   
screening every 5 






CEPAC model  
ICER US$1,570/QALY for 
screening every 5 years over 
current practice ECER of 
US$1,720/QALY over current 
practice.  
Annual screening is 
very cost-effective 
based on the 









 South Africa 
 
Treatment at CD4 
count 200 (0), 
treatment at CD4 
count 350 (1), 
treatment at CD4 
count 500 (3), 
treating at all CD 







South Africa  
Compared with current 
scenario expanding to <500 
prevents additional 583,000 
new infections in 5 years and 
3 million new infections over 
40 years  
Increasing the 














Prior to 2008, no CE comparison had assessed the question of the budgetary 
requirements of each HAART. By comparing no HAART (0), HAART with first line 
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only (1), and HAART with first and second line (3) while including budgetary 
analysis, Cleary et al. (2008) contributed to the evidence regarding the effect of the 
budget on the cost-effectiveness of HIV/AIDS interventions. They showed that with 
a budget of US$10 billion, HAART with first line only (1) would be cost-effective 
while with a budget of between US$10 and US$12 billion; HAART with first and 
second line (3) would be cost-effective.  
 
Other questions regarding HAART concerned inefficiency in screening methods. 
Bendavid et al. (2008) contributed to the evidence in this respect by comparing 
screening of HIV/AIDS patients for HAART based on symptoms (0), screening based 
on CD4 counts (1), and screening based on both CD4 counts and viral load (2). 
They found that relative to screening of HIV/AIDS patients for HAART based on 
symptoms (0) screening based on CD4 counts (1) resulted in lifetime cost-savings 
of US$464 per person while screening based on both CD4 counts and viral load (2) 
had an ICER of US$5,414 per life year gained over (1).  
 
The study of the CE of screening for HIV infections is important as it facilitates 
linking patients to HAART. This first appeared in the literature in 2011. Walensky et 
al. (2011) compared the CE of different options to screen for HIV infection. The 
comparison included current screening practice (0), one time screening (1), 
screening every five years (3), and annual screening (4). It study found that the 
incremental cost per QALY gained of screening every five years and annual 
screening (4) relative to current screening practice (0), was US$1,570.  
 
The earlier treatment policy adopted by the South African Government in 2011 
stimulated further CE analysis in 2012. Rather than focusing on the benefits of 
treatment in terms of AIDS and deaths reduction, Granich et al. (2012) focused on 
the preventative benefits of treatment in terms of new infections averted over the 
short term (5 years) and long term (40 years). The prevention benefits were 
compared for starting HAART at CD4 count of 200 (0), at CD4 counts of 350 (1), at 
CD4 counts of 500 (2), and at all levels of CD4 counts (3).  The study found that 





CD4 counts (3) prevented an additional new infections of 583,000 over 5 years and 
3 million new HIV infections over 40 years.  
 
4.1.1.2 Biomedical prevention interventions 
 
PMTCT emerged earlier in the literature in the biomedical interventions category 
(PMTCT, HAART prophylaxis, microbicides, and condom usage). The evolution of the 
CE of PMTCT followed a series of randomised clinical trials in developed and 
developing countries9. These trials had shown that provision of HAART to mother 
and infant, at specific times during pregnancy and after birth, significantly reduced 
HIV transmission to the infant (from 66% to 50%). Table 4.6 shows CE studies of 











                                       
9 The first trial in this series was the Multi-Centre AIDS Clinical Trials Groups (ACTG 076) conducted in France and 
the United States. This trial, which involved providing Zidovudine to pregnant women from week 14 until the time 
of delivery reduced infection by 66%. Participants in the trial were non-breastfeeding women and its relevance to 
low income countries was limited due to the duration of the therapy (costly at that time) and the fact that the 
majority of women in low income countries rely on breastfeeding. The efficacy of a shorter trial in Thailand 
(reduction of infection by 50%) which consisted of Zidovudine twice daily from week 36 of pregnancy and every 
three hours from the onset of labour until delivery provided hope (Shaffer et al., 1999) but this was still considered 
unaffordable and not relevant to breastfeeding women. Trials on this type of patient in Cote d ’ Ivoire and Burkina 
Faso (women with an oral regime of Zidovudine  twice daily, a single oral dose  at the onset of labour and 7 days of 
Zidovudine twice daily after birth) reduced transmission by 38% (Dabis et al., 1999) while in Uganda, HIVNET012, 
which consisted of a single dose of Zidovudine to the mother at week 36, a single dose of Nevirapine (NVP) at the 
onset of labour, a  dose of Zidovudine every three hours during labour, and  a single dose of nevirapine to the 












Evolution of CE 
studies   








 Methods  Results  Recommendatio
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The study by Wilkinson et al. (1998), which was the first to compare the CE of 
some PMTCT trial options, used data on pregnant women in Hlabisa, a rural area in 
KwaZulu-Natal. The options compared were: no PMTCT (0), provision of Zidovudine 
with current infrastructure (1), and provision of Zidovudine with enhanced 
infrastructure (2).  The results of the study were that relative to no PMTCT (0), 
provision of Zidovudine with current infrastructure (1) reduced HIV infections by 
15% at a total cost of US$574,825, while provision of Zidovudine with enhanced 
infrastructure (2) reduced infections by 47% at a total cost of US$764,901. 
Wilkinson et al.’s (1998) study was based on trials conducted in developed 
countries which had been deemed inappropriate to conditions in the developing 
world. Soderlund et al. (1999) supplemented the evidence on the CE of PMTCT by 
comparing several short-term options such as ARV with breastfeeding and ARV 
without breastfeeding to provide PMTCT; and found that options with formula 
feeding were the most cost-effective.  
 
While Soderlund et al. (1999) compared the CE of such options on hypothetical 
cohorts of 20,000 pregnancies; Wilkinson et al. (2000) modelled the CE of a short 
course of Zidovudine with formula milk for four months nationwide (1), comparing 
this option with no PMTCT (0). The study found that without PMTCT (0), 63,397 
infections would occur annually. They further estimated that averting these 
infections with PMTCT (1) would cost R155.9 million (about US$17 million).  
 
A related study by Wood et al. (2000) compared different scenarios of PMTCT 
rollout nationwide, notably no PMTCT (0), 25% of PMTCT coverage (1), 75% 
coverage (3) and 100% PMTCT coverage (4). According to the study results, 
110,000 HIV-positive births could be prevented by a short course of antiretroviral 
therapy. Table 4.7 summarises CE studies of PMTCT, which focused on more 
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week 20,  (0) and 
early and late 
pregnancy 
screening (week 
20, and 34 or 36)  



























(24)  (21)  
 
These analyses focused on the costs of government’s refusal to provide PMTCT and 
how many times and when HIV screening of pregnant women on PMTCT should be 
done to maximise the benefits of the intervention. In this respect, Skordis and 
Nattrass (2002) estimated that the cost of infant infections in terms of social 
assistance and treatment of opportunistic infections, which the government was 
compelled to pay for by law, outweighed the cost of PMTCT. They argued that the 
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government’s refusal to implement PMTCT meant paying (for the treatment of 
opportunistic infections and social assistance) to waste lives (Skordis & Nattrass, 
2002:1). Their arguments were confirmed to some extent by Geffen et al. (2003), 
who estimated that significant costs of treating opportunistic infections would be 
saved if PMTCT was run at coverage of 90% alongside other major HIV/AIDS 
interventions.  
 
While the CE of PMTCT in the above studies was based on once-off screening for 
HIV/AIDS at week 20 of pregnancy, Soorapath et al. (2006) argued that HIV 
infections that could not be detected at week 20 could be detected later in the 
pregnancy. This led them to compare the CE of screening once in week 20 of 
pregnancy (0) and screening twice, in week 20 of pregnancy and later during the 
pregnancy (1). The study found that rescreening was cost-effective whether or not 
HAART was sufficiently available. Table 4.8 shows CE studies of other biomedical 
interventions, notably condom usage, circumcision, and antiretroviral drugs 





















Table 4:8 Summary of CE studies of other biomedical prevention interventions in South Africa 
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The earliest study comparing the CE of condom usage was conducted by Marseille 
et al. (2001) who compared the CE of using male condoms only (0) and using both 
male and female condoms (1), among casual sex workers in Mpumalanga. Marseille 
et al. (2001) found that using both male and female condoms (1) would generate a 
net saving of US$5,421 at a prevalence rate of 25%.  A related study by Dowdy et 
al. (2006) was conducted at international level and involved South Africa and Brazil. 
This study compared the CE of using male condoms only (0) and using both male 
condoms and nitrile female condoms (1). The results of the study showed that 
using both male and female condoms was more cost-effective in South Africa than 
it was in Brazil.   
 
Kahn et al. (2006) examined the CE of circumcision.  Using data from Orange Farm 
in Gauteng, the study compared the CE of no adult male circumcision (0) and adult 
male circumcision (1). It found that relative to no adult male circumcision (0), the 
incremental cost per infection averted by adult male circumcision (1) would be 
$181 with an HIV prevalence rate of 25%. Although their study, like other studies 
elsewhere, showed that it was cost-effective to circumcise adult men, the 
intervention recommendation was made against the backdrop of a likely increase in 
risky behaviour among circumcised men.  
 
The CE of treatment of other sexually transmitted diseases, which has been rather 
less controversial, was investigated by Vickerman et al. (2006). The study 
compared the CE of syndromic management without periodic presumptive 
treatment (0) and syndromic management with periodic presumptive treatment 
(1). It found that, relative to syndromic management without periodic presumptive 
treatment (0), the incremental cost per DALY averted by syndromic management 
with periodic presumptive treatment (1) was US$31. 
 
Other CE studies on biomedical prevention interventions compared the CE of 
providing antiretrovirals to people who are more exposed to HIV infections. In this 
regard, Christofides et al. (2006) compared the CE of not providing antiretroviral 





(0) and providing antiretroviral drugs prophylaxis to a person after being raped (1). 
The study found that the cost-saving of post-exposure prophylaxis (1) relative to no 
post-exposure prophylaxis (0) would be US$31,630 per case of HIV infection 
averted. In 2010, CE studies of other biomedical interventions were conducted on 
pre-exposure prophylaxis and microbicides as shown in Table 4.9.  
 
Table 4:9  Summary of CE studies of other biomedical prevention interventions in South Africa 
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(31), (28)  
 
Pretorius et al. (2010) compared no provision of antiretroviral drugs to a person 
exposed to risks such as needle pricks, that is, no pre-exposure provision of 
                                       
13 The first and second number of each study in the 5th column of the Table denotes the study comparison and the 
study count respectively. There are more comparisons than studies because some studies made comparisons which 
spanned different categories of interventions. The study comparisons and count are numbered consecutively from 






antiretroviral drugs (0) and pre-exposure provision of antiretroviral drugs (1). The 
study found that pre-exposure provision of antiretroviral drugs (1) targeted at age 
15-35 years old would avert 10 to 15% of HIV infections.  
 
Verguet & Walsh (2010) focused on the CE of using microbicides.  Microbicides are 
chemical ointments which are applied by women prior to sexual intercourse to 
protect them from infection. However the effectiveness of microbicides in 
randomised controlled trials has been disappointing. Verguet & Walsh (2010) 
estimated the CE of not using microbicides (0) and the CE of using microbicides (1) 
comparing these results in South Africa and in the US. The comparison of the 
results showed that using microbicides (1) was more cost-effective in South Africa 
than it was in the US.  
 
4.1.1.3 Behavioural prevention interventions   
 
Despite behavioural HIV/AIDS prevention interventions being the earliest HIV/AIDS 
interventions category, the review unearthed only a few CE studies, most of which 
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(2011)  
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The earliest study in the reviewed period is the study by Muirhead et al. (2001) 
which compared the CE of the 4th Soul City series. This was a multi-media 
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campaign to provide education about HIV/AIDS. In evaluating the CE of this 
intervention, Muirhead et al. (2001) compared the CE of no 4th Soul City series (0) 
and the 4th Soul City series (1). The cost per change in the knowledge of HIV/AIDS 
was estimated to be very low. 
 
While this study was conducted in the early 2000s, the remaining studies on 
behavioural prevention interventions are very recent. One such study by Jan et al. 
(2011) compared the CE of no Intervention with Microfinance for AIDS and Gender 
Equity that is, no IMAGE (0) and IMAGE (1).  Relative to no IMAGE (0), the 
incremental cost per intimate partner violence averted by IMAGE (1) was US$711.  
Another study by Walensky et al. (2011) analysed VCT by comparing the CE of 
current screening practice (0), one time screening (1), screening every five years 
(3)  and annual screening (4). The study found that the incremental cost per QALY 
gained of annual screening (4) relative to the current screening practice (0) was 
US$1,570.  
 
With regard to how these HIV/AIDS interventions’ options were compared, Tables 
4:1 to Table 4.10 above provided a summary of the CE comparison of each 
category of HIV/AIDS interventions but did not provide details on how cost and 
effectiveness were analysed. This is discussed in the next section.     
 
4.1.2 Methodology of CE studies in South Africa  
    
In analysing the cost and effectiveness of HIV/AIDS interventions, the CE studies in 
South Africa defined, for each of the compared interventions, the characteristics of 
patients, how the follow-up was done, how the cost and effectiveness were 
measured, and the criteria that formed the basis for the recommendation of any 
HIV/AIDS intervention. Table 4:11 shows that, CE analysis in South Africa complied 








Table 4:11 Descriptive summary of the conduct of CE studies of HIV/AIDS interventions in South Africa 




   
-Followed up actual population of patients  
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-Sites as sources of baseline information  
-The literature as a source of baseline 
information  
-The perspective of analysis defined  
-Government perspective  
-Included societal perspective  
-Discount of costs were explicitly referred to  
-3% per cent  discount rate was applied  
-Exclusive use of  partial measures of health  
-Included at least multidimensional health 
measure (DALY, QALYs) 
-The cost were measured in international dollars   
60% of  reviewed studies  
30% of  reviewed studies  
90% of all studies  
90% of reviewed studies  
20% of reviewed studies   
70% of all studies  
70% of studies reporting discount rate  
20% of all studies  
 
60% of all studies  
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-Result reported using  ICER   
-Generalisation by sensitivity analysis  
-Generalisation by changing selected variables 
(one-way, two-way, multi-way sensitivity 
analysis)  
-Generalisation by changing all variables  
90%  of reviewed studies  
100% of reviewed studies  
 
 
40% of all studies  




recommendation   
-Indicated the basis for CE recommendations  
-Basis was the willingness to pay  
-The basis was affordability (portion of budget)  
-The basis was CER threshold by WHO  
60% of reviewed studies  
35% of all studies with a recommendation basis  
10% of all studies with a recommendation basis  






Briefly, CE analysis consists of a systematic assessment of both the cost and 
effectiveness in terms of the health outcomes of alternative HIV/AIDS policy 
options for consideration by policy makers (Drummond et al, 2005:15). The 
options usually involve the baseline intervention or the comparator such as 
those noted (0) in Tables 4:1-to 4:10, with which the proposed HIV/AIDS 
intervention is compared. CEA considers the proposed HIV/AIDS intervention to 
be cost-effective (worthwhile) if the additional health benefits are worth the 
additional costs, reported in terms of the ratio of additional costs to additional 
effectiveness; this is known as the incremental CE ratio (ICER). The worthiness 
of the intervention is based on established ICER thresholds, on cost per unit of 
health benefits usually expended on related health care interventions, the 
portion of the budget the intervention requires, and on the cost-saving nature of 
the intervention (the intervention costs less than the comparator for the same 
effectiveness). The role of CEA in policy making is limited at the proposal stage 
to the ultimate decision on whether to select the proposed HIV/AIDS 
intervention or the comparator. This is the prerogative of the policy maker, who 
has to make a decision based on many considerations such as ethical issues, 
budgetary requirements, and political interests. 
 
In assessing the costs and effectiveness of HIV/AIDS interventions, CE studies in 
South Africa followed up patients in each of the compared HIV/AIDS 
interventions by either observing costs and effectiveness in an actual population 
of patients or modelling such costs on a hypothetical population of patients. It is 
noted that 90% of the reviewed studies followed up a hypothetical population of 
patients using models which assumed the proportion of patients in HIV stages 
over time; these assumptions formed the basis of the measurement of costs and 
effectiveness. The most common models used were decision tree, CE of 
preventing AIDS complications (CEPAC), Markov states transition models, and 
population projection models. Of the modelled CE studies, 60% of the costs and 
effectiveness data were based mainly on baseline information from cohort sites, 
while the rest were based on evidence from the literature. While the estimation 
of costs in each of the modelled HIV/AIDS interventions used evidence on costs 
and effectiveness in HIV stages from the literature, some studies made 
estimations based on data observed at some sites (for example, Cleary et al., 






Regarding the analysis of costs, the studies in South Africa took account of the 
fact that the cost to be included depended on the perspective of the funder. 
Ninety percent (90%) of CE studies of HIV/AIDS interventions in South Africa 
clarified the perspectives of the analysis. The government or public sector 
perspective was the most considered in CE studies.  Of the studies reviewed, a 
small percentage (20%) included analysis that took account of the costs to 
society despite the recommendations of the panel of experts in CEA to consider 
such costs (Gold et al., 1996). With regard to the time preference of HIV/AIDS 
interventions, 70% of the studies reported on discounting. Of these studies, 
70% applied a discount rate of 3% as recommended by the panel of experts in 
CEA (Gold et al., 1996).  Finally, 90% of the reviewed studies reported costs in 
international Dollars or US$ to allow for comparison with the results of other 
studies.    
 
Measures of effectiveness ranged from output measures, to intermediate 
measures and final measures. Output measures consisted of condom distribution 
(see Marseille et al., 2001 for example), while intermediate measures consisted 
of infections averted (see Hausler et al., 2006 for example) and final measures 
consisted of life-years gained, QALYs gained or DALYs averted (see Bachmann et 
al., 2006 for instance). Of the reviewed studies 20% exclusively used partial 
measures of effectiveness, whilst 60% used at least a multi-dimensional 
measure of effectiveness such as DALY or QALYs as recommended by the panel 
of experts in CEA (Gold et al., 1996). QALYs are measures where the quality of 
life is applied (% of perfect health) to the total number of years in each HIV 
stage to give the total number of years of perfect health (QALYs) achieved by an 
HIV/AIDS intervention, while disability weight (% of perfect health lost) is 
applied to total number of years in a health state to determine the total number 
of perfect years lost (DALYs) in each HIV/AIDS intervention.  
 
The results of CE studies in South Africa were generalised to the population by 
conducting sensitivity analysis on uncertain parameters. Of the reported results, 
60% were generalised on the basis of the sensitivity of the results to changes in 
selected parameters such as exchange rate, whilst 40% were generalised on the 






Studies in South Africa used many criteria to recommend HIV/AIDS 
interventions as cost-effective to policy makers. These criteria consisted of the 
willingness to pay (the cost per effectiveness comparable to the cost usually paid 
by policy makers for other health care interventions) or CE thresholds suggested 
by experts. Other criteria were the extent to which an HIV/AIDS intervention 
was affordable or the extent to which it absorbed available budget.   
 
Of the studies reviewed, 35% recommended HIV/AIDS interventions on the 
basis of the cost of related health care interventions. Wilkinson et al. (2000), for 
instance, indicated that PMTCT, which cost US$17 per DALY averted in KZN and 
US$46 per DALY averted in the Western Cape was cost-effective as the cost was 
in line with the cost of other HIV/AIDS interventions such as immunisation, 
which cost US$25-30 and family planning, which cost US$100-150 per DALY 
averted.  
 
While 35% of the reviewed studies recommended HIV/AIDS interventions on the 
basis of the CE of related health care interventions, 20% of the reviewed studies 
recommended HIV/AIDS interventions on the basis of CE thresholds suggested 
by the WHO. These CE thresholds consisted of estimates of cost per life-year 
gained or per DALY avoided. Using life-years gained as health outcome 
measures, the WHO estimated that any health care intervention with CE 
estimates below a CE threshold of US$100 per life-year gained (WHO, 2002) is 
cost-effective, while using DALY, the WHO estimated that an intervention is 
“cost-effective” if its cost per DALY is less than three times GDP per capita and 
“highly cost-effective” if its cost per DALY is less than GDP per capita (WHO, 
2003). 
 
For example, based on the WHO criteria, Geffen et al. (2000) indicated that 
PMTCT was cost-effective because the cost per life-year gained was less than 
US$100. Moreover, Jan et al. (2011) found the cost per DALY averted of 
US$7,688 in a trial intervention and US$2,307 in a large scale-up of the trial to 
be cost-effective and highly cost-effective, respectively on the basis of the WHO 






Other studies recommended HIV/AIDS interventions on the basis of their 
affordability or the portion of the budget absorbed by such an intervention. 
Wilkinson et al. (2000) suggested that PMTCT would be cost-effective since it 
would absorb only 1% of the health budget or US$0.49 per person living in 
South Africa. While a number of studies recommended HIV/AIDS interventions, 
it is important to note that a significant number of reviewed studies (60%) 
recommended these interventions as cost-effective without specifying the 
criteria which guided their recommendations. Such studies include Verguet & 
Walsh (2010), among many others. 
 
With regard to how the results were reported, the ICER was the most common 
reported statistic. The ICER is calculated as the ratio of the difference in costs to 
the difference in effectiveness for two interventions: the HIV/AIDS intervention 
under analysis and the comparator. The ranges of ICERs per measure of 
effectiveness in reviewed studies comparing no HIV/AIDS intervention (0) and 

































Table 4:12 Summary of ICERs per effectiveness measure and per type of HIV/AIDS intervention 
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(2006); Bachman (2006);  
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Jan et al.(2011) 
These results are compiled from the summary of CE studies results in Table 4.1 to 4.10. Source of data are 
indicated in the text. The sign “–“means that estimates are not available in the reviewed literature. 
 
Despite the WHO (2003) recommending such comparison (2003), Table 4:12 
shows that only a few of the reviewed studies compared the CE of HIV/AIDS 
interventions (1) relative to no HIV/AIDS interventions (0). Furthermore, the 
table shows that a very limited number of studies reported the ICER in terms of 
recommended multi-dimensional measures of effectiveness (QALYs and DALYs). 
This deficiency in the evidence makes it difficult to compare HIV/AIDS 
interventions nationally and internationally.    
 
In terms of ICER estimates per type of HIV/AIDS intervention, Table 4:12 shows 
that these estimates varied considerably. For non–HAART treatment 
interventions, the ICER per life-year gained relative to no intervention ranged 
from US$17-US$244 (Bachmann, 2006). For the same category of HIV/AIDS 
interventions, the ICER per DALY avoided ranged from US$31 to US$78 
(Vickerman et al., 2006). Per infection averted, the ICER of non-HAART 






For HAART, the incremental cost per QALY gained ranged from US$54 (Badri et 
al., 2006) to US$1,701 (Cleary et al., 2006). The incremental cost per life-year 
gained ranged from US$908 to US$2,443 (Bachman, 2006; Boulle et al., 2002; 
Badri et al., 2006). For PMTCT, the incremental cost per DALY averted ranged 
from US$54-57 (Wilkinson et al., 2000). The incremental cost per infection 
averted ranged from US$1,484 to US$3,845 for PMTCT (Wilkinson et al., 2000).  
 
 
4.2 Patterns of cost effectiveness studies    
 
Despite some CE evidence on HIV/AIDS interventions in South Africa, an 
analysis of the studies’ patterns, in terms of their coverage of different types of 
HIV/AIDS interventions, the timing of the studies and the type of cost and 
effectiveness evidence used, shows that policy makers in South Africa were not 
provided with sufficient CE evidence. In terms of the type of HIV/AIDS 
interventions covered, the review found that the evidence was not sufficient as 
some HIV/AIDS interventions were understudied. In terms of timing, the 
evidence has been insufficient because it was not presented to policy makers at 
the relevant time, while in terms of the type of evidence used by the studies, 
most relied on observational cost and effectiveness data in pilot facilities in some 
provinces rather than on national, representative randomised data. Table 4:13 

















 Table 4:13  Patterns of Cost-effectiveness evidence in South Africa 
Interventions  Number of study 
and percentage  
Type of intervention  
Prevention 
Treatment and care 
Total  
 
Biomedical prevention interventions 
Behavioural prevention interventions 
Total  
 
Biomedical prevention (PMTCT) 
Other biomedical prevention  
 
HAART-based treatment and care 
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Biomedical prevention interventions 
Behavioural prevention interventions   
Treatment with HAART intervention  
Biomedical prevention  interventions  
Behavioural prevention interventions 
Treatment with HAART intervention  
 
Biomedical prevention interventions  
Behavioural  prevention 
 interventions 
Treatment with HAART intervention  
 
Type of evidence  
 
 Type of intervention  
Per type of evidence site 
 
One-site  evidence 
Multiple-site evidence  
 
Randomness status of the data 
 




















Source: Reviewed studies in Tables 4.1 to 4.10. 
 
As Table 4:13 shows, the patterns of the coverage of HIV/AIDS interventions are 
such that policy makers did not receive sufficient CE evidence on some of these 
interventions. Despite a fair coverage of HIV/AIDS prevention and treatment 
interventions by CE studies (51% versus 49%, respectively) over the period of 
review, Table 4:13 shows that the evidence was relatively insufficient for some 
interventions in each category. For instance, CE studies of biomedical prevention 
interventions represented 77% of all studies on prevention interventions, 






An insufficiency of evidence is also noted for biomedical prevention interventions 
(condom usage, prophylaxis, microbicides, circumcision, treatment of STDs) 
other than PMTCT. A review of the evidence revealed that more than half of the 
studies (54%) in the category of biomedical prevention interventions were 
conducted on the CE of PMTCT. Within the treatment and care category, the 
evidence on the CE of HIV/AIDS care is relatively deficient when compared with 
the CE evidence on HAART, which accounts for 60% of the CE evidence produced 
for HIV/AIDS treatment and care.    
 
Furthermore, the patterns of the timing of CE evidence in Table 4:13 indicate 
that policy makers in South Africa were not exposed to CE evidence at relevant 
times. In particular, not only was there little CE evidence on behavioural 
interventions, but the evidence that was available reached policy makers too 
late. As shown in Table 4:13, no CE studies of behavioural prevention 
intervention were conducted before 2000, despite such interventions dominating 
HIV/AIDS responses at the time. Even during the period 2001-2008, CE studies 
of behavioural prevention interventions remained sparse, with only one such 
study, representing 10% of all CE evidence on prevention interventions during 
this period. CE studies of behavioural interventions,  such as Walensky et al. 
(2011) and Jan et al. (2011) who analysed the CE of VCT nationwide and the CE 
of combining microfinance and HIV/AIDS training in Limpopo, respectively, were 
conducted very recently. Despite the fact that CE studies of behavioural 
prevention interventions would have been useful in providing CE evidence on 
efficient ways of influencing risky behaviours in the early days of the epidemic, 
this evidence emerged when it was too late.  
 
The limitation of the evidence in terms of the patterns of the studies’ timing is 
also noted in studies of HAART interventions. While 85% of the CE studies of 
HAART took place in the period 2002-2008 when they were most needed, the 
decrease in the rate of HAART studies since 2008, despite the evolution of the 
guidelines for HAART interventions, points to the limitations of the evidence. 
Only two studies in the public domain, Walensky et al. (2011) and Granich et al. 






Finally, the patterns of the evidence on cost and effectiveness, which tended to 
be facility-specific and region-specific, resulted in policy makers receiving 
evidence which was not representative of the whole country even though it was 
useful at provincial or local level.  An analysis of the cost and effectiveness 
evidence patterns reveals that 89% of the studies used cohort data from one 
site as baseline information to argue the efficiency of the intervention, 
sometimes at national level (see Wilkinson et al., 2000 for one example). 
Furthermore, especially for HAART, such data were relevant to high HIV 
prevalence provinces such as KZN (Boulle et al., 2002,) or in provinces where 
the cohort sites were based, notably the Western Cape (Cleary et al., 2004, 
2006; Badri et al., 2006). Few studies combined evidence from many sites as 
has been the case elsewhere (Freedberg et al., 2001). While the sources of data 
implied lack of national representation of the results, another issue was the 
reliability of such data, which were mainly observational rather than random. Of 
the reviewed studies in South Africa, the data that have been recommended in 
CEA, random data, were only used in 3% of the studies; Jan et al. (2011) is an 
example.    
 
The patterns of the evidence discussed above highlight the extent to which the 
evidence was limited. Policy makers received insufficient evidence for some 
interventions, some of the evidence was provided too late and most of it was not 
nationally representative although the latter point is not necessarily a weakness.   
 
4.3. Extent of most needed CE evidence    
 
The extent of the evidence of CE studies in South Africa can also be gauged by 
assessing whether or not the most needed evidence has been presented to 
policy makers. In South Africa, policy makers have a particular need for CE 
evidence in order to optimise the use of resources in dealing with high levels of 
new infections, potential HIV virus drug resistance and HIV/AIDS and TB co-
infection.  An assessment of the evidence shows that it has been inadequate 
either in terms of the absolute quantity of studies or in relation to the evidence 







Table 4:14 Inadequacy of CE studies in South Africa 
 
 
Despite the high prevalence of risky behaviours in South Africa which have 
fuelled high levels of infection, there have been few CE studies on how best to 
prevent new HIV infections. Table 4:14 shows only three such studies, Muirhead 
et al. (2001), Walensky et al. (2011) and Jan et al. (2011).  One would not 
expect these three studies to provide overwhelming evidence to guide policy 
makers. Many other studies could have been conducted. Research conducted 
elsewhere, for instance, included studies comparing different methods of mass 
Area of need   Type of absolute inadequacy  Type of relative inadequacy  
Prevention    
Change in risk 
behaviours  
Evidence is  limited on the  basis 
of the limited number of studies 
comparing the CE of mass media, 
the CE of VCT and the CE of 
preventing partners violence 
(Muirhead et al., 2001; Walensky 
et al., (2011) and  Jan et al. 
(2011)   
Elsewhere, evidence is available  
comparing the CE of mass media, 
CE of couple counselling versus 
individual counselling, CE of  
provider initiated counselling 
versus patients initiated 
counselling, and CE of screening 
different strata of risk levels 
among patients (Hsu et al., 
2012); John et al. (2008);   
Sanders (2005)   
Treating STD  The evidence is limited on the basis 
that only one study compared the CE 
of preventing HIV infections  by 
treating STD   
(Vickerman et al., 2006) 
Further CE studies could have 
added to the evidence in South 
Africa had they been conducted , 
such as comparing different ways 
of managing specific STD  
Condom usage and 
circumcision  
No CE study on condom usage was 
available in the public domain while 
only one study (Kahn et al., 2006) has 
been conducted on the CE of 
circumcision  
CE comparison options by Martin 
et al. (2007); Binagwaho et al. 
(2010) and Gray et al. (2007) on 
circumcision, could have added 
to the evidence in South Africa 
had they been conducted  
Intervention to deal with 
virus resistance  
The absence of CE options of 
dealing with virus resistance in 
South Africa 
 
The absence of CE options for 
dealing with virus resistance in 
South Africa and the presence of 
such evidence elsewhere (Sax et 
al., 2005; Munakata et al., 2006)  
 
Task shifting  Only two studies examined the CE 
of task- shifting; one on providing 
ARV from home (Marseille et al., 
2009)  and another on down 
referral of patients from doctor-
managed  hospital-based clinics to 
nurse-managed primary health 
care facilities (Long et al., (2011) 
 
The absence in South Africa of 
studies such as comparing the CE 
of integrating HIV/AIDS services 
with primary health care 
(Sweeney et al., (2012) or 
different ways of task shifting 
found elsewhere (Chung et al., 
2008)    
 
Dealing with HIV/AIDS and 
TB co-infections  
The absence of CE studies on 
options shown to be effective. 
 
No studies were found in South 





media (Hsu et al., 2012) and different methods of counselling. Studies on the CE 
of individual versus couple counselling, patient-initiated versus provider-initiated 
counselling and low risk versus high risk patient counselling (John et al., 2008; 
Sanders, 2005; Long et al., 2010) could have improved the evidence base in 
South Africa.  
 
The lack of studies on the CE of prevention is manifest in the inadequacy of CE 
evidence on preventing HIV infections through the treatment of sexually 
transmitted infections. STDs create a favourable environment for HIV 
transmission, especially in countries with high HIV/AIDS prevalence (White et 
al., 2008). There is overwhelming evidence that STDs promote  HIV 
transmission in South Africa (Auvert, 2001; Johnson & Budlender, 2002: 10; 
Johnson et al., 2005; Johnson, 2008). Despite the CE of treating STDs being of 
great importance in South Africa, only one study presented such evidence 
(Vickerman et al., 2006).  Had studies elsewhere, such as Gilson et al. (1996) 
which compared the CE of preventing STDs in two settings with different 
prevalence levels, Kania et al. (2009) which compared the CE of options to 
screen for HIV, Syphilis and Hepatitis, and Price et al., (2006) which compared 
the CE of different ways of managing specific STDs such as Trichomoniasis, been 
conducted in South Africa, the evidence base would have increased significantly.  
  
The evidence on the CE of prevention is inadequate when assessed from the 
point of view of interventions which the literature has shown to be most 
effective, such as circumcision (Auvert, 2005; Gray, 2007) and condom usage 
(Bedimo, 2002). Only one study in the public domain (Kahn et al., 2006) 
provided CE evidence on circumcision in South Africa. CE evidence on condom 
usage was also provided by just one study (Marseille et al., 2001) and this 
evidence is relatively old. The kinds of CE comparisons of circumcision found 
elsewhere such as Martin et al., 2007 and Binagwaho et al., (2010) but not in 
South Africa are again indicative of the inadequacy of CE evidence for HIV/AIDS 
interventions.  
 
The review also revealed inadequacies in terms of the CE evidence in relation to 
options to prevent virus resistance. Virus resistance is an expected outcome that 





risky behaviours such as in South Africa. Evidence has shown that HIV-positive 
people on treatment increase risky behaviours once their health status has been 
restored (Attia et al., 2009:1400); these risky behaviours may include non-
adherence to treatment. Non-adherence to treatment has been identified as a 
source of serious virus resistance to the therapy, which can results in increase in 
deaths. Consequently, CE options to deal with this issue are vital. The lack of CE 
options to deal with virus resistance is testimony to the paucity of the CE 
evidence on HIV/AIDS interventions in South Africa. CE studies on virus 
resistance such as those conducted in countries where HAART has been made 
universally available to patients (Sax et al., 2005; Munakata et al., 2006) are 
needed in South Africa.  
 
The shortage of resources has also been a critical issue in South Africa due to 
the burden of HIV/AIDS and an inadequate health care system.  The literature 
has shown that delegating some tasks normally performed by senior staff to 
junior staff (task-shifting) or integrating HIV/AIDS services with low cost routine  
health services (Ekman et al., 2008) reduces costs while not compromising 
effectiveness (Maharaj & Cleland, 2005; Babigumira et al., 2009; Callaghan et 
al., 2010; Mdege et al., 2012). In South Africa, delegating some medical tasks 
to community workers or delegating costly hospital HIV/AIDS services to 
primary health care facilities has proved beneficial (Uys & Heshner, 2009; 
Harling et al., 2007). Despite this evidence, the CE of task-shifting has not been 
subjected to intense research efforts in South Africa. A review of CE studies 
showed that only two studies assessed the CE of task-shifting, one on providing 
ARVs from home (Marseille et al., 2009)  and another on down-referral of 
patients from doctor-managed hospital-based clinics to a nurse-managed 
primary health care facility (Long et al.,2011). This evidence is not sufficient 
given the extent of the burden of HIV and the scarcity of resources to respond to 
it. The absence of studies comparing the CE of integrating HIV/AIDS services 
with primary health care services in South Africa, which have been conducted 
elsewhere (Sweeney et al., 2012) indicates a lack of evidence on this issue.     
 
Tuberculosis (TB) and HIV/AIDS co-infection is a serious health threat in South 
Africa (Gandhi et al., 2006). High mortality rates among patients co-infected 





resistance. Dealing with TB and HIV co-infection is resource intensive and the 
lack of resources has led to complaints about the lack of HIV/AIDS and TB co-
infection services (Mannak, 2009). While effective options to deal with HIV/AIDS 
have been identified (Abdool Karim & Lawn, 2009; Abdool Karim et al., 2009), 
evidence on the CE of such options is not available. The absence of such studies 
indicates the limited CE evidence in South Africa.   
 
4.4 Extent of contextual CE evidence    
   
Cost-effectiveness comparisons of HIV/AIDS interventions across contexts are 
particularly deficient in South Africa despite the potential importance of such 
studies in optimising resource allocations. This optimisation of resources arises 
from the possibility that an intervention may not be equally effective across 
contexts. The effectiveness of an intervention is measured by its ability to 
reduce the impact of HIV/AIDS. Since this impact is generated by factors not 
primarily targeted by HIV/AIDS interventions and these factors prevail to a 
different extent and pattern across contexts, an HIV/AIDS intervention may 
achieve different effectiveness across contexts and hence different CE. This 
difference in CE presents opportunities for the optimal allocation of resources in 
defined epidemiological and socio-economic contexts in South Africa.   
 
Despites these opportunities, CE studies in South Africa have not directly 
compared HIV/AIDS interventions across epidemiological and socio-economic 
and contexts with a view to informing South African policy makers on resource 
allocation across contexts. Rather, these studies benefitted international policy 
makers by providing the cost and benefit of HIV/AIDS interventions across 
international contexts (Dowdy et al., 2006; Verguet & Walsh, 2010). The studies 
conducted in South Africa have provided little evidence on how resources could 
be distributed in geographical contexts on the basis of CE evidence that arises 
from the interaction between HIV/AIDS interventions and these context 
dynamics.  
 
One study which compared the CE of HIV/AIDS interventions across contexts in 
South Africa is that conducted by Verguet and Wash (2010).  This study 





one year for a hypothetical population of patients showed that the cost and 
effectiveness in the US and South Africa were different. Over one year, the 
intervention would prevent 1,908 new infections in South Africa, while it would 
only prevent 21 new infections in the US. In South Africa, the intervention would 
save US$6,712 per infection averted, when compared with the cost of treatment 
(in cases where a microbicide is not used). The study showed that the cost per 
infection averted by microbicides would amount to US$405,077 in the US and 
concluded that the intervention is cost-effective in South Africa, but not in the 
US.   
 
While this study was an important contribution to the literature it aimed to 
inform international rather than South African policy makers. The study 
compared the relative benefits and costs of funding HIV/AIDS interventions in a 
HPC (South Africa) and a LPC (US). A related study by Dowdy et al. (2006) 
compared the CE of nitrile female condom across South Africa and Brazil. 
Although these countries are comparable in in terms of socio-economic status 
and risky behaviours, the CE results were different. The study found that, over a 
period of three years using 1,000 hypothetical patients, expanding female 
condom use to 10% would avert 604 infections at US$20,683 in Brazil, while in 
South Africa, 9,577 infections could be averted at US$985 per infection averted. 
Again the results of the study are useful to global rather than South African 
policy makers. 
 
In South Africa, Wilkinson et al. (2000) compared the CE of PMTCT from a 
perspective that is comparable with the present study. The study estimated the 
CE of PMTCT relative to no PMTCT in different provinces. The results of this study 












Table 4:15 Cost effectiveness results per province for the prevention of mother-to-child 
transmission (PMTCT) programme in South Africa  
 
Provinces  Prevented HIV 
infections  
Cost per infection 
averted (R) 
Cost per DALY(R) 
Gauteng  3,809 6,625 210 
North West 2,357 6,463 205 
Northern Province 1,678 9,799 310 
Mpumalanga  2,507 5,918 187 
Free State 2,046 6,255 198 
Northern Cape 204 9,495 300 
Eastern Cape  3,171 7,669 247 
KwaZulu-Natal 6,769 4,232 134 
Western Cape  640 11,656 369 
South Africa  23,181 6,724 213 
Source: Data extracted from Table 1 of Wilkinson et al. (2000:796).  
 
While the study provided evidence on how the CE of PMTCT compares across 
South Africa’s provinces, its aim was to advise policy makers on the costs and 
benefits of HAART nationally and per province, rather than on how resources 
should be distributed across these provinces on the basis of the results. 
Furthermore, the comparison involved only one HIV/AIDS intervention, PMTCT, 
and did not take into account the impact of the interaction between the 
HIV/AIDS intervention and the context of its implementation on the CE of that 
intervention over time.        
 
Another context-related CE analysis in South Africa is a study by Vickerman et 
al. (2006). The study examined whether there should be presumptive treatment 
(PPT) in patients with high risk behaviour, as opposed to the usual syndromic 
management of STDs in low risk groups.  While the study provided evidence on 
how best to treat STDs in contextually different groups of patients, this evidence 
may not be applicable to patients in different geographical contexts.   
 
The above discussion highlights why contextual CE evidence in South Africa has 
been limited despite its potential importance to policy makers. Although some of 
this evidence related to South Africa, it was more relevant to international policy 
makers needing to direct funding to the countries where it would achieve the 
greatest benefits, given the costs. Contextual CE comparisons conducted in 
South Africa were also limited in that they did not aim to inform policy makers 
how resources should be distributed in HIV/AIDS interventions across contexts.  





interventions but did not distinguish the analysis in epidemiological contexts and 




This chapter reviewed the extent of CE evidence in South Africa. It found that 
the evidence is limited on the basis of the distribution patterns of the studies, in 
terms of interventions timing over time, in terms of coverage of the most 
important interventions for the country and in terms of CE comparisons of 
HIV/AIDS interventions across geographical contexts. The next chapter 



























This chapter discusses the need to compare CE of HIV/AIDS interventions across 
epidemiological and socio-economic contexts in South Africa. Section one  
argues this case on the basis of increasing evidence in the literature regarding 
the dependence of HIV/AIDS interventions’ effectiveness on contexts and the 
implications of such dependence for costs. Section two focuses on theoretical 
arguments concerning such dependence and section three discusses the 
empirical evidence; while section four analyses the relevance of such an 
approach in the South African situation. 
 
5.1. Context–dependent effectiveness and cost    
 
Linking CE analysis of HIV/AIDS interventions to contexts is necessary because 
of the likely dependence of the costs and effectiveness of such interventions on 
the contexts. The literature claims that the effectiveness of HIV/AIDS 
interventions depends on the contexts; hence the likelihood that the costs of 
such interventions also depend on the contexts. CE analysis in contexts is 
necessary because of uncertainty about the extent to which the CE of HIV/AIDS 
interventions compares across contexts.  CE analysis in contexts becomes even 
more crucial in the event that such analysis results in significant differences in 
CE estimates across contexts. Such differences constitute opportunities for 
efficiency in allocating resources and since these opportunities would not be 
revealed without CE analysis, the conduct of the latter is necessary.  
 
As early as 2001, studies started putting forward claims that interventions 
should be designed according to the context for greater effectiveness (Grassly et 
al., 2001; Wegbreit et al., 2006). For instance, Grassly et al. (2001: 1121) 
proposed that it would be worthwhile to measure the variables describing 
epidemiological contexts in order to use such variables to choose interventions 
which best suit the context. Other studies have claimed that HIV/AIDS 
prevention interventions are complex and made up of singular components to 





particular target group in order for the intervention to be optimally effective 
(Bonell & Imrie, 2001: 156).  
 
Noting that prevalence varied across South Africa’s provinces, Kleinschmidt et al. 
(2007: 1163) suggested that maps of HIV prevalence could be used to 
effectively focus intervention on contexts of particular need. In their report, 
Shisana & Simbayi (2002:15) noted that greater attention should be given to the 
relative effectiveness of HIV/AIDS interventions across contexts in order to 
improve the response to HIV/AIDS. Meyer-Rath (2007) observed that South 
Africa needed to set priorities. In countries such as Uganda and Thailand where 
responses to HIV/AIDS have been most successful, tailoring interventions to 
epidemic dynamics has been considered a factor of success (Wegbreit et al., 
2006:1124). 
 
The much vaunted dependence of HIV/AIDS interventions’ effectiveness on 
context in the literature implies that CEA of HIV/AIDS interventions across 
epidemiological and socio-economic contexts is necessary. Epidemiological and 
socio-economic contexts represent specific contexts with different circumstances 
in which the impact of HIV/AIDS in terms of new infections, AIDS cases and 
deaths takes place, with HIV/AIDS interventions’ effectiveness consisting of the 
reduction of the impact. Because the extent of the reduction of the impact of 
HIV/AIDS depends on how the intervention interacts with the circumstances 
influencing the impact in each context, and because these circumstances differ 
across contexts, the latter become important determinants of HIV/AIDS 
interventions’ effectiveness (Grassly et al, 2001; Weigbreit et al, 2006). Such 
dependence is a source of efficiency because the difference in effectiveness 
across contexts for a given cost of HIV/AIDS interventions opens up 
opportunities for efficient resource allocation.  
  
While on the one hand, HIV/AIDS interventions’ effectiveness depends on 
contexts, on the other, HIV/AIDS interventions’ activities, and hence the costs of 
such interventions, also depend on contexts. Other studies analysing the factors 
influencing the costs of HIV/AIDS interventions only examined the change in 
costs in relation to the duration and scale of the intervention (Dandona et al., 





interventions. The influence of contexts on the cost of interventions can be 
argued on the basis of the influence of the contexts on the impact of HIV/AIDS. 
Contexts influence the impact of HIV/AIDS in terms of severity of illness or the 
number of people affected.  In influencing illnesses, contexts also influence the 
cost of interventions, at least indirectly. The contexts influence the cost of 
interventions because the latter earmark specific activities for specific types of 
impact (for example, severity and intensity). Since the contexts determine the 
type of impact, they also determine the type of activities of interventions and 
ultimately the cost of the interventions.  
 
The above discussion implies that HIV/AIDS interventions’ effectiveness and 
costs depend on epidemiological and socio-economic contexts. This  suggests 
that HIV/AIDS interventions might achieve different incremental CE ratios 
(ICERs) across these contexts. Since different ICERs imply different 
opportunities for efficiency in allocating resources, it is necessary to conduct CE 
studies across epidemiological and socio-economic contexts.   
 
5.2 Theoretical arguments  
 
CEA across epidemiological and socio-economic contexts is necessary because 
the theoretical determinants of the impact of HIV/AIDS depend on the context 
on the one hand while on the other, the effectiveness (reduction of the impact) 
and the cost of interventions depends on the impact of HIV/AIDS. Like the 
impact of any other illness, the determinants of the impact of HIV/AIDS range 
from contextual factors to individual factors which cannot be expected to be the 
same across different contexts or even across similar contexts. These factors 
affect the effectiveness and cost of HIV/AIDS interventions in an uncertain 
manner. Consequently, not only can the patterns of the CE of HIV/AIDS 
interventions not be predicted across contexts, but also their extent. The 
insufficiency of the evidence on the pattern and extent of the CE of HIV/AIDS 
interventions across contexts implies a need to estimate them.   
 
A social theory of the determinants of health status which has recently 
dominated the literature in explaining health status, ties the impact of illness to 





relevant to this study in that it shows the factors influencing health, which can 
differ from a context to another.  
  
 
Source: Spanish Commission for Reducing Health Inequalities (2007) 
Figure 5:1 Model of the socio-economic determinants of health outcomes  
 
In this theory, social and economic levels are the deepest determinants of health 
status. Social and economic levels are characterised by income levels, education 
and gender relationships, and relate to health outcomes through material 
circumstances, psychosocial and behavioural factors, access to health and social 
cohesion (Valentine & Solar, 2011; Marmot & Wilkinson, 2005). The theory 
postulates that lower social and economic status are associated with lower 
income and education levels and unhealthy gender relationships. The theory has 
mainly been used to explain disparities in health across regions with differing 
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An implication of the social theory with respect to HIV/AIDS is that socio-
economic contexts of lower status are associated with lower income levels to 
respond to HIV/AIDS, lower levels of education in general and knowledge about 
HIV/AIDS in particular and more exposure to risky behaviour such as injecting 
drugs and exchanging sex for money. A lower socio-economic position is also 
associated with environmental hazards, which cause stressors which in turn lead 
to drug addiction, alcoholism and consequently the risk of HIV/AIDS infection. In 
other words, the impact of HIV/AIDS in terms of new infections, AIDS cases and 
deaths at an individual level is on average higher in contexts with lower socio-
economic status.  
 
Models embedded in this theory have tended to focus on specific factors. Some 
focused on cultural factors, stating that an unfavourable HIV/AIDS cultural 
environment is expected in contexts with lower socio-economic status 
(Airhihenbuwa, 2004). Other models such as social capital theory have focused 
on social cohesion. Social capital theory explains that social cohesion, trust and 
networking help to achieve common health goals (DiClemente et al., 2002). In 
the case of HIV/AIDS, social capital facilitates the reduction of stigma. As a 
result, the impact of HIV/AIDS is reduced in contexts in which greater social 
capital exists.  
 
While this theoretical framework suggests that contexts with lower socio-
economic status are associated with the increased impact of HIV/AIDS relative 
to contexts with higher socio-economic status, the question remains: to what 
extent is this case? The factors underlying the differences in the impact of 
HIV/AIDS in one pair of contexts, say an LPC and a HPC, might be different from 
the factors underlying the impact in another pair of an LPC and a HPC. For 
instance, while higher alcohol abuse might be responsible for the difference in 
the impact of HIV/AIDS in a pair of an LPC and a HPC, in another pair of an LPC 
and a HPC, gender violence might be the main factor. Even where the same 
factor, say gender violence, underlies the difference in the impact for the two 
pairs, the extent of the factor might be greater in one pair than in another.  
 
The discussion in the paragraph above applies to pairs of different contexts, say 





of similar contexts, say an LPC and LPC?  The extent of the impact of HIV/AIDS 
may be even more difficult to predict from one pair of similar contexts, say an 
LPC and LPC to another pair of an LPC and LPC because of the complex 
outcomes of the interaction between the contextual factors and individual factors 
in these two pairs of contexts. However, with modelling, this impact can be 
estimated.  
 
Theories explaining individual factors in the impact of HIV/AIDS have indicated 
that these factors may or may not depend on the contexts in which the 
individual lives. Most of the individual factors influencing the impact of HIV/AIDS 
have been explained by psychosocial theories or theories of individual behaviour. 
These theories focus on how factors such as learning influence risky behaviour 
(Bandura, 1986; Becker, 1976). According to these theories, the impact of 
HIV/AIDS in a group of patients will be reduced depending on their ability and 
willingness to learn how to avoid risky behaviour. Other theories have 
concentrated on beliefs, attitudes and behaviour (Rosenstock, 1974; Fishbein & 
Ajzen, 1975; Ajzen, 1991). According to these theories, a person consistently 
behaves in relation to what they believe is right and in relation to their beliefs 
regarding the benefits and costs of such behaviour. The extent of the impact of 
HIV/AIDS would depend on the extent of such beliefs, on unsafe sex for 
example. The model by Fisher & Fisher (1992) and  Fisher et al.(1994) focusing 
on HIV/AIDS risk behaviours and incorporating aspects of learning, attitudes and 
behaviour implies similar conclusions. Some of these theories include distal 
factors, that is, factors in society which influence a person’s behaviour such as 
the person’s perception of and compliance with social norms. The theories posit 
that individual behaviour interacts with social factors such that the impact of 
HIV/AIDS across socio-economic contexts depends on the extent and outcomes 
of such interactions.  While these theories imply that the extent of the impact in 
a given context will depend on the preponderance of these factors and their 
interaction with contextual factors, their pattern and the extent of the impact of  
HIV/AIDS, the interventions’ effectiveness and costs are not predictable across 
contexts, again implying the need to estimate such costs and effectiveness.   
 
Economic theory can also be used to explain individual risky behaviour. The 





that most human behaviour can be seen as rational and utility maximising. 
According to Becker (1976)’s theory, an individual balances the benefits and 
costs of any behaviour. Related to Becker’s theory are theories by Levy (2002), 
Oster (2007), Bhattacharya et al. (2007), and Phillipson & Posner (1993).  The 
most commonly used of these theories in empirical work is Philipson & Posner’s 
(1993) theory. This theory explains that unsafe risky behaviour takes place 
mainly because of mutual benefits from sexual partners who each make a 
rational choice, given their individual expected benefits and costs of unsafe 
sexual behaviour. In terms of this theory, the benefit of unsafe sexual 
intercourse is the avoided disutility of condoms while the costs of unsafe sex are 
the cost of infection ranging from pecuniary costs such as treatment costs to 
non-pecuniary costs such as stigma and suffering. 
 
The way in which the theory explains the dependence of the impact of HIV/AIDS 
on context is that the ratio of safe sex to unsafe sex is positively correlated with 
factors which increase the prevalence of HIV/AIDS such as location, gender, and 
age and not only with the individual preferences of sexual partners. In other 
words, the expected utility and costs which shape unsafe sex will depend on the 
characteristics of individuals and the characteristics of the contexts in which they 
live with respect to the risk of infection. As these factors influence unsafe sex, so 
they also influence the impact of HIV/AIDS.  The complexity is however, that 
increased awareness of the impact might not translate into safer sex because of 
other factors. Individuals consider many other aspects of life in choosing safe 
sex and sometimes trade off poverty against the risk of infection by accepting, 
for example, unsafe sex for money. The link is however, complex as some 
people may avoid risky behaviour because of their inability to afford the costs of 
treatment. These arguments point to the fact that the impact of HIV/AIDS in any 
area may be a complex result of all these factors and the net impact of these 
factors can be estimated through modelling.       
 
In contrast, most epidemiological models pay little attention to the incentives 
which push an individual to act. In particular, most epidemiological theories tend 
to ignore the fact that increased awareness about the costs and benefits of safe 
behaviour cause individuals to adopt safer behaviour. These models state that 





not on behaviour; what the literature has termed “random sorting” (Geoffard & 
Phillipson, 1996). Random sorting implies that people will choose partners 
irrespective of the information they have about the risk of infection. While the 
economic model postulates that higher prevalence and related consequences 
increase the costs of risky behaviour, which might discourage people demanding 
such behaviours, epidemiological models ignore such factors. Since the extent to 
which people perceive increased cost can vary from one context to another and 
the epidemiological model may work to varying degrees in different contexts, 
the impact of HIV/AIDS depending on the context is difficult to predict.   
 
Whether or not these factors highlighted by psychosocial, economic and 
epidemiological theories influence the impact of HIV/AIDS independently of the 
contexts in which individuals live, the patterns of these factors and the extent to 
which they influence the impact of HIV/AIDS across epidemiological contexts or 
socio-economic contexts cannot be easily predicted. Consequently, not only does 
the extent to which HIV/AIDS interventions reduce the impact across a context 
depend on the context; it is also not easy to predict across contexts.  Therefore, 
the effectiveness of HIV/AIDS interventions which depends on factors 
predominating in given socio-economic contexts needs to be estimated.    
 
Arguments for the need to conduct CEA across socio-economic contexts can be 
transposed to epidemiological contexts. Contexts with lower socio-economic 
status may also be contexts with high prevalence status and contexts with 
higher socio-economic status contexts may have low prevalence. While this may 
be true, the need to conduct CEA of HIV/AIDS interventions across 
epidemiological contexts is also supported by the existence of a multitude of 
factors. For instance, individual level factors in a context with low socio-
economic status, which are independent of the socio-economic status might 
create different prevalence contexts (a low prevalence context for instance) 
which are do not comply with what is expected in a context with a lower socio-
economic status.  One of the reasons why prevalence contexts may not be easily 
distinguished is the fact that many factors may be at work to make up such a 
context. For instance, Halett et al. (2007) note that, a decrease in risky 
behaviours in a given context to transform it into a low prevalence context, 






The need to analyse CE across epidemiological and socio-economic contexts 
separately is due to the fact that these contexts might be embedded in each 
other with independent factors determining the impact of HIV/AIDS in each area 
(Ferry et al., 2001). This idea is illustrated in Figure 5:2. 
 
                       A                      B 









High socio-economic status context 
 





Source: Author.  
Figure 5:2  Combinations of differences between socio-economic and epidemiological contexts  
 
As Figure 5:2 shows, one might find two contexts with differing prevalence levels 
in each type of socio-economic status context (Column A of Figure 5:2) and a 
low socio-economic status and high socio-economic status context in each type 
of prevalence context (Column B of Figure 5:2).  
 
These theoretical discussions highlight the fact that not only the patterns but the 
extent of the factors determining the impact of HIV/AIDS depend on 
epidemiological and socio-economic contexts. The discussion also highlighted 
that these patterns and extent may vary across similar socio-economic and 
A low socio-economic status 
context 
A high socio-economic status 
context 
A low HIV prevalence context 
A high HIV prevalence context  
A Low HIV prevalence context  
A high HIV prevalence context   
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epidemiological contexts.  While HIV/AIDS interventions’ effectiveness depends 
on these factors, the complexity of the interaction between contextual factors 
and individual factors makes it difficult to predict the extent of costs and 
effectiveness across contexts. Therefore, for the sake of resource allocation 
across contexts, these costs and effectiveness need to be estimated.  
 
5.3 Empirical evidence  
 
The dependence of the cost and effectiveness of HIV/AIDS interventions on 
contexts is not limited to claims in the literature, but is also based on empirical 
evidence. The dependence of the CE of HIV/AIDS interventions on contexts 
stems from the dependence of the impact of HIV on contexts.  The evidence 
reveals that most of the factors underlying the impact of HIV/AIDS prevail in a 
given context with patterns which are different from the patterns in another 
context (Kahn, 1996). The evidence also points to the fact that these factors 
indirectly underlie the impact (effectiveness) of HIV/AIDS interventions (Kahn, 
1996). Consequently, the CE of HIV/AIDS interventions also depends on the 
context.   
 
Factors underlying the impact of HIV/AIDS in a given context are empirically 
complex. These factors include risky behaviour, poverty, social norms and policy. 
In most cases, these factors are intertwined and their relationship cannot be 
disentangled. The prevalence of these factors in any context is diverse and the 
factors that dominate the influence of the impact depend on the context. This 
implies that even in similar contexts, factors may exert an influence on the 
impact to a different extent because of the complexity of the interaction between 
broad factors and individual-level factors. 
 
In epidemiological contexts, empirical evidence indicates that mortality rates, 
infection rates, and AIDS cases are lower in an LPC than they are in a HPC. For 
example, Geoffard & Phillips (1996) point out that high rates of infections in a 
HPC are explained by proximity to the infected. Over time however, a HPC can 
experience fewer infections because of increased awareness of the dangers 
associated with the epidemic. Consequently, there might be a reduction in AIDS 






At an individual level, mortality and high HIV/AIDS prevalence which are typical 
of a HPC are expected to reduce risky behaviour in that context as predicted by 
economic theory. However some evidence shows that risky behaviour can 
increase because of despair caused by factors such as the constant loss of 
relatives (Caldwell, 2000).  Other evidence has demonstrated that biological 
factors are important. For instance a context with multiple female partnerships is 
likely to suffer a greater burden of the epidemic than a context where such 
partnerships are limited. This difference may stem from the evidence that HIV 
infection is transmitted more efficiently in females than in males (Nicolosi et al., 
1994). Biological factors such as the prevalence of STDs also explain the impact 
of HIV/AIDS. Empirical evidence in this respect has been produced for Tanzania 
and Uganda. Treatment of STDs reduced HIV transmission to a greater degree in 
Tanzania than in Uganda because in the latter country, HIV transmission was 
taking place outside the core groups with high STI rates targeted by STI 
interventions (Korenromp, et al. 2005). 
 
In socio-economic contexts, empirical evidence shows a greater impact in 
relatively deprived regions. In high income countries as well as low income 
countries, most afflicted people are from deprived and impoverished 
communities. For instance, 95% of all people infected with HIV/AIDS live in low 
income countries with only 5% in high income countries (UNAIDS, 2012). These 
patterns are also observed within sub-regions of these countries. For instance, 
sub-Saharan Africa, the poorest part of the world, is home to 68% of the world’s 
infected adults and 90% of its infected children (Alistar & Brandeau, 2010:106). 
Factors such as poverty and related stressors such as intravenous drug 
injections have played a role in explaining differences in the impact across 
contexts with different socio-economic status.  Poverty has been cited as leading 
to hopelessness and fearlessness about HIV/AIDS. Related to poverty is a lack of 
social support which accounts for higher infection rates in poor communities. 
 
Despite evidence that factors such as the better health, education levels and 
well-being of better-off communities are at the centre of reduced HIV/AIDS 
impact, the complexity of the evidence lies in the fact that urban contexts in 





prevalence rates than rural contexts (Shisana & Simbayi, 2002). This results 
from the concentration of youth in the city as a result of urbanisation, making 
this age group one of the driving factors of the epidemic (Adimora, 2012). 
Factors other than economic factors have been also found to be important. In 
Zambia, the proportion of female-headed households was the main determinant 
of infection, while fertility was negatively related to prevalence (Ojteg, 2008).   
 
Further evidence shows that factors which are theoretically expected to 
contribute to the reduction of HIV/AIDS played the opposite role. According to 
theory, the well-educated are expected to be more knowledgeable about health 
and to avoid risky behaviours. However, in Zambia the HIV/AIDS rate was 
highest among the well-educated (Ojteg, 2008) while in Cote d’Ivoire, the well-
off had more sexual partners (Cogneau & Grimm, 2006), although the impact 
could be offset by greater use of condoms (Snelling et al., 2007). Analysing the 
socio-economic determinants of HIV/AIDS prevalence across nations, Zanakis et 
al. (2007) found that lower GNP was not a determinant of prevalence, but that 
lower population densities and better health care systems were. Psycho-
sociologists also predict that educated people are more likely to change risky 
behaviour as they acquire more information (Bandura, 1986). 
 
Culture has been found to relate unfavourably to HIV/AIDS in low socio-
economic contexts. Bowden et al. (2006) found that cultural factors such as 
misconceptions and intercommunity discrimination are important in contexts 
with lower socio-economic status in the US. In Africa, the subordination of 
women has contributed to HIV infection (Laga et al., 2001).  However, using 
religion as a proxy for culture, Tiruneh (2009) showed that in better-off southern 
Africa countries such as South Africa and Botswana, Christianity was 
unfavourable in relation to the culture in northern African countries which are 
predominantly Muslim. The reason given for this difference was that the Muslim 
rules prohibiting sexual intercourse before marriage, were stricter than those in 
the Christian religion. Other structural factors have been found to be at the 
centre of the impact of HIV/AIDS (Marshall et al., 2009). 
 
The above discussion shows that the factors which influence the impact of 





importance in a given context or across contexts is uncertain. The implication is 
that the impact of HIV depends on contexts in an uncertain manner, which 
implies that the effectiveness and cost of HIV/AIDS interventions also depends 
on contexts.  
 
Given that the effectiveness of HIV/AIDS interventions is measured in terms of a 
reduction in the impact of HIV/AIDS, the factors influencing the impact also 
influence the effectiveness of HIV/AIDS interventions. The evidence shows that 
the factors influencing the impact of HIV/AIDS are somewhat related to the 
effectiveness of HIV/AIDS interventions. In Tanzania for example, the 
prevalence of STD was lower than in Uganda, as was the prevalence of 
HIV/AIDS. When treatment of STDs to prevent HIV infections was undertaken in 
these two countries, greater effectiveness was achieved in Tanzania 
(Korenromp, et al., 2005).  
 
Vickerman et al. (2006 b) analysed the way in which the impact of microbicide 
on HIV infection is affected by behavioural factors in two African settings, 
Cotonou, Benin and Johannesburg, South Africa, considered an LPC and a HPC, 
respectively. They found that the impact of the intervention was different 
because the two settings differed in terms of STD prevalence.  Microbicide had a 
greater impact in Cotonou than in Johannesburg. The study also found that in 
Cotonou, most infections averted were among commercial sex workers while this 
was not the case in Johannesburg; it concluded that the context was important 
in influencing the outcome of microbicide. The effect of the different parameters 
underlying the differences in the impact of HIV/AIDS has also been documented 
by Ferry et al. (2001), who found that risk factors such as early sexual debut 
were important determinants of infections in urban populations with high 
prevalence (Ndola and Kisumu). These factors were however, less important in 
urban populations with low HIV prevalence (Cotonou and Yaoundé).    
 
The dependence of the impact of HIV/AIDS on context implies that both the cost 
and effectiveness of HIV/AIDS interventions depend on context. This is mainly 
due to the fact that the costs are different in different settings but most 
importantly, the costs of intervention are correlated with HIV prevalence. 





interventions in two regions with different socio-economic characteristics were 
also different.   
 
Evidence that the CE of HIV /AIDS interventions depends on the context is 
presented more directly in some studies.  In the US, for instance, Cohen et al. 
(2004) found that the CE of HIV/AIDS interventions depended on the prevalence 
levels and on the cost per person reached. In particular, the study found that in 
a low prevalence heterosexual population, the most cost-effective interventions 
were those that targeted structures such as mass media and condom 
distribution. In contrast, the study found that targeting interventions at an 
individual level was more cost-effective in a high prevalence homosexual 
population. Earlier studies by Kahn (1996) and Holtgrave & Kelly (1996) found 
that HIV prevention targeting was more cost-effective. 
 
Furthermore, a study analysing the cost and effectiveness of a set of HIV/AIDS 
interventions across the East African region (Afr-E)  and East Asian region (Sear-
D) (Hogan et al., 2005) found that the cost and effectiveness of HIV/AIDS 
interventions considered individually or in combination with other HIV/AIDS 
interventions depended on the regions as shown in Table 5:1. The evidence from 
these regions, which differ on the basis of epidemiological status and socio-
economic status, shows that the CE of HIV/AIDS interventions depends on 















Table 5:1 Variation in CE results across epidemiological regions 
Interventions  Average cost effectiveness ratio:$ 
international per DALY averted  
Afr-E Sear D 
Individual HIV interventions  
Mass media  
Peer education for sex workers  
Peer education and treatment of STIs 
School-based education  
Voluntary counselling and testing  
Prevention of mother- to- child transmission  





















Source: Adapted from Hogan et al. (2005: 3).  
 
The empirical evidence presented above shows that the CE of HIV/AIDS 
interventions depends on the context. The fact that many factors are at the 
centre of such dependence with a certain degree of complexity requires the 
estimation of the CE of HIV/AIDS interventions across contexts. The need to 
conduct CEA of HIV/AIDS interventions in epidemiological and socio-economic 
contexts is more evident for South Africa as discussed in the next section. 
 
5.4 Relevance of contextual CE analysis to South Africa  
 
Contextual analysis of CE in South Africa is relevant due to the paucity of CE 
evidence discussed in Chapter 4 and the absence of context-related policies 
outlined in Chapter 3. The fact that South Africa comprises distinct rural and 
urban contexts, and LPCs and HPCs also makes CE comparisons across contexts 
relevant. Such comparisons discussed earlier (section 4.4) would result in the 
efficient allocation of resources.  
5.4.1 Epidemiological contexts  
 
It has been claimed that the best way of responding to HIV/AIDS is to tailor the 
response to the epidemiological contexts of the epidemic (Grassly et al., 2001; 
Parker & Aggleton, 2002; Walker, 2003). Such a response is difficult, however, 
because of the concurrent influence of the characteristics of the contexts and 





South Africa, these complex relationships imply that the CE of interventions 
across the two contexts is not obvious. 
 
For some time, there have been proposals to consider contexts of intervention in 
terms of responding to HIV/AIDS (Grassly et al., 2001:1121). The rationale for 
these proposals is that an HIV/AIDS intervention can have different success 
rates, depending on the prevalence context in which it is implemented. The 
extent to which an intervention succeeds depends on its net effect between the 
risk factors and its own effect on reducing the impact (Weigbreit et al., 2006).  
 
Risk factors are diverse, and range from structural, to epidemiological, 
environmental and cultural factors (Parker & Aggleton., 2002; Airhihenbuwa, 
2004; Pronyk et al., 2006; Raogupta et al., 2008). Risk factors have been found 
to influence health theoretically and empirically through their influence on 
health-seeking behaviour, attitudes towards health interventions (Bandura, 
1986; Becker, 1974; Geoffard & Phillipson, 1996), and their linkage with culture 
(Airhihenbuwa, 2004). They are consequently expected to be at the centre stage 
of differences, even in the presence of HIV/AIDS interventions, in new infections, 
sickness and deaths.  
 
Calls to respond in epidemiological contexts appear to be very relevant for South 
Africa. Although the generalised HIV/AIDS epidemic in South African would seem 
to imply the need for a response targeting the general population (Whiteside & 
Smith, 2009), prevalence levels in the general population have been consistently 
different across the provinces (Statistics South Africa, 2010; 2011; 2013). 
Despite this feature of the HIV/AIDS epidemic, major HIV/AIDS interventions 
have failed to account for how these interventions would fare in contexts with 
different characteristics. In the context of limited resources to meet the demand 
for HIV/AIDS services, the question revolves around whether HIV/AIDS 
interventions could be more optimal in some contexts with specific prevalence 
levels, than in others. This question can only be answered through hard evidence 
on cost and health outcomes; hence the need to compare the CE of HIV/AIDS 







5.4.2 Socio-economic contexts  
 
In response to the HIV/AIDS epidemic, South Africa has recently adopted 
universal coverage with highly active antiretroviral therapy (HAART) and has 
decided to start treatment earlier (at a threshold of 350 CD4 count) rather than 
later (at a threshold of 200 CD4 count). Although they might improve the 
welfare of the population, these policies will require considerable resources. 
 
With some evidence available that the effectiveness and cost of HIV/AIDS 
interventions depend on contexts (Wilkinson et al. 2000), the on-going question 
is how to optimise the use of resources by allocating them according to the CE of 
HIV/AIDS interventions in a rural context and an urban context in South Africa. 
Rural and urban contexts are defined as distinct contexts because their 
environments, livelihoods and way of life are different.   
 
The evidence that the impact of HIV/AIDS in a rural context and an urban 
context depends on the factors underlying the impact in these contexts provides 
a clue that the effectiveness of HIV/AIDS interventions also depends on these 
factors. Since HIV/AIDS interventions do not address all these factors, some of 
these factors’ influence will persist even in the presence of HIV/AIDS 
interventions. The extent of such persistence is expected to be different across 
rural and urban contexts.  
 
A number of factors have been identified as important determinants of the 
impact of HIV/AIDS in South Africa. Booysen et al. (2004) and Muntinta et 
al.(2011) highlighted poverty as a factor that aggravates the impact of 
HIV/AIDS.  Using poverty related stressors, Kalitchman & Simbayi (2006) found 
that educational level, unemployment, discrimination, violence and crime were 
factors underlying the differences in the impact of HIV/AIDS across three 
communities: African townships, racially integrating townships and urban 
residential neighbourhoods, with different socio-economic status. Lower socio-
economic status was positively correlated with the overall index reflecting no 
condom use, multiple partners, and exchange of sex for money, STI history and 
genital ulcers. Using logistic regression, Kleinschmidt et al. (2007:1164) mapped 





proportion of residents who were Black, the proportion of women aged 20-64 
years old who were unemployed, the proportion of informal households, and the 
proportion of 15-19 year-old persons who had not completed school were 
significantly associated with HIV infection. 
 
While in general lower socio-economic status was associated with a greater 
impact of HIV/AIDS, some studies have shown a greater incidence in urban than 
in rural contexts. Kleinschmidt et al. (2007:1165), for instance, noted a lower 
incidence of HIV in a rural inland context in the Western Cape in relation to the 
incidence of HIV in the city of Cape Town. One study also reported that there 
were more sexual partners and earlier sexual debut in urban contexts than rural 
contexts due to the lack of parental control (Mathews, 2010).   
 
A study by Bouare (2009) that modelled the contextual determinants of the 
prevalence of HIV/AIDS in South Africa found the determinants of risky 
behaviour to be fearlessness/low perception, poverty, hopelessness and gender 
dependence. The factors highlighted by Bouare (2009) seem to emphasise that 
the factors influencing the impact of HIV/AIDS are shaped by the contexts in 
which they occur. Fearlessness accords with the evidence that poor people in 
rural contexts are unaware of the danger of the epidemic. Pelitzer’s (2009) study 
highlighted the factors associated with the level of knowledge about HIV/AIDS. 
These factors, which underlie the different impact across rural contexts, are also 
expected to underlie the effectiveness of HIV/AIDS interventions.   
 
The literature on socio-economic determinants of HIV/AIDS also reveals to some 
extent how socio-economic status can influence the cost of HIV/AIDS 
interventions. Socio-economic status can influence cost because people of 
different socio-economic standing use health care differently in terms of intensity 
and patterns. While a greater rate of usage of HIV/AIDS interventions will 
increase the costs, the patterns of usage such as delaying usage until health 
status has seriously deteriorated can exacerbate costs. Since the usage rate and 
patterns can depend on socio-economic contexts, the costs of HIV/AIDS 






The contention that the performance of HIV/AIDS interventions depends on the 
contexts of their implementation and the stark differences in the dynamics in 
urban and rural contexts in South Africa (Department of Health, 2003 c), raise 
the question of whether the CE of HIV/AIDS interventions is the same across 
such contexts. If the CE of an HIV/AIDS intervention across these contexts is 
different, this difference could serve as an opportunity to achieve optimal 
resource allocation.  
 
While optimal resource allocation can be achieved by intensifying interventions 
where they can attain the highest outcomes given the cost, this has not been 
routine policy in South Africa. To inform such policy, a comparison of the CE in 




In conclusion, this chapter has argued the case for CEA of HIV/AIDS 
interventions across socio-economic and epidemiological contexts in South 
Africa, which consists of geographical comparisons of these contexts. This is 
based on the dependence of the effectiveness and cost of HIV/AIDS 
interventions on contexts, on theoretical and empirical support for the notion of 
such dependence and on the relevance of contextual analysis of the CE of 
HIV/AIDS interventions for South Africa. The next chapter examines how such 
















Chapter 6 : General methodology  
 
 
This chapter describes the general methodology used in this study and discusses 
specific details of the methodology used in the subsequent analysis chapters. 
Patients in HIV/AIDS interventions are followed up over time using Markov 
modelling and the ASSA2008 AIDS model or Spectrum Policy Modelling System 
projections.  Cost and effectiveness are estimated and the effect of the 
interaction between the contexts and HIV/AIDS interventions on the cost and 
effectiveness of these interventions is taken into account by using context-
specific data and by incorporating context-specific assumptions in these models. 
Section one describes the design of the study, section two discusses the Markov 
states transition model, section three presents population projection models and 
section four explains data collection, while section five deals with data analysis.  
6.1 Study design  
 
For each HIV/AIDS intervention in the following contexts: a low HIV prevalence 
context (LPC), a high HIV prevalence context (HPC), a rural context and an 
urban context, a follow-up of patients is done and CE is estimated. The CE of a 
given HIV/AIDS intervention in one context is then compared with its own CE in 
another context. This comparison is done for voluntary counselling and testing 
(VCT), sexually transmitted infections (STD), prevention of mother-to- child 
transmission (PMTCT) and highly active antiretroviral (HAART) for adults and 
HAART FOR CHILDREN. An LPC and a HPC are termed epidemiological contexts 
while a rural context and an urban context are termed socio-economic contexts. 
 
The design distinguishes different types of follow-up. In one type of follow-up, 
the same size patient cohort starts in the same HIV/AIDS state across contexts 
and this size changes as a result of death only. In another type, different sizes of 
patient cohorts start in different HIV/AIDS states across contexts and these sizes 






It is assumed that the distribution of patients in HIV/AIDS states over time 
depends on the interaction between HIV/AIDS interventions and the contexts in 
which such interventions are implemented. In the follow-up, estimates are made 
of costs, effectiveness and the CE of HIV/AIDS interventions in each context 
over a specified time horizon of HIV/AIDS interventions. The study uses two 
types of time horizons, the lifetime horizon of the interventions in which an 
evaluation of cost and effectiveness stops when all members of a cohort of 
patients in that intervention die and a specific time horizon in which the 
evaluation of cost and effectiveness stops at a specific date while some patients 
are still alive.   
With regard to the scope of the study, CE comparisons are only done within 
epidemiological contexts or socio-economic contexts. In other words, the CE of a 
given HIV/AIDS intervention in an LPC is only compared with its own CE in a 
HPC for epidemiological contexts and the CE of a given HIV/AIDS intervention in 
a rural context is compared with its own CE in an urban context for socio-
economic contexts. Therefore, the CE of a given HIV intervention is compared 
across two contexts at a time. The study acknowledges other contextual 
comparisons of HIV/AIDS such as the comparison of the CE of a given 
intervention in an LPC and in a rural context. These comparisons are not 
considered and are referred to future research due to space and time 
constraints. Furthermore, the study does not attempt to identify the specific 
factors influencing cost-effectiveness in the contexts considered or focus on a 
particular group of patients such as males and females.  
 
Two types of comparisons are considered in this study. The first compares the 
average CE ratio (ACER) of intervening with a given HIV/AIDS intervention in 
one context relative to intervening with the same intervention in another 
context. The second is a comparison of the incremental CE ratio (ICER) of a 
given intervention relative to USUAL CARE (care in the case of the absence of an 
HIV/AIDS-specific intervention) in one context with the ICER of the same 
intervention relative to USUAL CARE in another context. In both types of 
comparison, the CE of an HIV/AIDS intervention in one context is compared with 
its own CE in another context using ACER and ICER as a comparison statistic. In 





which the size of the cohort of patients is the same and starts in the same 
HIV/AIDS state in either context, or a situation in which the size of the cohort of 
patients is different and this cohort of patients starts in different HIV/AIDS 
states.  
 
The effectiveness of an HIV/AIDS intervention in terms of improved health 
status is estimated using a one-dimensional measure of effectiveness such as 
survival, deaths averted and life-years gained, and a multidimensional measure 
of effectiveness which simultaneously takes survival and the quality of life in that 
survival (QALYs) into account. QALYs are obtained by multiplying the percentage 
of perfect health in a given health state (say AIDS state) by the time (in years) 
spent in that state, hence providing perfect years produced by an intervention.   
 
Briefly, the design of the study is such that CE comparisons are conducted from 
different points of view. This is achieved by including CE comparisons of 
HIV/AIDS interventions with same and different sizes of cohorts of patients, with 
and without USUAL CARE, with and without multidimensional measures of 
effectiveness, and with and without lifetime horizon. These multiple points of 
view are considered in one of the two modelling approaches, Markov modelling 
using cohort simulation and epidemiological modelling using the ASSA2008 AIDS 
model and SPMS. 
 
6.2 Markov model  
 
This section discusses the Markov model. It briefly discusses the theoretical 
aspects of the model and its empirical application, and shows how the model is 
applied in this study.   
 
6.2.1 Theory and empirical application  
 
A Markov model is used when the patients across the two contexts are assumed 
to be of the same size and start in the same HIV/AIDS state. A Markov model 
tracks a hypothetical cohort of patients in successive periods (cycles) of equal 
intervals over the time horizon of an HIV/AIDS intervention (Sonnenberg & 





exclusive HIV/AIDS states, “non-infected”, “infected”, “AIDS” and “deaths” 
chosen in terms of their influence on health status and costs. Belonging to a 
mutually exclusive HIV/AIDS state means that a patient cannot be in two 
HIV/AIDS states in one period. 
 
The Markov model shows the distribution of a cohort of patients in HIV/AIDS 
states in short and successive periods of the interventions’ time horizon. The 
model determines the costs/health outcomes of an HIV/AIDS state by applying 
the HIV/AIDS state’s cost/ health outcomes to the number of patients in that 
HIV state. The numbers of patients in each HIV/AIDS state are obtained by 
means of the proportion of patients, called transition probabilities, who usually 
fall into that state from other HIV/AIDS states when a cohort of patients is 
followed up. The costs and health outcomes of any one period of the successive 
periods is obtained by summing over costs/health outcomes of HIV/AIDS states 
in that period. The costs/health outcomes of the model over the term of analysis 
are obtained by summing over cost/health outcomes of successive periods.  
 
Technically the Markov model tracks patients in HIV/AIDS states in successive 
periods of the time horizon for the analysis by associating a transition 
probabilities matrix with each period.  The transition probabilities matrix in the 
current period shows the proportions of patients in HIV/AIDS states who have 
transited to these states from other HIV/AIDS states in the previous period. 
Table 6:1 shows an example of the transition probabilities matrix for a current 
period.  
 









                   Transition to current period  
 State 1 State 2 State 3 
State 1 P11 P12 P13 
State 2 P21 P22 P23 
State 3 0 0 1 
 P11+P21 P12+P22 P13+P23+1 






In Table 6:1, the second column from the left shows HIV/AIDS states in the 
previous period, the alive states (State 1 and State 2) and the dead states 
(State 3). The second row from the top of the table shows HIV/AIDS states in 
the current period. Cell P11 shows for instance, the proportion of patients from 
State 1 in the previous period who remain in State 1 in the current period. Cell 
P12 shows the proportion of patients from State 1 in the previous period that 
move to State 2 in the current period. The other cells in the table are defined 
similarly.  The number of patients in each HIV/AIDS state of the current period is 
obtained by applying a specific size of a cohort of hypothetical patients in HIV 
states in the previous period to the proportions (transition probabilities) in Table 
6:1.  
 
To get the proportion of patients in HIV/AIDS states in the next period, the 
proportion of the cohort in HIV/AIDS states in the current period (P11+P21, 
P12+P22, P13+P23+1) are now in State 1, State 2 and State 3, respectively of 
the second column of the transition probability matrix of the next period. In this 
period, they are distributed in HIV/AIDS states according to the transition 
probabilities matrix of that period.  Since only patients in the alive states transit 
to other states, the proportion of patients in the dead states (State 3) transit 
only to State 3 (indeed, they remain in State 3 and no transition takes place); 
over time the size of the remaining cohort to apply to the successive transition 
probability matrix shrinks. When almost all patients are dead no further 
transition is possible; the lifetime horizon of Markov modelling is reached.  In 
this case, a hypothetical cohort of patients is applied to the model to obtain the 
different number of patients in HIV/AIDS states in successive periods. The cost 
and effectiveness evidence in HIV/AIDS states is then applied to these patients. 
The total cost and effectiveness of the model are then summed up. It should be 
noted that the comparison of the CE of two interventions implies running two 
Markov models.   
 
A number of states transition models have been used to analyse the impact and 
cost of HIV/AIDS interventions. One of the most commonly used models is the 
CE of preventing AIDS complications (CEPAC) model. The Markov model is 





interventions as it tracks the movement of patients back and forth in HIV/AIDS 
states, which is characteristic of HIV disease. The Markov states transition model 
has been recommended for diseases of this nature (Sonnenberg & Beck, 1993; 
Briggs & Sculpher, 1998) and has been extensively applied to analyse the 
consequences of HIV/AIDS both in high-income countries (Chancellor et al., 
1997; Freedberg et al., 2001;) and low-income ones (Goldie et al., 2006; 
Walensky et al., 2008; Badri et al., 2006; Cleary et al., 2006).   
6.2.2 Markov modeling and this study  
 
In epidemiological contexts, this study uses one pair of Markov models for each 
HIV/AIDS intervention. One Markov model is constructed for an LPC and another 
for a HPC. A HPC includes the Eastern Cape, Free State, Gauteng, KZN and 
North West; while an LPC includes the provinces of Limpopo, Mpumalanga, 
Northern Cape and the Western Cape. A HPC has had an antenatal prevalence 
rate above 25%, while an LPC has had a rate below 25%. South Africa as a 
whole is already a HPC on the basis that it is a generalised epidemic country with 
an HIV/AIDS  prevalence rate above 5% in the general population (UNAIDS 
2010; UNAIDS/WHO, 2009). However, this study classified provinces as HPC and 
LPC in order to capture the effects on outcomes and costs of HIV/AIDS 
interventions of the differentiated epidemic which has characterised the country.  
 
In each model, the movement of patients in HIV/AIDS states over time is first 
tracked using the transition probability matrix of the first three-month period 
determined by collecting related evidence from the literature about the 
proportion of patients who usually transit from a given state to another (see 
Section 6.4). Second, the movements of patients in HIV/AIDS states in 
subsequent three-month periods are tracked by making assumptions about such 
movements on the basis of the evidence of projection models in relation to 
trends in the epidemic.    
 
In socio-economic contexts, two pairs of Markov models are constructed for each 
intervention. One pair consists of a model of an HIV/AIDS intervention for the 
rural context and a model for the same HIV/AIDS intervention in the urban 





CARE15. Therefore, another pair consists of a Markov model for USUAL CARE in 
the rural context and a Markov model for USUAL CARE in the urban context for 
patients who would have used that intervention. The process of tracking patients 
in various HIV/AIDS states over time is the same as in epidemiological contexts 
for the first three-month period and in subsequent periods.  
 
In either context, it is assumed that all members of the cohort of patients start 
in the “non-infected” states for prevention interventions; while for HAART 
interventions, it is assumed that patients start in the “AIDS” state. The same 
size cohort of patients is also assumed in each context. The interaction between 
the context and the intervention is captured by basing the progression of 
patients in HIV/AIDS states over time in each context on the context-specific 
projections by epidemiological models which take such interactions into account 
(see Section 6.3).  
 
In either context, the Markov model tracks (or simulates in the terminology of 
Markov modelling) a hypothetical cohort of patients in different HIV/AIDS states 
over successive three-month intervals, in line with previous studies conducted in 
South Africa (Cleary et al., 2006) until everyone in the cohort is dead. The 
cohort is assumed to be similar to the population of patients who would have 
been using HIV/AIDS interventions since 2007. The year 2007 is chosen as the 
starting point of simulation because it is the year which marked the South 
African Government’s serious commitment to tackle the HIV epidemic (Meldrum, 
2006). This study aims to advise South African policy makers on the economic 




                                       
15 It is important to note that USUAL CARE is no longer an option in the sector of 
HIV/AIDS interventions. However to capture the full benefit and costs of HIV/AIDS 
interventions in a context, the USUAL CARE and related costs had to be accounted for to 






6.3 Epidemiological projection models  
 
In a situation when the cohorts of patients across contexts are assumed to be of 
different sizes and start in different HIV/AIDS states, epidemiological projections 
in relevant contexts are used to estimate cost-effectiveness.  The ASSA2008 
AIDS model is used in epidemiological contexts, while SPMS is used in socio-
economic contexts.  
 
6.3.1 ASSA2008 AIDS models  
 
The ASSA2008 AIDS model is used to make annual projections of patients using 
an HIV/AIDS intervention and health outcomes over the period 2007-2020 in 
epidemiological contexts, namely an LPC and a HPC as explained above. These 
numbers of patients are used as the basis for estimating the annual costs of that 
HIV/AIDS intervention by applying the annual cost per patient.   
 
The ASSA2008 AIDS model is an updated version of the AIDS Models of the 
Actuarial Society of South Africa (ASSA). The first AIDS model was ASSA500. 
Subsequent improvements on the model resulted in ASSA600, ASSA2000, 
ASSA2003 and ASSA2008. In 2002, the year in which the ASSA2000 model was 
released, the AIDS Committee decided to name the models after the year of 
antenatal prevalence data used to construct the model. This means that 
ASSA2000, ASSA2003, and ASSA2008 were constructed based on antenatal 
prevalence data for 2000, 2003 and 2008.  
 
ASSA2008 is an improvement on ASSA2003. The construction of ASSA2003 was 
founded on the assumption that HIV spreads via heterosexual encounters. The 
modelling distinguished the variables PRO, STD, RSK, and NOT; each capturing a 
different level of risk of infection. The PRO variable represented the group of 
people with the highest risk of infection. This group consisted of sex workers. 
The STD was a variable for the group of people with the next highest risk of 
infection and was made up of frequent carriers of other STDs. The third variable, 
RSK, referred to the group of people with the next highest risk of infection. This 
group was made up of people at risk of infection such as the youth, but not 





of infection, NOT, captured data for the group of people not at risk. The model 
also took account of the differences in the spread of HIV across age, and the 
gender composition of these risk groups. The model used data on sexual 
behaviour, the probability of infection, the progression of HIV, the effect of 
major interventions, census data (1970, 1996 and 2001), fertility rates, the 
1998 demographic and 2001 health surveys, international migration data, non-
AIDS mortality data and 2008 antenatal survey data in South Africa in different 
epidemiological contexts considered in this study as LPC and HPC to formulate 
such projections. The ASSA2008 improved on the projections of its predecessors 
in that it took account of increased condom usage, treatment with HAART, 
increases in survival rates among untreated HIV/AIDS patients and a lower 
incidence of MTCT than had been previously modelled.   
 
The annual cost of an HIV/AIDS intervention over the period 2007-2020 is 
calculated on the basis of annual projections of patients using the intervention.  
Where an HIV/AIDS intervention is absent, it is assumed that patients in an LPC 
or a HPC use USUAL CARE. Therefore, the same annual projections of the 
number of patients are also used to estimate the annual costs of USUAL CARE 
over the period 2007-2020. ASSA2008 AIDS model projections are expected to 
depict the effect of the interaction between an HIV/AIDS intervention and the 
LPC or HPC on the CE of that HIV/AIDS intervention. 
6.3.2 Spectrum Policy Modeling System (SPMS) 
 
The SPMS is used to make projections of the annual number of patients using an 
HIV/AIDS intervention over the period 2007-2020 in socio-economic contexts, 
notably the rural context and the urban context. The SPMS is a modular 
programme designed to assist policy makers with current and future information 
on the impact of HIV/AIDS, the effectiveness of HIV/AIDS interventions and 
resource requirements for planning purposes. It does this by allowing the 
interaction between a demographic projection module, an AIDS impact module 
and an HIV/AIDS intervention module.  The SPMS is updated every two years to 






The SPMS has been extensively used to inform policy-making at national (Rehle 
& Shisana, 2003; Wood et al., 2000) and sub-national levels (Mekonnen et al., 
2002). One of the model’s most recent applications was the estimation of the 
impact of expanded access to antiretroviral therapy in 10 sub-Saharan African 
countries, including South Africa (Anema et al., 2011).  
 
To make annual projections in a rural and an urban context, SPMS requires 
context-specific data on demographic and HIV epidemic and HIV/AIDS 
interventions parameters. Demographic inputs, notably the population per age 
and gender for the base year (1981), are collected from the United Nations 
Population Division. This year is chosen as the base year for the demographic 
projection due to the recommendation of the model builders to start the 
projection two years before the first AIDS case in the country; AIDS was first 
observed in South Africa in 1983 (Abdool Karim et al., 2010:39).  
 
Assumptions are made about life expectancy at birth and international migration 
over time. Life expectancy is assumed to be higher among females than males 
(Statistics South Africa, 2010), but no differences are assumed regarding 
patterns of life expectancy across rural and urban contexts over time, given the 
absence of evidence in this regard. The default UN Population Division’s 
international migration variable provides country-level international migration 
data and was adjusted to include rural-urban migration.   
 
With regard to the age distribution of fertility, that is, how age groups share the 
number of births over time, it is assumed that there are more births among 
young females in the urban context than in the rural context, given the tendency 
of younger women to move to an urban context. The total fertility rate in each 
area - the average number of children born to a woman in her lifetime - is set at 
South Africa’s total fertility rate as reported in the literature (UN Population 
Division, 2011) due to the absence of such data in each context.   
 
The impact of AIDS has not been routinely reported in a rural context and an 
urban context in South Africa, and thus also had to be modelled. Shisana & 
Simbayi (2002) found that HIV/AIDS prevalence was higher in an urban context 





(townships) and urban formal (metropolitan) areas, while the rural context was 
made up of tribal areas and farm areas.  
 
The present study combined urban informal and urban formal areas to comprise 
an urban context, and tribal and farm areas to comprise a rural context, 
recalculated the prevalence of HIV/AIDS in urban and rural contexts based on 
the sample weights in each sub-area and assumed greater HIV/AIDS prevalence 
in an urban context up to 2010 (Shisana & Simbayi, 2002; HSRC/MRC/CADRE 
2005; HSRC/MRC/CADRE, 2009). After 2010, it is assumed that the difference in 
the prevalence rate between rural and urban contexts decreased to converge by 
2020, given evidence of the recent increase in the infection rate in rural contexts 
and a decrease in infection in the urban areas (Stover, 2009).  
 
For the purposes of estimating the annual impact of HIV/AIDS in each context 
with the SPMS, annual HIV/AIDS prevalence is incorporated. The available 
evidence on HIV prevalence in rural and urban contexts is incorporated in the 
Estimation and Projection Package (EPP). The EPP has been used for the same 
purpose in other studies in South Africa (see, for example, Rehle & Shisana, 
2003). The prevalence rate assumptions beyond 2010 were directly incorporated 
in the SPMS. 
 
The next step in the projection of CE is to incorporate the effectiveness data for 
HIV/AIDS interventions. For PMTCT, it is assumed that in the absence of PMTCT 
the infection rate would be 30%, with a range of 25-40% among breastfeeding 
communities following evidence in this regard (Shaffer et al., 1999). In line with 
recent evidence on the effectiveness of PMTCT, the infection rate with PMTCT is 
assumed to be 3.5% (Leach-Lemens, 2011). The study assumes that the median 
time from infection to AIDS death is 10.5 years for adults. The median time from 
eligibility for treatment (at CD4 count 350) to death is assumed to be 7.9 years 
for adults.  The annual survival rate on antiretroviral drugs is assumed to be 
90% for adults and 85% for children (UNAIDS, 2009). Table 6:2 provides a 
summary of key demographic and epidemiological parameters used in the 






Calibration is done to establish how these assumptions’ results compare with 
other projections. These are presented below. The main input parameters in 
Table 6:2 and projections in Figure 6:1 compare favourably with other sources.  
 
Table 6:2 Key parameters in a rural context and an urban context 
Rural  areas 
Baseline parameter  Base-case Value  
Source 
Total population in 1981 
 
Baseline total fertility rate  
 






Perinatal transmission among 
breastfeeding women  
 
 
Median time from infection to death (no 
intervention) 
 
HIV prevalence rate (general population) 
 





















UN Population Division  
 




UN Population Division 
  









(Shisana & Simbayi,2002) 
 
Statistics South Africa (2010) 
Urban areas 
Total population in 1981 
 
Baseline total fertility rate  
 





Perinatal transmission among 
breastfeeding women  
 
Median time from infection to death (no 
intervention) 
 





















UN Population Division  
 




UN Population Division 
UN Population Division 
 
 







(Shisana & Simbayi,2002), Statistics South 
Africa (2010) 
Notes: Data are produced at a national level and then adjusted based on infection trends in rural 






Source:  ASSA (2011), Stover (2011).  
 
Figure 6:1 Comparison of modelled data with population data and prevalence data 
 
6.4 Data collection  
 
This section explains how data are collected for the Markov models and 
epidemiological projection models. 
 
6.4.1 Data collection for Markov models  
 
Transition probabilities for the first three-month period are collected from the 
literature in relevant epidemiological or socio-economic contexts.  In subsequent 
periods, transition probability data are generated based on trends suggested by 
projection models in each context. In epidemiological contexts, such data are 
based on mortality and infection rates over time in an LPC and a HPC as 





based on infections and mortality rate over time as suggested by the SPMS 
which projects the impact of interventions in rural and urban contexts. The 
average infections and mortality rates every year are transformed in a 3-month 
transition probability.  
 
Effectiveness data collected consist of utility weights data. Utility weights 
equivalent to quality of life from South African studies (Jelsma et al., 2005; 
Louwagie et al., 2007; O’Keefe & Wood, 1996) are used. Using community 
responses about their quality of life in HIV/AIDS stages, these studies 
transformed data into utility weights employing empirical predictions based on 
expected utility methods that yielded these predictions using community 
responses in high income countries (Euroqol Group, 1990).    
 
The costs are collected in the relevant literature. Cost data from a perspective 
other than the government’s are adjusted to reflect the latter perspective, since 
the South African Government is the main funder of HIV/AIDS interventions.  
The study includes the societal perspective to account for the full costs of 
HIV/AIDS interventions by adding patient transport costs and waiting time. The 
US Panel of Experts has recommended that the societal perspective be taken 
into account in CE analysis (Gold et al., 1996). All costs and health outcomes are 
discounted at 3% in the base-case analysis taking the beginning of 2007 as time 
zero. Real costs are used, with 2007 as the base year. Data collected in the form 
of rates are transformed into transition probabilities using the formula 
rte1 suggested in the literature (Sonnenberg & Beck, 1993:30). 
 
6.4.2 Data collection for projection models  
 
In epidemiological contexts, the annual cost per patient is collected in the South 
African literature in relevant epidemiological or socio-economic contexts. Annual 
cost per patient is separately gathered for an LPC and a HPC. The costs are 
adjusted to reflect full opportunity costs and the government and societal 
perspectives as in the case of data for the Markov models. 
 
The annual number of patients using VCT and STD in an LPC and a HPC over the 





patients benefiting from an intervention in the country. This proportion is then 
applied to the population of a given context. The annual number of patients for 
PMTCT and HAART over the period 2007-2020 is obtained directly from 
ASSA2008 AIDS model projections.  
 
In socio-economic contexts, the annual cost per patient is collected in the 
literature in relevant contexts. The annual cost per patient is separately 
gathered for a rural context and an urban context.  The annual number of 
patients using PMTCT, HAART FOR ADULTS and HAART FOR CHILDREN in a rural 
context and an urban context over the period is obtained directly from model 
projections. As in epidemiological contexts, the annual cost per patient is applied 
to estimate the cost over the period.  
6.5 Data analysis, uncertainty and limitations of the methodology 
 
This section deals with the analysis of the data. It explains how Markov and 
epidemiological projection models were used in the analysis and how uncertainty 
was handled and finally, it presents the limitations of the methodology.  
 
6.5.1 Data analysis with Markov model  
 
In the Markov model, data are analysed using TreeAge Pro software. Cohort 
simulation is conducted. A hypothetical cohort of 100,000 patients is applied to 
different transition probability matrices corresponding to the time horizon of the 
analysis. The outcomes of the simulation are the number of patients surviving in 
different HIV/AIDS states over the lifetime of the cohort. The cost and the 
effectiveness collected from the literature are applied to patients in HIV/AIDS 
states and the results are summed up. The cost and effectiveness of a given 
HIV/AIDS intervention in two contexts are compared.  
 
The comparison of HIV/AIDS interventions is done using the ACER and the ICER.   
The ACER is used for comparison of HIV/AIDS interventions across contexts 
which do not take USUAL CARE into account, while ICER is used for comparisons 





ICER of an HIV/AIDS intervention compared to USUAL CARE is calculated in each 
context and the ICERs of that intervention across contexts are compared.  
 
The extent to which the CE of an HIV/AIDS intervention in one context compares 
with the CE in another context is measured by comparing the ACER or ICER of 
that intervention in two contexts. When an ACER or ICER of an HIV/AIDS 
intervention in context one expressed as percentage of the ACER or ICER of that 
intervention in context two is less (more) than 100%, that HIV/AIDS  
intervention is more (less) cost-effective in the former context. The farther the 
percentage is below (above) 100%, the greater (lesser) is the CE of that 
HIV/AIDS intervention in context one.    
 
6.5.2 Data analysis with epidemiological model  
 
The number of patients in the Markov model in different HIV/AIDS states is one 
of the most important determinants of the cost and effectiveness of 
interventions.  According to the Markov model, a change in these numbers over 
time is only due to death rather than migration and new births. Since one cannot 
ignore migration and new births when modelling population over a long period, 
this study compared cost-effectiveness from a different perspective by using 
epidemiological models which take deaths, migrations, and new births into 
account in modelling.  
 
In this respect, epidemiological models are used to compare HIV/AIDS 
interventions which involve USUAL CARE. Projections of the annual health 
outcomes of HIV/AIDS interventions in terms of infections, deaths and life-years 
are recorded for the period 2007-2020 for USUAL CARE and a specific HIV/AIDS 
intervention. The effectiveness of an HIV/AIDS intervention is measured as 
infections averted, death averted and life years gained relative to USUAL CARE. 
The annual number of patients in an LPC and a HPC from 2007 to 2020 are 
projected using the ASSA2008 AIDS model for each of the modelled HIV/AIDS 
interventions. The projected number of patients for each HIV/AIDS intervention 
is also used for the intervention’s USUAL CARE. In a rural and an urban context, 
the annual numbers of patients over the period 2007-2020 are projected by the 





annual number of patients in a rural context and an urban context in the case of 
USUAL CARE (absence of intervention).  
 
The cost of HIV/AIDS interventions are estimated based on the annual number 
of patients using such interventions for the period of interest, namely 2007-
2020.  For an HIV/AIDS intervention, these numbers are estimated based on the 
guidelines of HIV/AIDS interventions and the usage rate (in epidemiological 
contexts) or directly obtained from the projection models (in socio-economic 
contexts). The costs of USUAL CARE for patients who use a specific HIV/AIDS 
intervention are estimated under the assumption that these patients would use 
USUAL CARE had there not been such an HIV/AIDS intervention.   
 
The ICER is used to compare the CE of an HIV/AIDS intervention in one context 
with the ICER of the same intervention in another context. As in the case of 
Markov modelling explained above, the ICER of an HIV/AIDS intervention 
compared with USUAL CARE is calculated in each context and the ICERs of that 
intervention across contexts are compared.  
 
6.5.3 Uncertainty and limitations of the methodology   
 
Uncertainty is usually present in these types of analysis. Two types of analysis of 
uncertainty are conducted, probabilistic sensitivity analysis in the Markov model 
and scenario analysis in the projection models. Probabilistic sensitivity analysis 
considers all parameters in a model to be random variables, with specific 
probability distributions.  One thousand random samples were drawn from the 
distribution of these parameters, average cost and effectiveness were calculated 
from these samples and the ICER or ACER was used to compare interventions.   
 
Scenario analysis is conducted to assess the comparability of the CE of HIV/AIDS 
interventions across contexts in case of changes in some parameters. 
Specifically, scenario analysis is conducted to assess changes in the conclusion 
of the base-case analysis in case of a drop in adherence, in case of different 






Turning to the limitations of the methodology, it is acknowledged that modelling 
can only depict part of reality. AIDS models in particular, no matter how well 
they are modelled, may not capture the full reality and dynamics of HIV/AIDS. 
Other CE methodological limitations such as possible inaccuracy in assumptions, 
data and other issues have been surveyed by Raftery (1999) and referred to in 
the review of CE evidence in Africa (Creese et al., 2002; Walker, 2003). Despite 
the shortcomings of modelling, it has become an important tool in advising 




In conclusion, this chapter presented the methodology used in this study, 
consisting of Markov modelling and epidemiological projection models in each 
context. The latter projection models are used to make assumptions about 
future progression in HIV/AIDS states. Two types of uncertainty are conducted, 
one that considers uncertainty on all parameters and another which includes 
scenario analysis on the basis of potential trends in adherence to HIV/AIDS 
interventions. This chapter outlined the general methodology; specific details are 
presented in the analysis chapters. The analysis chapter comparing the CE of 



















Chapter 7 : Cost-effectiveness of HIV/AIDS interventions 
in low and high HIV prevalence contexts  
 
  
This chapter compares the CE of HIV/AIDS interventions across an LPC and a 
HPC. In each context, a hypothetical cohort of 100,000 patients in an HIV/AIDS 
intervention is followed up over time by means of a Markov states transition 
model. The proportions of patients, the costs and the quality of life data in 
various HIV/AIDS states, are collected from the literature. The effect of the 
interaction between an HIV/AIDS intervention and the context on the CE of such 
an intervention is taken into account. This is done  by collecting the evidence in 
that context and modelling transitions in HIV/AIDS states over time as per 
trends suggested by the ASSA2008 AIDS model projections in that context. The 
effectiveness is measured in terms of survival or survival adjusted for the quality 
of life (QALYs). The CE of an HIV/AIDS intervention is compared across an LPC 
and a HPC using the ACER of that intervention in each context. Section one 
elaborates on the methods used; section two presents the results; and section 




Markov states transition models are constructed for each of the modelled 
interventions. Transitions probabilities, costs and quality of life data are collected 
from the literature, after which a sensitivity analysis is conducted.  
 
7.1.1 Markov models  
 
A pair of Markov models is constructed for each of the four interventions: 
voluntary counselling and testing (VCT), sexually transmitted diseases (STD), 
Prevention of Mother- to-Child Transmission (PMTCT) and treatment with highly 
active antiretroviral drugs (HAART). One Markov model tracks a hypothetical 
cohort of 100,000 patients in various HIV/AIDS states over the lifetime of the 
cohort in an LPC. Another Markov model does the same in a HPC. The Markov 






Briefly, the model represents patients in HIV/AIDS states in short and successive 
periods of the interventions’ time horizon. The model determines the 
costs/health outcomes of an HIV/AIDS state by applying the HIV/AIDS state’s 
costs/health outcomes to the number of patients in that HIV/AIDS state. 
Patients in each HIV/AIDS state are obtained by means of the proportion of 
patients, called transition probabilities, that usually falls in that HIV/AIDS state 
from other states when a cohort of patients is followed up. The cost and health 
outcomes of any one period of the successive periods are obtained by summing 
over costs/health outcomes of HIV/AIDS states in that period. The cost/health 
outcomes of the model over the term of analysis are obtained by summing over 
cost/health outcomes of successive periods. 
 
To track a cohort of patients over time in prevention interventions (VCT, STD, 
and PMTCT), four HIV states are used: “non-infected’, “infected with no AIDS”, 
“infected with AIDS” and “dead”. The state “infected with no AIDS” refers to the 
state in which patients are infected but not yet in need of antiretroviral drugs as 
per 2007 guidelines (below CD4 counts 200)16. The state “infected with AIDS” 
refers to the state when infected patients are in need of treatment. 
 
While the main purpose of prevention interventions is to avoid new infections, 
avoiding costly and worse health outcomes in subsequent use of treatment 
interventions have also been acknowledged as benefits of prevention. To show 
these benefits, treatment-relevant HIV/AIDS states are added to the Markov 
state transition structure of prevention interventions.  
 
A hypothetical cohort of 100,000 patients is assumed to start in a “non-infected” 
HIV/AIDS state and is followed up (simulated) in each prevention intervention 
over the lifetime of the cohort, that is, when almost all patients are dead. At one 
time in the future (the lifetime of the cohort) all patients who transit to the state 
“dead” do not transit any more. Therefore, eventually, all patients will 
accumulate in the “dead” state. The lifetime in the model is assumed to be 
reached when at least 95% of the cohort is dead. In each of the 3-month 
                                       
16  These guidelines have changed since 2011 but the analysis here considers 2007 
guidelines because of the absence of systematic cost and effectiveness data for the 2011 





successive periods, some patients remain in the “non-infected” state, others 
move to “infected” and still others to “AIDS”. A typical Markov cycle tree 
structure for prevention intervention is shown in Appendix 1 (p.245). 
 
In HAART intervention, the Markov state transition model tracks a cohort of 
patients in three HIV/AIDS states, namely, “non-AIDS”, “AIDS” and “death”. 
“Non-AIDS” refers to the state when patients are infected but have improved 
their CD4 count above the treatment threshold (CD4 count >200). “AIDS” refers 
to the state when patients have reached a serious stage of the illness, with a lot 
of serious opportunistic infections (CD4 count below 200). A hypothetical cohort 
of 100,000 patients is assumed to start in the “AIDS” state, and, in a 3-month 
period, some members remain in the same health state, while others move to 
the “non-AIDS” state in response to treatment, and still others to the “dead” 
state. Strata of CD4 counts are used to depict important stages of HIV 
progression in line with evidence that CD4 count is a major predictor of HIV 
progression (Egger et al., 2002; Hogg et al., 2001), health outcomes and costs.  
A typical Markov cycle tree structure for treatment interventions is presented in 
Appendix 2 (p.246).  
  
The structure of the Markov model for a given intervention is assumed to be the 
same regardless of whether the intervention is conducted in an LPC or in a HPC. 
For example, the four HIV/AIDS states defined for a typical prevention 
intervention in an LPC are the same for that intervention in a HPC. Similarly, the 
3-month transition period considered for a given intervention in an LPC applies 
to the same intervention in a HPC.  
 
The lifetime (until at least 95% of the cohort is dead) costs, health outcomes 
and CE of HIV/AIDS interventions are simulated. The model tracks or simulates 
these costs and health outcomes in successive 3-month periods for a cohort of 
100,000 patients in each context since 2007. The starting time for the analysis is 
motivated by the fact that this is when HIV/AIDS started receiving proper 
attention from the South African Government. The simulation is expected to 
estimate the economic implications of such commitment. To take account of the 





patients in HIV/AIDS states in subsequent 3-month periods are pegged on the 
ASSA2008 AIDS model projections (see Appendix 15 for more on this, p. 259).  
 
7.1.2 Data and analysis 
  
The transition probabilities (proportions) of patients in HIV/AIDS states from 
other HIV/AIDS states are gathered from the literature, notably HIV/AIDS cohort 
studies. Transition rates reported for periods other than 3 months are adjusted 
to take account of the 3-month period used in the Markov model. The rates, that 
is, the number of patients who move to a given HIV/AIDS state in a period of 
time, are converted into a 3-month transition probability using the formula 
rtep 1  suggested in the literature (Sonnenberg and Beck, 1993:330) where p 
is the transition probability, r is the rate or the number of patients who transit in 
a period of time, t. The time is transformed in the number of 3-month periods 
either through multiplication or division depending on whether t is greater or 
less than a 3-month period. Table 7:1 provides a summary of transition 
probabilities used in the base-case analysis for VCT and treatment of STD.   
 
Table 7:1 Transition probabilities data for the base-case comparison: VCT and STD 
VCT  Low HIV prevalence context  High HIV prevalence context   




Evidence sources  
Value   
Evidence sources  
Non-infected to non-infected  
Non-infected to infected with no AIDS 
Non-infected to infected with AIDS 
Non-infected to death  
Infected with non-AIDS to infected with no AIDS   
Infected with non-AIDS to infected with AIDS 
Infected with non-AIDS to death  
Infected with AIDS to infected with non-AIDS 
Infected with AIDS to infected with AIDS 











Model derived  
ASSA (2011) 
Rehle et al. (2007) 
Anderson  et al. 2006)  
Model derived  
Stover (2009) 
Badri et al.(2006) 
Model derived  
Badri et al. (2006) 











Model derived  
Rehle et al. (2007) 
ASSA (2011) 
Anderson  et al. 2006)  
Model derived  
ASSA (2011) 
Rehle et al. (2007) 
Model derived  
Cleary et al. (2006) 
Bachman (2006) 
STD     
Non-infected to non-infected  
Non-infected to infected with no AIDS 
Non-infected to infected with AIDS 
 
Non-infected to death  
Infected with non-AIDS to infected with non AIDS   
Infected with non-AIDS to infected with AIDS 
Infected with non-AIDS to death  
Infected with AIDS to infected with non-AIDS 
Infected with AIDS to infected with AIDS 
















Anderson  et al.(2006)  
Model derived  
Johnson et al. (2005) 
Badri et al. (2006) 
Cleary et al. (2004) 













Model derived  
Auvert (2001) 
Johnson & Budlender 
(2001) 
Anderson et al.(2006)  
Model derived   
Gilson et al. (1996) 
Model derived  








The 3-month data adjustment reported for VCT and STD is also reported for 
PMTCT and HAART. Table 7:2 shows such data. 
 
Table 7:2 Transition probabilities data for the base-case comparison: PMTCT and HAART 
PMTCT Low HIV prevalence context  High HIV prevalence context   
Transition probability  Base-case 
Value  
 
Evidence sources  
Value   
Evidence sources  
Non-infected to non-infected  
Non-infected to infected with no AIDS 
Non-infected to infected with AIDS 
Non-infected to death  
Infected with non-AIDS to infected with no 
AIDS   
Infected with non-AIDS to infected with AIDS 
Infected  with non-AIDS to death  
Infected with AIDS to infected with non-AIDS 
Infected with AIDS to infected with AIDS 












Model derived  
Skordis & Natrass(2002) 
Soorapath et al.(2006) 
Anderson  et al. (2006)  
Model derived  
 
Stover (2009) 
Cleary et al.(2004) 
Badri et al. (2006) 
Model derived  












Model derived  
Wilkinson et al. (2000) 
Stover(2009) 
Anderson  et al.(2006)  
Model derived  
 
Stover (2009) 
Boulle et al. (2002) 
Boulle et al. (2002) 
Model derived  
Granich et al. (2012) 
HAART     
Non-AIDS to non-AIDS 
Non-AIDS to AIDS 
Non-AIDS to deaths  
 
AIDS to non-AIDS 
AIDS to AIDS 










Model derived  
Badri et al. (2006) 
Cleary et al. (2004) 
 
Ferrer et al.(2004:1727) 
Model derived  










Model derived  
Boulle et al. (2002) 
Natrass & Geffen 
(2005) 
Granich et al. (2012) 
Model derived  
Walensky et al. (2011) 
 
The costs in HIV/AIDS states are also collected from the literature. This chapter 
only considers the costs that reflect the full opportunity costs of each 
intervention. Since the South Africa Government funds two-thirds of the 
HIV/AIDS response (Stewart, 2010), the base-case value analysis is considered 
from the government perspective. However, a societal perspective is also 
analysed to facilitate comparison of results with other studies as per CE expert 
recommendations (Gold et al., 1996:166). A societal perspective takes account 
of full opportunity costs, that is, interventions’ costs and patients’ costs. A 
societal perspective includes estimates of transport, funeral and waiting time 
costs in addition to government perspective costs. Real costs are used in the 
analysis using 2007 prices and are discounted at 3% in line with the 
recommendation from CE analysis experts (Gold et al., 1996). Undiscounted 
results are also reported for the sake of comparison with studies that have 
reported such results. All analyses are performed using TreeAgePro (DATA TM) 
software and data are transferred to excel for graphical and numerical analyses 
(see Appendix 16 for an example on p.261). The baseline cost data are 





Table 7:3 Three-month cost data for the base-case comparison (in US$) 
NB: Societal perspective (SP) costs are estimated based on the available evidence on the average cost of transport, waiting time and funeral costs in 




HIV state                 Low HIV prevalence context                           High HIV prevalence context   











Evidence sources  
Non-infected  
Infected with no AIDS 
AIDS  
Deaths 









McConnell et al. (2005), Geffen et al. (2003) 
Walensky et al. (2011) 
Bachmann (2006) 










McConnell et al. (2005), Geffen et al. (2003) 
Walensky et al. (2011) 
Bachmann (2006) 
Case et al. (2006) 
STD GP SP Evidence sources GP SP Evidence sources 
Non-infected  












Vickerman et al. (2006) 
Vickerman et al. (2006) 
Badri et al. (2004) 









Vickerman et al (2006) 
Vickerman et al (2006) 
Badri et al. (2004) 
Case et al. (2008) 
PMTCT  GP SP Evidence sources GP SP Evidence sources 
Non-infected  












Soorapath et al. (2006) 
Soorapath et al. (2006) 
Cleary et al. (2004) 









Soorapath et al. (2006) 
Soorapath et al.(2006) 
Cleary et al. (2004) 
Case et al. (2008 










Badri et al. (2006) 
Cleary et al. (2004) 







Badri et al. (2006) 
Cleary et al. (2004) 





The health outcome in an HIV/AIDS state is calculated based on the duration 
and quality of life of that state. To this end the chapter collects the quality of life 
data from the South African literature (O’Keefe & Wood 1996; Jelsma et al., 
2005; Louwagie et al., 2007). Quality of life data in South Africa has been 
collected using instruments that contain descriptive questions whose answers 
provide the measure of overall health. The community average health related 
quality of life (HRQoL) has been taken as the average HRQoL from the 
representative sample. 
 
In CE analysis, however, individual responses need to reflect preferences. 
Individual responses can be transformed into preference measures or utility 
indices using an algorithm that predicts a utility score for a set of responses 
from an individual. The prediction model was developed based on the responses 
in a sample of the UK population (Dolan, 1997; Dolan et al., 1995). The same 
algorithm has been used to produce the value of the responses from the 
instrument used in South Africa. Using a Euroqol, an instrument that asks 
questions about mobility and pain/discomfort in a health state, Jelsma et al. 
(2005) produced values of quality of life for patients receiving HAART over a 
one-year period in Cape Town. Using the same instrument in the Free State, 
Louwagie et al. (2007) analysed the value of quality of life for HIV/AIDS patients 
receiving and not receiving treatment. This chapter uses these values in different 
health states of the model. The base-case values used in the analysis are 







 Table 7:4  Quality of life data  
N.B: Utility weights are assumed to be the same across an LPC and a HPC. BCV means base-case values. 
 
 
HIV state                 Low HIV prevalence context                           High HIV prevalence context   











              Evidence base 
 
Non-infected  
Infected with no AIDS 
AIDS  
Deaths 







Jelsma et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 








Jelsma  et al. (2006) & O’Keeffe & Wood  (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
STD BCV                                  Evidence base BCV                      Evidence base 
Non-infected  








Jelsma et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 






Jelsma  et al. (2006) & O’Keeffe & Wood  (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
PMTCT  BCV                                 Evidence base  BCV                       Evidence base  
Non-infected  








Jelsma et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 






Jelsma  et al. (2006) & O’Keeffe & Wood  (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 







Jelsma et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 





Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 





7.1.3 Assumptions  
 
Since the activities of interventions are the same, the costs in the same 
HIV/AIDS state are assumed to be the same across an LPC and a HPC, as is the 
quality of life. However, the simulation includes an assumption of economies of 
scales in HIV/AIDS states, with unit costs moving in an inverse relationship with 
the number of patients in HIV/AIDS states. Due to the unavailability of evidence 
regarding the effects of the changes in the PMTCT and HAART guidelines in 2010 
and 2011, the analysis is conducted under the assumption of the 2007 
guidelines. The possible effects of these changes are discussed outside of the 
modelling. Uncertainty, expected to arise from any parameter, is handled by 
probabilistic sensitivity analysis in which lognormal distributions and triangular 
distributions were used for cost and effectiveness values, respectively.  
 
7.2 Results  
 
This section presents the results. It distinguishes the costs, effectiveness, and 
CE results, in this presentation.   
 
7.2.1 Costs  
 
In order to understand the CE of intervening in a HPC and an LPC, it is useful to 
analyse the data relating to the cost and the effectiveness of intervening in these 
contexts separately. This analysis starts with the costs.  
 
The costs of intervening in an LPC and a HPC depend on the distribution of 
patients and the unit cost in HIV/AIDS states in these contexts. Assuming an 
equal unit cost in the same HIV/AIDS state across an LPC and a HPC implies that 
the pattern of costs depends on the distribution of patients in HIV/AIDS states 
across contexts. The average cost results of this analysis are summarised in 









LPA (low prevalence area or context), HPA (high prevalence area or context). Source: based on the results of 
Markov models’ simulations.  
 
Figure 7:1 Stage costs in an LPC versus a HPC 
 
As expected, the average cost is greater in a HPC than in an LPC. The difference 
in cost arises because over time, relatively more patients are in costly HIV/AIDS 
states in a HPC than they are in an LPC. However, the assumption of the same 
set up of interventions across the contexts implies similar fixed and variable 
resources in HIV/AIDS states. An implication of this assumption is that different 
distributions of patients in these HIV/AIDS states might result in different unit 
costs because of economies of scale. The chapter investigated this question by 
assuming an inverse relationship between the growth of the number of patients 
in HIV/AIDS states and the unit costs in the HIV/AIDS states. Figure 7:2 
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presents the patterns of average costs for the government perspective which 
would be similar to the pattern for the societal perspective. 
 
LPA (low prevalence area or context), HPA (high prevalence area or context). Source: Based on the results of 
Markov models’ simulations.  
 
Figure 7:2 Costs of intervening in an LPC and a HPC 
 
The results suggest  different patterns in average costs across an LPC and a HPC 
with PMTCT and STD exhibiting the greatest differences.  In comparison with the 
previous discussions in this chapter, an assumption of economies of scale 
changes the cost levels, but not the pattern across an LPC and a HPC except for 





than would be expected. This result is due to the fact that, the chapter included  
subsequent benefits in treatment of HIV/AIDS states for prevention interventions 
assuming linkages of prevention to treatment. Table 7:5 presents the results of 
a comparison of the costs of HIV/AIDS interventions using numbers rather than 
graphs.  
 
Table 7:5 Comparison of average lifetime costs across an LPC and a HPC (costs discounted at 
3%, government perspective)  
 
HIV/AIDS Intervention  LPCC  HPCC Costs  in an LPC as 
% of the costs in a 
HPC 
VCT 



























Source: Author, based on the results of Markov models’ simulations. LPCC: Low prevalence 
context’s costs, HPCC: High prevalence context’s costs.  
 
The Table shows that the average cost of STD and PMTCT are greater in an LPC 
than they are in a HPC, while the average cost of VCT and HAART are less in an 
LPC than they are in a HPC. Table 7:5 also shows that the costs of an HIV/AIDS 
intervention in an LPC as a percentage of its costs in a HPC are different across 
interventions, ranging from 14% to 122%. This result indicates that the extent 
of costs (how close the cost of an HIV/AIDS intervention in one context as a 
percentage of its own cost in another context is to 100%) is also different across 
HIV/AIDS interventions. It is worth noting, however that these estimates have 
very wide confidence intervals. For instance, the lower bound of the VCT costs is 
US$62 with an upper bound of US$1898 while the average is US$400. The 
variation of the average value farther away from the upper and lower bound 





This section presents the effectiveness of HIV/AIDS interventions across an LPC 
and a HPC. It discusses effectiveness in terms of survival, and survival adjusted 





7.2.2.1Survival   
  
This section analyses effectiveness by comparing survival differences across the 





























Source: Author, based on the results of Markov models’ simulations. Key: LPA (low prevalence area or 
context), HPA (high prevalence area or context), infect200+ (infected with CD4 count above 200), infect200<   
(infected with CD4 count below 200).  
 
Figure 7:3 Survival patterns across an LPC and a HPC in South Africa  
 
As shown in Figure 7:3, the patterns of survival across an LPC and a HPC are 
quite different, with the greatest differences apparent in HIV/AIDS states “non-
infected” and “dead”. The smallest differences are observed in the HIV/AIDS 








different across HIV/AIDS interventions. The results show that in general, 
survival is greater in an LPC than in a HPC.  
 
While it might be speculative to point to the exact reasons for the differences, 
the results reflect that the same intervention results in different survival 
outcomes across an LPC and a HPC. These results partially answer the study’s 
initial question of whether or not the interaction of the intervention and the 
context has an effect on cost-effectiveness. These results show that this might 
be the case and hence suggest that policy makers in South Africa should take 
account of the prevalence level in contexts when implementing HIV/AIDS 
interventions.   
 
Differences in intervention outcomes can be explained by a number of social 
theories of health behaviour according to which differences in health status 
depend on people’s perception of risk which in turn depends on personal 
characteristics (Becker, 1974) or the characteristics of the society in which they 
live (Bandura, 1986). On the other hand, empirical research has reached 
different conclusions about how interventions interact with cultural norms 
(Airhihenbuwa, 2004). Some studies have concluded that risk behaviour 
reduction would be greater for people witnessing a real threat from an epidemic, 
in this case a HPC (Geoffard & Phillips, 1996; Sweat et al., 2000:113). While 
some of these conclusions may be relevant to South Africa, it seems that the 
effectiveness of an HIV/AIDS intervention depends on the area of such 
intervention.     
 
In comparing the effectiveness of intervening in an LPC and a HPC using survival 
for prevention interventions, we cannot ignore the fact that the latter’s main 
purpose is to prevent new infections. However, nor can we ignore the evidence 
that beneficiaries of different prevention interventions fare differently in 
treatment interventions (Sweat et al., 2000). To reflect these two facts, the 
chapter compared the proportion of “non-infected” patients over time with the 
proportion of patients in treatment-relevant HIV/AIDS states across an LPC and 








Source: Author, based on the results of Markov models’ simulations. Key: LPA (low prevalence area or 
context), HPA (high prevalence area or context), infect200+ (infected with CD4 count above 200),  infect200<, 
infect200- (infected with CD4 count below 200).  
 
Figure 7:4 Proportions of non-infected, infected and proportions of patients surviving in treatment 
states  
 
Figure 7:4 shows that over time an LPC produces a greater proportion of 
patients in “non-infected” and “infected CD4 200-” states than a HPC. Moreover, 
the figure depicts a more rapidly decreasing proportion of patients in “infected 
CD4 200-”  in a HPC than it does for an LPC. In summary, this result suggests 
that intervening in an LPC with prevention interventions not only  results in more 
infections averted but also in more future treatment benefits than in a HPC. 
Again, with interventions’ activities being the same, this difference in results can 
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be attributed to differences in the interaction between the context type and the 
intervention.    
 
7.2.2.2 Survival adjusted with quality of life  
 
This section compared effectiveness using survival years adjusted with quality of 
life. Comparisons using this measure were motivated by the fact that two 
interventions might achieve same survival rates, but different quality of life. 
Multiplying survival years in a HIV/AIDS state with percent of perfect health in 
that HIV/AIDS state (considered as quality of life) yielded the number of perfect 
years of life across contexts, called quality adjusted life years (QALYs). Using 
QALYs as a measure of effectiveness of intervening in an LPC and a HPC, 



















Source: Author, based on the results of Markov models’ simulations. Key: LPA (low prevalence area or 
context), HPA (high prevalence area or context), infect200+ (infected with CD4 count above 200), infect200< 
(infected with CD4 count below 200).   
 
Figure 7:5 Comparison of QALYs across an LPC and a HPC  
 
This Figure shows that QALY outputs are greater in an LPC than in a HPC. The 
greatest differences across contexts in total QALYs is observed for non-ARV 
interventions (STD and VCT) particularly in the HIV/AIDS state “non-infected”. 
Once again, the fact that QALYs from the same intervention and on the same 
kinds of patients are different across contexts is indicative of the different effect 
on QALYs of the interaction between an intervention and the context of 
intervention.   
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While graphical analysis provides a picture of how the effectiveness of HIV/AIDS 
interventions compares across an LPC and a HPC, a comparison of differences in 
the extent of effectiveness requires a presentation of effectiveness in terms of 
numbers of QALYs. Table 7:6 shows and compares the effectiveness of HIV/AIDS 
interventions, expressing effectiveness in an LPC as a percentage of the 
effectiveness in a HPC.   
 
Table 7:6 Comparison of average lifetime effectiveness of HIV/AIDS interventions across an LPC 
and a HPC (QALYs discounted at 3%) 
 
HIV/AIDS Intervention  LPC E HPC QALYs in an LPC as 
% of QALYs in a 
HPC  
VCT 



























Source: Author, based on the results of Markov models’ simulations.  Keys: LPCE: low prevalence 
context’s effectiveness, HPCE: high prevalence context’s effectiveness.  
 
 
The effectiveness results in epidemiological contexts show that the effectiveness 
of each HIV/AIDS intervention in an LPC, as a percentage of its effectiveness in 
a HPC, is greater than 100%. This result suggests that each of the modelled 
HIV/AIDS interventions is more effective in an LPC than it is in a HPC.   
 
7.2.3 Cost-effectiveness  
 
Having gained some understanding of the pattern of costs and effectiveness, it is 
now time to discuss the relative CE of intervening in an LPC and a HPC. This is 
analysed using, as per the literature, the ratio of cost to effectiveness, known as 
the CE ratio (CER). The results of Monte Carlo simulation for the government  








Table 7:7 Lifetime costs and effectiveness 
 Inter
vention  










an LPC as 
% of  
















































































































































































Source: Author, based on the results of Markov models’ simulations. LPCC: low prevalence 
context’s cost, LPCE: low prevalence context’s effectiveness, LPCACER: low prevalence context’s 
average cost-effectiveness ratio, HPCACER: high prevalence context’s average cost-effectiveness 
ratio.  
 
The results in the Table show that prevention interventions result in greater 
QALYs and smaller costs than treatment interventions, regardless of the context 
in which they are conducted. For example, in a HPC, VCT has smaller costs of 
US$130.50 per QALY (see column 4, row 2 in Table 7:7) while the corresponding 
value for HAART is US$ 846.36 per QALY (see column4, row 5 of Table 7:7. This 
result is in line with the literature (Canning, 2006). The results also indicate that 
intervening in a HPC with ARV-based interventions, namely, PMTCT and HAART, 
is less cost-effective. 
 
Notable in the results is the different extent of the relative CE ratio across 
contexts and interventions.  For example, across contexts, one notes that the 
average CE ratio for VCT in an LPC is 61% of the average CE ratio of the same 
intervention in a HPC.  In fact, the average cost effectiveness ratio (ACER) in an 





shown in Table 7:8, which means that HIV/AIDS interventions are more cost-
effective in an LPC than they are in a HPC.  Furthermore, the average The CE 
ratio of VCT in a HPC is US$130.50 per QALY, while it is about sevenfold, US$ 
846.36 per QALY, for HAART in the same context. 
 
Table 7:8 Comparison of the extent of cost-effectiveness across contexts and across 
interventions in an LPC and a HPC (in US$/outcome) 
 
ACER in LPC per QALY ACER in HPC per QALY ACER in an LPC as % of 
ACER in a HPC 
                               VCT  
80 130 61 
                               STD  
105 107 98 
                              PMTCT  
163 263 61 
                              HAART  
635 846 75 
Source: Author, based on the results of Markov models’ simulations.  
 
This result means that HIV/AIDS interventions are more cost-effective in an LPC 
than they are in a HPC since the ACERs in an LPC are lower than those in a HPC. 
It is interesting to note that despite these trends, the extent of CE is different 
across interventions. Specifically, VCT and PMTCT are more cost-effective in an 
LPC than any other intervention. The ACER of VCT and of PMTCT in an LPC is 
61% of their respective ACERs in a HPC.  While VCT and PMTCT are the most 
cost-effective in an LPC, STD is the least cost-effective in that context. The ACER 
of STD in an LPC is 98% of its ACER in a HPC.    
 
The uncertainty surrounding these results is however, immense. The chapter 
sought to ascertain the robustness of the conclusion that intervening in an LPC is 
more cost-effective. Using 1,000 samples drawn from values of parameters 
distributions, the proportion of time that intervening in an area is cost-effective 










Source: Author, based on the results of Markov models’ simulations.  
Figure 7:6 Results of probabilistic sensitivity analysis  
The results suggest that intervening in an LPC is more cost-effective than 
intervening in a HPC. As shown in Figure 7:6, the probability of achieving this 
outcome, arrived at through Monte Carlo simulation, results in expected values 
of costs and effectiveness which range between 90% and 100%.  
 
For PMTCT, the above analysis was conducted utilising the guidelines used until 
2010.  These guidelines consisted of a single dose of Nevirapine around the time 
of birth combined with options to breastfeed or not breastfeed. A more 
expensive but more effective guideline was adopted in 2010 consisting of 
compound Zidovudine (AZT) from week 14 for infected mothers. Some evidence 
indicates that the new guidelines are effective but the way in which they affect 
CE depends on the relative increase in cost and effectiveness. While their effect 
on the CE ratio in an LPC and a HPC is incontestable, the pattern of CE across an 
LPC and a HPC does not change, given the unchanged dynamics of the 
interaction between intervention and contexts. The same argument applies to 
the more expensive but more effective new guidelines adopted in 2011 to 








7.3 Discussion of the results 
 
The evidence presented so far in this chapter has shown that modelled HIV/AIDS 
interventions are more cost-effective in an LPC than they are in a HPC. If 
HIV/AIDS interventions were equally cost-effective in an LPC and a HPC, the 
average CE ratio (ACER) of each intervention in an LPC as a percentage of its 
average CE ratio in a HPC would be 100%. The farther this percentage is below 
100%, the more the intervention is cost-effective in an LPC and, the farther it is 
above 100%, the less the intervention is cost-effective in an LPC. The results 
have shown that the ACER in an LPC as a percentage of an ACER in a HPC is less 
than 100%, meaning that modelled HIV/AIDS interventions are generally more 
cost-effective in an LPC.  
 
Another feature in the evidence is that the extent of CE is different across 
HIV/AIDS interventions. It is noted that, although all interventions are more 
cost-effective in an LPC, some are more cost-effective than others. For instance 
the results illustrate that HAART and STD are least cost-effective in an LPC, with 
its ACER in an LPC representing 75% and 98%, respectively of its ACER in a 
HPC. 
 
These results mean that the CE of HIV/AIDS interventions not only depends on 
the context but also on the type of intervention. Reverting back to how the 
modelling of these results was conducted - with the same size cohort, same 
HIV/AIDS states and similar design of interventions - the results are expected to 
be the same. However, the opposite is observed. This observation answers the 
research question on whether or not the CE of HIV/AIDS interventions is 
influenced by the context in which they are implemented. The claim that the 
performance of HIV/AIDS interventions depends on contexts has featured in the 
literature for some time. However, thus far it has not been supported by 
sufficient, formal CE evidence; the evidence presented in this chapter therefore 
contributes to this body of knowledge.   
 
Many factors explain why the CE of HIV/AIDS intervention might be different in 
different contexts. These factors influence the costs and effectiveness.  





interventions to influence not only health outcomes but also costs. This 
interaction explains why these costs and health outcomes are different across 
contexts. Since an intervention is standard across the contexts, the prevalence 
of contextual and individual factors to a different degree in these contexts 
influences the health outcomes and the cost of intervention.  
 
Furthermore, these factors explain why the extent of CE across HIV/AIDS 
interventions is also different. Since each HIV/AIDS intervention interacts in a 
unique way with these factors, the outcomes across interventions cannot be 
expected to be the same. The outcomes of such interactions are expected to 
depend on the intervention and explain why interventions achieve different 
levels of CE from one context to another.  
 
Due to the fact that many factors are likely to influence the outcomes of 
interventions in different contexts, the empirical outcomes of such interaction 
can guide policy makers. The CE difference observed across contexts can 
possibly be understood from the patterns of its components, notably costs and 
effectiveness.   
 
This analysis found that the effectiveness of HIV/AIDS interventions was greater 
in an LPC than a HPC. This could be explained by relatively smaller rates of 
infection in a cohort and therefore little progression to worse HIV/AIDS state in 
an LPC. However, Philipson & Posner (1993) predict more infections in an LPC 
due to limited information on the cost of infections.  
 
The behaviour of the costs of HIV/AIDS interventions in an LPC relative to a HPC 
is even more complex. The costs of STD and PMTCT were found to be greater in 
an LPC than in a HPC while the opposite was found for VCT and HAART. The 
costs are expected to depend on the impact, since the activity of the 
intervention depends on the HIV/AIDS state. If more patients are found in worse 
HIV/AIDS states in one context than another, the costs are expected to be lower 
in an LPC. The costs could also increase as a result of usage. As the usage 
increases with greater knowledge of the dangers of the disease and the benefits 
of HIV/AIDS interventions, greater costs are expected in a HPC. However this is 





differences in costs across an LPC and a HPC. While there are specific trends in 
the costs of the modelled HIV/AIDS intervention across an LPC and a HPC, it is 
difficult to ascertain the reasons for the differences in cost-effectiveness, as 
many other factors may influence the costs of HIV/AIDS interventions. It is 
preferable to comment on the outcomes of the interaction in terms of the 
observed results.   
 
Relating the results of this study to the literature, it is noted that similar 
effectiveness results were obtained elsewhere. For instance, one study compared 
the effectiveness of treating STDs to prevent HIV transmission in a low 
prevalence context (Tanzania) and a relatively high prevalence one (Uganda). It 
was  found that the treatment of STDs reduced HIV transmission to a greater 
degree in Tanzania than in Uganda because in the latter country HIV 
transmission was taking place outside the core groups with high STI rates, which 
were being  targeted by STI interventions (Korenromp et al. 2005). 
  
Despite the complexity involved in explaining the results in order to answer this 
study’s research questions, it should be noted that there has been insufficient 
evidence on the CE of HIV/AIDS interventions to assist policy makers in deciding 
how to allocate budgets already committed to HIV/AIDS interventions. The little 
evidence which exists was produced internationally and was therefore aimed at 
international policy makers.  
 
Consequently, the results of this study have profound policy implications. The 
results show policy makers that the pattern of the CE and extent of HIV/AIDS 
interventions are different across contexts and across interventions. These 
patterns of effectiveness could be used to guide the distribution of resources first 
across contexts according to whether or not contexts use resources efficiently 
and then according to how efficient an intervention is in this context relative to 
other contexts. Recent undertakings by the South African Government will 
require more resource inputs and consequently more efficient management of 
HIV/AIDS interventions. 
 
Other CE studies have guided policy makers on how the next budget should be 





health outcomes might result if resources already committed were reallocated. 
The chapter proposes a policy based on efficiency principles that are compatible 
with current ethical and equity policy tenets. Since intervening in an LPC results 
in more health outcomes per cost and the extent is different across different 
types of intervention, the optimal allocation of resources in these circumstances 
requires the allocation of resources proportionate to the efficiency of the context 




To sum up, this chapter compared the CE of HIV/AIDS interventions in an LPC 
and a HPC in South Africa and found that HIV/AIDS interventions were more 
cost-effective in an LPC. It also found that the extent of CE varied across 
contexts and across HIV/AIDS interventions. Policy makers should allocate 

























Chapter 8 : Cost-effectiveness of HIV/AIDS interventions 
across a rural context and an urban context 
 
This chapter compares the CE of HIV/AIDS interventions in a rural context and 
an urban context. In each context, a follow-up is undertaken of the patients in 
an HIV/AIDS intervention and in USUAL CARE. The incremental CE ratio (ICER) 
of an intervention relative to USUAL CARE is calculated in each context and the 
ICERs of the same intervention are compared across contexts. To take account 
of the interaction between an HIV/AIDS intervention and the context, 
assumptions about the progression of patients in HIV/AIDS states are pegged to 
projections made by the Spectrum Policy Modelling System (SPMS).   
Effectiveness is measured in terms of survival and survival adjusted for the 
quality of life (QALYs). Sensitivity analysis is conducted on all model parameters.  
Section one elaborates on the methodology used; section two presents the 
results and section three discusses the results.    
 
8.1 Methods  
 
To estimate and compare the CE of an HIV/AIDS intervention across a rural 
context and an urban context, a Markov model for a rural context and a Markov 
model for the urban context are constructed for that intervention. In the 
absence of an HIV/AIDS intervention, patients use USUAL CARE17 and therefore 
a Markov model in a rural context and a Markov model in an urban context are 
constructed for USUAL CARE of that intervention. Each Markov model tracks a 
cohort of 100,000 patients in HIV/AIDS states in successive 3-month periods 
until all patients die. The interventions modelled are PMTCT, HAART FOR ADULTS 
and HAART FOR CHILDREN. 
 
For PMTCT, patients are tracked in “uninfected”, “infected”, “AIDS” and “dead” 
HIV/AIDS states and those who develop AIDS are directly linked to care.  It is 
                                       
17 It is important to note that USUAL CARE is not a response option in the HIV/AIDS 
sector. However to capture the full benefits and costs of an HIV/AIDS intervention in a 
context, the costs and effectiveness are estimated in case patients of that intervention 
use USUAL CARE. USUAL CARE is therefore considered as a comparator of each of the 





assumed that a cohort of 100,000 pregnancies in infected mothers starts in the 
“uninfected” state; within 3 months, some progress to the “infected” state, 
others to the “AIDS” state and still others to the “dead” state. The cohort of HIV-
positive pregnant women is assumed to be on dual therapy PMTCT consisting of 
Zidovudine (AZT) at the 28th week of pregnancy and during labour, followed by 
Nevirapine (NV) for the new-born baby. The cohort is assumed to reflect HIV-
positive pregnant women in South Africa for 2007 in each context. Of these 
women, 20% exclusively breastfeed, 62% exclusively use formula milk and 18% 
use mixed feeding (Soorapath et al., 2006). It is assumed that in the absence of 
PMTCT, patients use USUAL CARE (antenatal care) in which case the Markov 
model tracks these patients in similar HIV/AIDS states modelled for PMTCT. The 
base-case Markov model structures for PMTCT and related USUAL CARE in a 
rural context are provided in appendices 3 and 4(pp.247-248), while the base-
case Markov model structures for the same interventions in an urban context are 
in appendices 5 and 6 (pp.249-250)  
 
For HAART FOR ADULTS, a cohort of 100,000 HIV infected adults starts in the 
“AIDS” state, that is, when their CD4 count is below 20018. In each of the 
successive 3-month periods, some members of the cohort remain in the 
HIV/AIDS state; others improve in health status to CD4 count above 200, that 
is, to “non-AIDS”, while the rest worsen to the “dead” HIIV/AIDS state. The 
cohort is assumed to have the socio-economic characteristics of HIV infected 
adults in 2007. In the absence of HAART FOR ADULTS, patients use usual health 
care services in which case the Markov model tracks these patients in similar 
HIV/AIDS states modeled for HAART FOR ADULTS. The base-case Markov model 
structures for HAART FOR ADULTS and related USUAL CARE in a rural context 
are in appendices 7 and 8 while the base-case Markov model structures for the 
same interventions in an urban context are in appendices 9 and 10(pp.251-254). 
 
For HAART FOR CHILDREN, a cohort of 100,000 HIV infected children starts in 
the “AIDS” state. In each of the successive 3-month periods, some members of 
the cohort remain in the “AIDS” state; others improve in health status to the 
                                       
18 According to the South African New Treatment Guidelines, treatment starts when CD4 count 
falls below 350 but evidence relating to these guidelines with respect to patients’ transition 
probabilities and costs is not widespread. The study used evidence with treatment at CD4 200 and 





“non-AIDS” state and the rest worsen to the “dead” state.  AIDS in children is 
defined as a stage at which there is severe illness, that is, stages 3 and 4 of the 
WHO guidelines (WHO, 2005). It is assumed that the cohort uses pediatric care 
(USUAL CARE) in the absence of HAART FOR CHILDREN in which case the 
Markov model tracks these patients in similar HIV/AIDS states modeled for 
HAART FOR CHILDREN. The cohort is assumed to have the socio-economic 
characteristics of HIV infected children in 200719. The base-case Markov model 
structures for HAART FOR CHILDREN and USUAL CARE in a rural context are in 
appendices 11 and 12 while the base-case Markov model structures for the same 
interventions in an urban context are in appendices 13 and14 (pp.255-258).  
 
To estimate the costs and health outcomes of each model, the proportions of 
patients in HIV/AIDS states in the first 3-month period and successive 3-month 
periods are required. The estimation starts with determining the proportions of 
patients in HIV/AIDS states in the first 3-month period. These proportions are 
reported in Table 8:1 for PMTCT, HAART FOR ADULTS and their respective 
USUAL CARE.   
 
                                       
19 It is common practice in Markov modelling to use a hypothetical cohort of patients. 
Since this hypothetical cohort of patients is not actually observed, its characteristics 
need to be assumed to be similar to the population studied. In other words the 
hypothetical population is assumed to be a sub-component of the population of interest. 
To this end, parameters collected in the population studied are applied to the 





Table 8:1  Transition probabilities data for the base-case comparison (PMTCT, HAART FOR ADULTS and their related USUALCARE) 
PMTCT                 Rural context                           Urban context  
















Non-infected to infected  
Non-infected to death  
Infected to AIDS  
Infected to death 













Goga et al. (2010) 
Model derived  
Goga et al. (2010) 
Goga et al. (2010) 















Model derived  
Soorapath (2006) 
Tindyebwa et al.(2006) 
Wilkinson et al. (2000) 
USUAL CARE                               Rural context                              Urban context 
Transition probability  BCV Range Source  BCV  Range Source 
Non-infected to infected  
Non-infected to death  
Infected to AIDS  
Infected to death 











Tindyebwa et al. (2006) 
Tindyebwa et al. (2006) 
Tindyebwa et al. (2006) 
Tindyebwa et al. (2006) 











Tindyebwa et al. (2006) 
Tindyebwa et al. (2006) 
Tindyebwa et al. (2006) 
Tindyebwa et al. (2006) 
Desmond & Boyce(2004) 
HAART FOR ADULTS                              Rural context               Urban context 
Transition probability BCV Range Source BCV Range Source 
Non-AIDS to AIDS 
Non-AIDS to death  
AIDS to non-AIDS 










Cleary et al.(2004) 
Model derived  









Badri et al. (2006:67) 
Badri et al. (2006:67) 
Model imputed  
Badri et al. (2006:67) 
USUAL CARE                            Rural context                            Urban context 
Transition probability BCV Range Source BCV Range Source 
Non-AIDS to AIDS 
Non-AIDS to death  
AIDS to non-AIDS 


























Badri et al. (2006). 
                                       
20 The literature documents that in the absence of HAART, no patients who start in the AIDS state would move to the non-AIDS state. 
Such patients would instead see their health deteriorate (Badri et al., 2006: 65). Since no patients move from AIDS to non-AIDS in 
USUAL CARE, no patients would transit from non-AIDS to any other HIV state. In the absence of transition probabilities for South Africa, 
African evidence such as in Tindyebwa et al. (2006) was used. Using evidence from other studies in situations comparable to the situation 
of a specific study is a norm in cost-effectiveness analysis. For instance, Walensky et al. (2011:29-30) and Backman (2006) used some 
parameters from Africa and Cote d’Ivoire in estimating the CE of VCT and HAART in South Africa, respectively.  
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Similarly, the proportions of patients in HIV/AIDS states in the first 3-month 
period are reported for HAART FOR CHILDREN. These data are reported in Table 
8.2. 
 
Table 8:2 Transition probabilities data for the base-case comparison (HAART FOR CHILDREN and 




                     Rural context                       Urban context  
 
Non-AIDS to AIDS 
Non-AIDS to death  
AIDS to non-AIDS 
AIDS to death    
 











Cleary et al.(2004) 
Model derived  










Badri et al. (2006:67) 
Badri et al. (2006:67) 
Model imputed  
Badri et al. (2006:67) 
USUAL CARE                  Rural context                     Urban context 
 
 
Non-AIDS to AIDS 
Non-AIDS to death  
AIDS to non-AIDS 
AIDS to death  
 
Value Range Sources  Value
s 

























Clealry et al.(2006) 
 
The proportion of patients in HIV/AIDS states in subsequent 3-month periods is 
assumed on the basis of trends observed in SPMS projections.  This assumption 
is based on the fact that these projections are done using parameters collected 
in these contexts. Therefore, the costs and effectiveness estimates based on 
SPMS projection trends are obtained taking into account the interaction between 
the intervention and the context. In each context, SPMS projections depict such 
interactions. The proportion of patients who become infected or die in the next 
period is determined by adjusting the proportion in the current period according 
to the proportion infected or dying as per SPMS projections. Appendix 15 on 
p.259 explains how this adjustment is done in low and high HIV prevalence 
contexts; these adjustment procedures are similar to the adjustment procedures 
used in this chapter with the only difference being that, in this chapter, the 
adjustments are based on the projections of SPMS.  
 
                                       
21 The literature documents that in the absence of HAART, no patients who start in the 
HIV/AIDS state would move to the Non-aids State. Such patients would instead see their 
health deteriorate (Badri et al., 2006: 65). Since no patients move from AIDS to non-







The cost applied to patients in various HIV/AIDS states is based on the evidence 
collected from the literature for the first 3-month period. This cost is assumed to 
be constant over time. Cost has been found to decrease further into the 
intervention, due to increased experience or economies of scale (Menzies et al., 
2012). The decrease in unit cost over time is not considered in the present 
analysis given its insignificant effect on the results observed from the previous 
analysis in Chapter 7. Unit costs are adjusted to reflect either the societal or 
government perspective. Estimates of unit costs for transport and waiting time 
in public sector facilities are used to estimate costs from the point of view of 
society. The costs are measured in constant 2007 US$ and discounted at 3% for 
the base-case comparison. Table 8:3 provides the evidence of cost measured 
from the government perspective.   
 
Table 8:3 Three-month cost data for the base-case comparison (government perspective) 
 
                                                                      PMTCT intervention  
                              Rural context                          Urban context   









$50   (0-100) 
Pelitzer et al. (2006) 
Desmond & Boyce (2004) 
Desmond  & Boyce (2004) 





Hussain  et al. (2011) 
Hussain  et al. (2011) 
Meyers et al. (2007) 
Case et al. (2008) 
                                                                     USUAL CARE 









Hoque et al. (2008) 
Hoque et al. (2008) 
Clealry et al. (2006) 






Sibeko & Moodley (2006) 
Badri et al. (2006) 
Meyer-Rath et al. (2012) 
Note: The cost in “death” was considered as once-off cost in the estimation of the cost for the 
cohort.  
The quality of life data in the rural context is assumed to be lower in the rural 
context than it is in the urban context in each HIV/AIDS state except the “dead” 
state. This assumption is based on the fact that a rural context abounds with 
circumstances which aggravate the health status of patients. It is based on the 
quality of life estimates which have been produced in the country (Jelsma et al., 
2005); O’Keefe & Wood, 1996; Louwagie et al., 2007). In each context, the 
quality of life in USUAL CARE is assumed to be lower (details in appendix 20 on 
p.267). The base-case values of the quality of life data used in the analysis are 
in Table 8.4. 
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Table 8:4 Quality of life data used in an intervention  
Note:  
 
HIV state                 Rural  context                           Urban  context   











              Evidence base 
 
Non-infected  









Jelsma et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 








Jelsma  et al. (2006) & O’Keeffe & Wood  (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 









Jelsma et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 





Jelsma  et al. (2006) & O’Keeffe & Wood  (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
 
HAART  FOR 
CHILDREN 







Jelsma et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 
Jelsma  et al. (2006), O’Keeffe & Wood (1996), Louwagie et al.(2007) 





Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
Jelsma  et al. (2006) & O’Keeffe & Wood (1996) 
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8.2 Results  
 
This section presents the results. It provides a detailed comparison of the costs 
of a given intervention in HIV/AIDS states across contexts; makes similar 
comparisons for effectiveness; compares the CE of the base-case analysis and 
conducts sensitivity analysis.  
 
8.2.1 Costs  
 
An understanding of how the CE of an HIV/AIDS intervention compares across a 
rural context and an urban context requires a separate analysis of the cost and 
effectiveness of that intervention. In this section, the analysis of cost is done by 
assessing additional cost, in each HIV/AIDS state, of an HIV/AIDS intervention 
relative to the costs of USUAL CARE. Figure 8:1 compares the additional cost of 
PMTCT with the cost of USUAL CARE for different HIV/AIDS states across a rural 






















































Source: Author, based on the results of Markov models’ simulations. 
 
Figure 8:1 Comparison of lifetime cost of PMTCT across a rural context and an urban context (in 
US$, government perspective)   
 
As Figure 8:1 shows, the cost of USUAL CARE is clearly less than the cost of 
PMTCT. However, how the areas between the PMTCT “infected” curves and 
                   Panel 1                                             Panel 2 
        
                   Panel 3                                              Panel 4 
            
                  Panel 5                                                    Panel 6    
        
           Panel 7                                                 Panel 8 







USUAL CARE “infected” curves compared across a rural and an urban context are 
not clear. Graphically, these curves appear to be similar (see Panel 3 and Panel 
4).  
 
In HAART FOR ADULTS however, the pattern of costs is somewhat different. 



























            Source: Author, based on the results of Markov models’ simulations. 
 
Figure 8:2  Comparison of lifetime costs of HAART FOR ADULTS across a rural context and an 
urban context (in US$, government perspective)   
 
Figure 8:2 indicates that the cost of USUAL CARE is lower than the cost of 
HAART FOR ADULTS regardless of HIV/AIDS state considered. The figure also 
           Panel 1                                           Panel 2 
     
            Panel 3                                           Panel 4           
       
               Panel 5                                       Panel 6 





shows that the difference between the cost curves of HAART FOR ADULTS and 
the cost curves of USUAL CARE is greater in an urban context than it is in a   
rural context for all HIV/AIDS states, at least on the basis of difference in scale 
(Panel 1 to Panel 6). This result indicates that HAART FOR ADULTS is more 
costly in an urban context than in a rural context.     
 
In HAART FOR CHILDREN, the costs of HAART are also greater than the cost of 




























































         Source: Author, based on the results of Markov models’ simulations.  
 
 
Figure 8:3 Comparison of lifetime costs of HAART FOR CHILDREN across a rural context and an 
urban context (in US$, government perspective)   
 
The areas between the cost curve of HAART for Children and that of USUAL 
CARE are greater for the urban context; this holds for HIV/AIDS states “non-
AIDS” and “dead”.  This result indicates that, relative to USUAL CARE, HAART for 
                Panel 1                                                      Panel2 
  
                Panel 3                                                     Panel 4 
   
                Panel 5                                                      Panel 6 







CHILDREN is more costly in the urban context than it is in the rural context 
except in the “AIDS” state where differences are not graphically clear (Panel 3 
and Panel  4) indicating that there is no difference in this state. 
 
Analysing the overall costs rather than the costs in each in HIV/AIDS state 
allows for an overall assessment of how the costs of HIV/AIDS interventions 























     
 
Source: Author, based on the results of Markov models’ simulations. 
 
Figure 8:4 Comparison of the lifetime overall cost of HIV/AIDS interventions across a rural 
context and an urban context (in US$, government perspective)    
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            Panel 1                                               Panel 2 
     
                                  HAART FOR ADULTS  
               Panel 3                                           Panel 4 
      
                                 HAART FOR CHILDREN 
               Panel 5                                        Panel 6 





As  the results in Figure 8:4 suggest, the difference between the costs of PMTCT 
relative to the cost of USUAL CARE in the rural context is much lower than the 
difference between the costs of PMTCT relative to the cost of USUAL CARE in the 
urban context (Panel 1 to 6). This result implies that PMTCT costs more in the 
urban context than it does in the rural context because of the inherent factors in 
each context that cannot be identified given the context of the study.   
 
The cost of HAART FOR ADULTS, relative to the cost of USUAL CARE, is also 
greater in the urban context than in the rural context. This also applies to HAART 
FOR CHILDREN. The next section discusses the effectiveness of HIV/AIDS 
interventions.  
 
8.2.2 Effectiveness  
    
This section compares the effectiveness of HIV/AIDS interventions across rural 
and urban contexts. It reports different types of comparisons across a rural and 
an urban context, notably: comparison of survival in the case of USUAL CARE; 
comparison of additional survival in terms of an HIV/AIDS intervention; 
comparison of life-years gained by an HIV/AIDS intervention; and comparison of 
QALYs (life-years adjusted with the quality of life) gained by an HIV/AIDS 
intervention.    
 
8.2.2.1 Comparisons of survival across a rural context and an urban 
context: USUAL CARE  
  
To grasp the extent to which the effectiveness of an HIV/AIDS intervention 
might differ across a rural context and an urban context, the analysis starts by 
comparing survival patterns across these two contexts in the case of USUAL 
CARE, that is, in the absence of any HIV/AIDS intervention.  Figure 8:5 shows 




























     Source: Author, based on the results of Markov models’ simulations  
Figure 8:5 Comparison of survival patterns across a rural context and an urban context in the 
absence of PMTCT   
 
Figure 8:5 shows that over time the proportions of cohorts in various HIV/AIDS 
states are not the same in a rural context as in an urban context despite an 
assumption that patients in each context start in the “non-infected” state. Panel 
1 of Figure 8:5 shows that over time, a rural context shows greater proportions 
of patients in the “non–infected” state than an urban context. This result 
conforms to the results in Panel 2 of the figure which show that, over time, an 
urban context shows greater proportions of patients in the “infected” state. 
While greater proportions of those in the “infected” state in the urban context 
seems to suggest worse health outcomes in the urban context, Panel 3 and 
Panel 4 of the figure show that the rural context accounts for greater proportions 
of patients in worse HIV/AIDS  states, notably “AIDS” and “deaths”. This result 
suggests that even though greater proportions of patients succumb to infections 
in the urban context, an even greater proportion among those infected in the 
              Panel 1                                        Panel 2 
   
              Panel 3                                                Panel  4 





rural context succumb to worse HIV/AIDS, states notably “AIDS” and “deaths”. 
The reason is that living conditions in the rural contexts are likely to propel the 
infected into these worse states. This gap could be narrowed by intervening in 
rural areas to improve living conditions, such as providing better nutrition. 
Figure 8:6 compares survival patterns across rural and urban contexts in the 



























                
 
 
             Source: Author, based on the results of Markov models’ simulations.  
 
Figure 8:6  Comparison of survival patterns across a rural context and urban context in the 
absence of HAART FOR ADULTS    
 
As Figure 8:6 shows, greater proportions of patients are in better HIV/AIDS 
states in the urban context than they are in the rural context. The Figure shows 
that greater proportions of patients are in the “AIDS” state in the urban context 
than in the rural context (Panel 1), while more patients are in the “dead” state in 
                                       Panel 1 
 
                Thee-month Markov periods                                  
                                      Panel 2 
 





the rural context than in the urban context (Panel 2). This result implies that 
there are fewer patients in severe HIV/AIDS states in the urban context than in 
the rural context due to poor living conditions in the latter context. It is worth 
noting that in the case of USUAL CARE, no patients are found in “non-AIDS” 
states. In fact, since all patients starts in AIDS states, one would not expect any 
improvement in the health of AIDS patients without HAART FOR ADULTS. The 
same survival patterns across these contexts apply to HAART FOR CHILDREN 























Source: Author, based on the results of Markov models’ simulations.  
 
Figure 8:7 Comparison of survival patterns across a rural context and an urban context in the 
absence of HAART FOR CHILDREN 
 
                                            Panel 1 
 






Again, it is noted in Figure 8:7 that the “AIDS” state accounts for greater 
proportions of patients in the urban context than the rural context (Panel 1). 
However, the opposite is true for the “dead” state, which accounts for greater 
proportions of patients in the rural context (Panel 2). Given that all patients start 
in the “AIDS” state, greater proportions of patients in the “dead” state in the 
rural context suggest worse survival patterns in the rural context due to more 
adverse contextual factors in the latter context.   
 
8.2.2.2 Comparisons of additional survival across a rural context and an 
urban context of an HIV/AIDS intervention 
 
The above results have shown that rural/urban contexts have an impact on 
survival patterns even in the absence of HIV/AIDS interventions. To take the 
impact of contexts into account, the additional survival of an HIV/AIDS 
intervention relative to the survival of USUAL CARE in a rural context, is 
compared with the additional survival of that intervention relative to the survival 











































As Figure 8:4 shows, health outcome curves for USUAL CARE and PMTCT in each 
context are different. Furthermore, the height between the curves for USUAL 
CARE and the curves for PMTCT for a given HIV/AIDS state are different across 
contexts, suggesting different effectiveness of PMTCT across a rural and an 
urban context. For instance, in the “non-infected” state, the height between the 
curves for USUAL CARE and the curves for PMTCT is greater in the urban context 
than in the rural context. The gap for the “AIDS” and “dead” states is also 
greater in an urban context than in a rural context though the differences in the 




Source: Author, based on the results of Markov models’ simulations. 
Figure 8:8 Comparison of effectiveness of PMTCT and USUAL CARE across a rural context and an 
urban context 
 
                   Panel 1                                                  Panel 2 
   
                     Panel 3                                             Panel 4 
     
                     Panel 5                                                Panel 6 
   
                     Panel 7                                             Panel 8 







Figure 8:8 shows that survival in HIV/AIDS state curves for USUAL CARE and 
PMTCT are different in each context. Furthermore, the height between the 
survival in HIV/AIDS state curves for USUAL CARE and survival in HIV/AIDS 
curves for PMTCT are generally greater in the urban context than in the rural 
context (see comparisons shown by Panel 1 and Panel 2, Panel 3 and Panel 4, 
Panel 5 and Panel 6).  
 
In HAART FOR ADULTS, the difference in effectiveness across a rural context and 























        Source: Author, based on the results of Markov models’ simulations.  
 
Figure 8:9 Comparison of effectiveness of HAART FOR ADULTS and USUAL CARE across a rural 
context and an urban context 
                    Panel 1                                                         Panel 2 
    
                   Panel 3                                               Panel 4 
          
                  Panel 5                                         Panel 6 






Figure 8:9 clearly demonstrates the effectiveness of HAART relative to USUAL 
CARE in an urban or a rural context. The first two panels (Panel 1 and Panel 2) 
of the figure show the HAART FOR ADULTS “non-AIDS” curve and USUAL CARE 
“non-AIDS” curve in each context. The panels show that the USUAL CARE “non-
AIDS” curve is on the horizontal axis in each context, indicating that none of the 
patients who start in the “AIDS” state in USUAL CARE transit to the “non-AIDS” 
state. 
 
In contrast, positive proportions of patients who have access to HAART FOR 
ADUTLS transit to the “non-AIDS” state in each context as shown in Panel 1 and 
Panel 2. These panels show further that, relatively more patients in the urban 
context transit to this state. This result is shown by a greater gap between the 
HAART “non-AIDS” curve and the USUAL CARE “non-AIDS” curve in the urban 
context (Panel 1 and Panel 2). The result provides evidence of the greater 
effectiveness of HAART FOR ADULTS in an urban context than in a rural context 
for this HIV/AIDS state.  
 
This pattern of results applies to “AIDS” (Panel 3 and Panel 4) and “death” 
states (Panel 5 and Panel 6). The figure shows that the gap between the HAART 
FOR ADULT “AIDS” curve and USUAL CARE “AIDS” curve is greater in the urban 
context than it is in the rural context (Panel 3 and Panel 4). Since the HAART 
FOR ADULTS curve is below the USUAL CARE AIDS curve in each context, the 
greater gap in the urban context implies that HAART reduces AIDS more in the 
urban context than it does in the rural context. Similarly, since in each context 
the HAART FOR ADULTS “death” curve is below the USUAL CARE “death” curve, 
the greater gap between the curves (Panel 5 and Panel 6) in the urban context 
implies that HAART reduces more deaths in the urban context than it does in the 
rural context. 
 
Briefly, these results demonstrate that HAART FOR ADULTS is more effective in 
the urban context than in the rural context. Some of the reasons could be that 
the rural context experiences adverse factors such as poor nutrition, a lack of 
access to basic sanitation, stigma that prevents people from accessing 





the urban context. The patterns of the results for HAART FOR ADULTS are 


























     Source: Author, based on the results of Markov models’ simulations.  
 
 
Figure 8:10 Comparison of effectiveness of HAART FOR CHILDREN and USUAL CARE across a 
rural context and an urban context  
 
As in previous analysis, HAART FOR CHILDREN results in positive proportions of 
patients moving to the “non-AIDS” state from the “AIDS” state, while USUAL 
CARE results in no one moving to the “non-AIDS” state. Figure 8:10, Panel 1 
and Panel 2 shows that the HAART FOR CHILDREN “non-AIDS” curve is above 
the USUAL CARE “non-AIDS” curve in each context. The fact that the gap 
between the two curves is greater in the urban context than in the rural context 
(Panel 1 and Panel 2) implies that HAART FOR CHILDREN causes more children 
              Panel 1                                                   Panel 2 
       
               Panel 3                                              Panel 4 
    
                  Panel 5                                         Panel 6 





to transit to the “non-AIDS” state in the urban context than it does in the rural 
context, suggesting greater effectiveness of this intervention in an urban 
context. However, the gap between the HAART FOR CHILDREN “AIDS” curve and 
USUAL CARE “AIDS” curve is greater in the rural context than in  the urban 
context (Panel 3 and Panel 4). A comparison of the data in Panel 5 and Panel 6, 
suggests that HAART FOR CHILDREN reduces more deaths in an urban context 
than it does in a rural context. Figure 8:11 compares the overall effectiveness of 


































































Source: Author, based on the results of Markov models’ simulations. 
Figure 8:11 Comparison of overall effectiveness (survival) of HIV/AIDS interventions across a 
rural context and an urban context 
 
Figure 8:11 indicates that relative to USUAL CARE, all interventions are not 
equally effective across rural/urban contexts. The results suggest that PMTCT is 
relatively more effective in the rural context on the basis of the gap between the 
PMTCT survival curve and the USUAL CARE survival curve, although the 
difference in the gap across contexts is not substantial (Panel 1 and panel 2).  
While the gap between the PMTCT and USUAL CARE curves across a rural and an 
urban context is almost insignificant, the gap is significant with HAART FOR 
                    PMTCT 
                       Panel 1                                             Panel 2 
  
          HAART FOR ADULTS                            
                      Panel 3                                               Panel 4 
   
                  HAART FOR CHILDREN  
                Panel 5                                            Panel 6 





ADULTS and HAART FOR CHILDREN (Panel 3 and Panel 4, Panel 5 and Panel 6). 
The reason for this may be that children in advanced stages of HIV/AIDS may 
not respond to HIV/AIDS treatment as well as adults. The results show that 
HAART FOR ADULTS and HAART FOR CHILDREN are relatively more effective in 
an urban context than they are in a rural context on the basis of the gap 
between the survival curves for the two interventions and the USUAL CARE 
curves. The fact that the gap is greater in the urban context than it is in the 
rural context means that these interventions are more effective in an urban 
context. This is probably due to the existence of welfare services in the urban 
context which cushion the impact of HIV/AIDS. 
 
8.2.2.3 Comparisons of life-years gained by an HIV/AIDS intervention 
across a rural context and an urban context  
 
The life-years gained by an intervention are an important measure of 
effectiveness. To estimate life-years in each Markov period, the cohort of 
patients is multiplied by the proportion of patients in an HIV/AIDS state and the 
number of years the cohort spent in this state, 0.25, since three months is 25% 
of a year.  
 
The cohort as well as the number of years in each 3-month period is constant. It 
follows that the patterns of effectiveness of HIV/AIDS interventions across 
contexts in terms of proportions surviving resemble the patterns of effectiveness 
of these interventions in terms of life-years gained. There is therefore no need to 
graphically represent this comparison and the conclusion drawn for survival as a 
measure of effectiveness applies to life-years gained. 
  
8.2.2.4 Comparison of QALYs gained by an HIV/AIDS intervention 
across a rural context and an urban context    
 
With quality adjusted life-years, the effectiveness pattern across a rural and an 
urban context might differ from that of survival measures because QALY 
measures involve quality of life which is different across rural and urban 
contexts22. Discounting also makes QALYs gained during later periods of 
                                       
22 The quality of life data were obtained from quality of life studies in South Africa (Jelsma et al. 2006; O’Keefe 





modelling worth less than QALYs gained in earlier periods. These considerations 
raise uncertainty about the comparability of the effectiveness of HIV/AIDS 





































Source: Author, based on the results of Markov models’ simulations.  
 
Figure 8:12 Comparison of effectiveness (QALYs) of HIV/AIDS interventions across a rural context 
and an urban context  
 
                                                                                                                       
quality of life of people who live predominantly a rural context, the black population. Similarly, the quality of 
life for the urban context was estimated on the basis of the average quality of life for the white population 
              Panel 1                                          Panel 2 
    
              Panel 3                                             Panel 4 
  
                 Panel 5                                            Panel 6 
    





As Figure 8:12 shows, except for PMTCT (Panel 1 and Panel 2), the results in 
terms of QALYs appear to be consistent with the results for survival (Panel 3 and 
Panel 4, Panel 5 and Panel 6). The results show that, in relation to USUAL CARE, 
HIV/AIDS interventions are generally more effective in the urban context than in 
the rural context when life-years adjusted for the quality of life (QALYs) are used 
as measures of effectiveness. As argued above, reweighting survival in the rural 




A good grasp of the performance of an HIV/AIDS intervention in a rural and an 
urban context ultimately requires the joint consideration of cost and 
effectiveness. Cost-effectiveness estimates measured in terms of ICER are 
presented alongside numerical measures of incremental costs and incremental 
effectiveness. The statistics of interest to the analysis in this section are 
























Table 8:5 Lifetime cost (US$), effectiveness (QALYs) and cost-effectiveness (US$/QALY) for a 
cohort of 100,000 patients  
 
Intervention  Rural context  Urban context  Value in a rural 
context as a % of the 
value in the urban 
context 
USUAL CARE 
Total costs (GP) 
Total costs (SP) 
Total effectiveness (QALYs) 
PMTCT 
Total costs (GP) 
Total costs (SP) 
Total effectiveness 
Incremental costs  








































Total costs (GP) 
Total costs (SP) 
Total effectiveness  
HAART FOR ADULTS  
Total costs 
Total effectiveness 
Incremental costs  
Incremental effectiveness (QALYs) 
ICER (GP) 



































Total costs  
Total effectiveness  
HAART FOR ADULTS 
Total costs GP 
Total costs SP 
Total effectiveness 
Incremental costs  




































Source: Author, based on the results of Markov models’ simulations.  
 
As can be seen in Table 8.5, HIV/AIDS interventions and USUAL CARE, achieve 
more QALYs in an urban context than they do in a rural context. Furthermore, 
the incremental effectiveness of an HIV/AIDS intervention is generally greater in 
an urban context than in a rural context. For example, the incremental 
effectiveness of PMTCT in a rural context is 53% of its incremental effectiveness 
in the urban context. This may be explained by better living conditions in the 
urban context that promote effectiveness of PMTCT. 
 
The table also shows that the total costs of an HIV/AIDS intervention and USUAL 
CARE are generally greater in an urban context than in a rural context. However, 
the incremental costs (IC) of each intervention over USUAL CARE do not follow 
this pattern. Table 8.5 shows that the IC of PMTCT in the rural context is less 





represents 29% of its ICER in the urban context. However, the opposite is true 
for HAART FOR ADULTS and HAART FOR CHILDREN whose incremental costs in 
the rural context represent 107% and 179% of their respective IC in the urban 
context. This may be considered an obvious result since in the urban context one 
can expect greater usage and therefore greater cost of care. 
 
Table 8:5 further shows that the ICER of PMTCT in a rural context is lower than 
its ICER in the urban context. Since ICER means cost per effectiveness, a lower 
ICER for PMTCT in a rural context means that PMTCT is more cost-effective in 
the rural context than it is in the urban context. The table shows that HAART 
FOR ADULTS and HAART FOR CHILDREN have greater ICERs in the rural context 
and consequently they are less cost-effective in this context. These results show 
that there is no specific pattern of CE common to all modelled interventions. In 
starting this study, this result was expected because of the expected complex 
interactions between the interventions, the factors in the contexts and the 
resulting outcomes. 
 
The fact that HAART is less cost-effective in a rural context can be explained by 
a number of factors. First, HAART may be adding more to the costs of USUAL 
CARE than it adds to the effectiveness of USUAL CARE in the rural context, 
resulting in greater ICER in the rural context. Alternatively, HAART may be 
adding less to the costs of USUAL CARE than it adds to the effectiveness of 
USUAL CARE in an urban context.   
 
If the equality of the CE of an HIV/AIDS intervention across contexts is defined 
as the equality of the ICERs of that intervention across these contexts, this 
implies that in case of such equality, the ICER value in Column 3 of Table 8:5 
would be 100. The results in Table 8.5 show that the ICER value in column 3 
varies to a greater extent around 100. Measuring the extent of the CE of an 
intervention across a rural and an urban context as the distance the ICER value 
is from 100, the extent of CE for modelled interventions becomes clear from 







Table 8:6 Summary comparison of cost-effectiveness of HIV/AIDS interventions in a rural context 
and an urban context (in US$/outcome) 
 
 
ICER rural  
 
ICER urban  
ICER in a rural context as % of ICER in an 
urban context 
                             PMTCT  
156 285 54 
                     HAART FOR ADULTS 
856 566 151 
                    HAART FOR CHILDREN 
985 650 151 
Source: Author, based on the results of Markov models’ simulations.  
 
Table 8:6 indeed shows that the extent of the CE of HIV/AIDS interventions is 
different. The table shows that HAART interventions are less cost-effective in the 
rural context than they are in the urban context. Their ICER relative to USUAL 
CARE in the rural context is greater than their ICER relative to USUAL CARE in 
the urban context. The ICERs in the rural context represent 151% of the ICERs 
in the urban context.  In contrast, PMTCT is more cost-effective in rural 
contexts. Its ICER relative to USUAL CARE in the rural context is less than its 
ICER in the urban context to the extent that the ICER in the rural context 
represents 54% of the ICER in the urban context.  
 
In summary, the results presented in Table 8:6 suggest that there is no specific 
trend in CE from a rural context to an urban context. Furthermore, the results 
show the different extent of CE across HIV/AIDS interventions. These results 
were subjected to probabilistic sensitivity analysis. Table 8:7 presents the results 
















Table 8:7 Results of probabilistic sensitivity analysis assuming no 2010 guidelines (US$, 3% 
discount rate, government perspective)  
  
             Average rural context          Average urban context  
 Intervention  Cost  ($)  (QALYs) Costs ($) QALYs 
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95% CI  
 

































Source: Author, based on the results of Markov models’ simulations. 
 
The results of the sensitivity analysis in Table 8.7 show that the conclusions of 
the base-case analysis do not change. They are, however, based on the 
evidence for the guidelines before 2010. Further sensitivity analysis is conducted 
to check the comparability of the interventions across contexts with the 
implementation of the 2010 guidelines.  Following the guidelines for PMTCT and 
HAART issued in 2010, South Africa adopted earlier HAART treatment in 2011. 
Incorporating the available evidence on earlier treatment and earlier PMTCT in 
base-case values and conducting probabilistic sensitivity analysis, the results are 














Table 8:8 Results of probabilistic sensitivity analysis with 2010 guidelines (3% discount rate, GP)  
  
   Average rural context          Average urban context  
 Intervention  Cost  ($)  (QALYs) Costs ($) QALYs 
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HAARTFOR ADULTS   



























      785 
 
                     456 
Source: Author, based on the results of Markov models’ simulations.  
 
With earlier implementation of PMTCT and HAART, the cost per QALY gained 
decreases. However this does not affect the comparability of each intervention 
across the contexts.   
 
8.3. Discussion of the results  
 
The results in this chapter have shown that the ICER of all modelled HIV/AIDS 
interventions across a rural and an urban context are different. This is illustrated 
by the fact that the ICER of an HIV/AIDS intervention in a rural context as a 
percentage of the ICER in the urban context is not 100%.  This result suggests 
that HIV/AIDS interventions are not equally cost-effective across a rural and an 
urban context as a result of many interrelated factors.  
 
The results have also shown that the trends in CE across a rural and an urban 
context are not the same. The ICER of PMTCT is lower in the rural context than it 
is in the urban context, while the ICERs of HAART FOR ADULTS and HAART FOR 
CHILDREN are greater in the rural context than they are in the urban context.  
This result indicates an absence of consistent trends in the CE of HIV/AIDS 
interventions across a rural and an urban context. This observation can be 
explained by a number of factors. For example, stigma is more likely in rural 
contexts; this can decrease the intention to seek medical care. A trend would 





percentage of the ICER in the urban context is consistently lower or greater than 
100%.  
 
Further to the lack of consistent trends in the CE of HIV/AIDS interventions 
across a rural and an urban context, it is observed that the extent to which the 
ICER of an HIV/AIDS intervention in a rural context as a percentage of its ICER 
deviates from 100% is different across interventions.  The ICER of PMTCT in a 
rural context as a percentage of its ICER in the urban context is 54%, while the 
corresponding percentages for HAART FOR ADULTS and HAART FOR CHILDREN 
are 125%.  The fact that the ICERs in a rural context as a percentage of the 
ICERs in the urban are farther away from 100% for PMTCT than they are for 
HAART FOR ADULTS and HAART FOR CHILDREN shows that the extent of CE 
across modelled HIV/AIDS interventions is not the same.  
 
With the ICER meaning the additional costs per health outcome, a lower ICER in 
a given context implies more cost-effectiveness. The evidence shows that PMTCT 
is more cost-effective in the rural context than it is in the urban context. By 
contrast, HAART FOR ADULTS and HAART FOR CHILDREN are less cost-effective 
in the rural context since their ICERs in this context represent 151% and 151%, 
respectively of their ICERs in the urban context.  
 
An initial question was whether or not comparing the CE of HIV/AIDS 
interventions across a rural context and an urban context would result in 
different CE results. This question is answered by these results. Indeed, the 
results presented in this chapter have shown that the CE of HIV/AIDS 
intervention depends on contexts.  
 
However, bearing in mind the design of CE in this chapter, the results are 
expected to be similar. In each context, the CE of an intervention was analysed 
on the same size cohort of patients, starting in the same HIV/AIDS state. The 
fact that the CE was shown to be different is at the centre of the rationale for 
this comparison.  
 
One would have expected the cost of interventions to be lower in an urban 





the degradation of health status as a result of HIV/AIDS, reduce the need to 
seek care and consequently reduced the costs of intervention over time.  The 
higher costs in urban contexts may in this case be explained by higher levels of 
usage of health care in these contexts.  
 
The comparison of HIV/AIDS interventions was grounded on the fact that the 
outcomes of HIV/AIDS interventions, particularly CE, are a result of the 
interaction between context, individual patients and the intervention.  These 
factors, which have been theorised differently in the literature, are expected to 
prevail differently across a rural context and an urban context both in terms of 
trends and extent. In turn, these differences may influence the outcomes of 
interventions, especially when one acknowledges that HIV/AIDS interventions do 
not necessarily target all contextual and individual factors. Due to the fact that 
the analysis took these interactions into account by pegging the progression of 
patients in HIV/AIDS states over time, these results were expected, although 
there was no indication as to the trends and extent of CE across a rural context 
and an urban context or across HIV/AIDS interventions.  
 
The observed extent of CE across HIV/AIDS interventions can be explained using 
the components of cost-effectiveness. The fact that PMTCT was more cost-
effective in the rural context means that, relative to USUAL CARE, it achieves 
relatively more effectiveness given additional costs in the rural context 
compared with the urban context.  Since PMTCT is conducted with pregnant 
women who use primary health care facilities in both rural and urban contexts, it 
is likely that the risk of infection is detected and prevented.  
 
By contrast, with low HIV screening rates in rural contexts, the impact of the 
epidemic is detected too late when health status has already deteriorated. In the 
case of an urban context, better living conditions can cushion the impact, 
resulting in HAART interventions being relatively more effective in the urban 
context than in the rural context 
 
Other studies have found that HIV/AIDS interventions have generally produced 
better effectiveness results in better socio-economic contexts (Kalitchman & 





lower socio-economic contexts in developing countries (Shisana and Simbayi, 
2002). This supports the finding that, depending on the underlying factors, 
different outcomes of HIV/AIDS interventions can be observed in different 
contexts.  
 
In a nutshell, one can conclude that the CE of HIV/AIDS interventions depends 
on the context. This conclusion has implications for South African policy makers.  
Policy makers, who have been allocating resources based on other 
considerations, could include consideration of the CE of HIV/AIDS interventions 
in socio-economic contexts to improve the efficiency of such interventions and so 
allocate their limited resources to the best effect.   
 
The results of this study need to be considered with care in light of the cost and 
effectiveness evidence used. The cost and effectiveness data have limitations 
and the results may suffer in terms of accuracy.  Despite these drawbacks, the 
study addressed the issue of uncertainty in order to ensure that its findings will 
be of value to policy makers in South Africa.  
 
Chapter summary  
 
In conclusion, this chapter compared the CE of HIV/AIDS interventions across a 
rural and an urban context using Markov models and QALYs as a measure of 
effectiveness. It compared the CE of an HIV/AIDS intervention in a rural context 
with the CE of that HIV/AIDS intervention in an urban context, taking into 
account the CE of USUAL CARE. The results show that generally, the 
effectiveness of HIV/AIDS interventions is lower in the rural context than in the 
urban context. The results also show that the costs in the rural context are lower 
than the costs in the urban context. In relation to the original research question 
of whether or not the CE of HIV/AIDS interventions depends on the context, the 
conclusion is that the CE of HIV/AIDS interventions indeed depends on the 
contexts. The policy implication is that policy makers should start considering 
the distribution of resources in HIV/AIDS interventions depending on contexts 
and on the extent of the CE of these interventions in such contexts.  The next 
chapter analyses the CE of HIV/AIDS interventions in South Africa using 





Chapter 9 : Cost-effectiveness of HIV/AIDS by 
epidemiological and socio-economic contexts   
 
This chapter compares the CE of HIV/AIDS interventions across an LPC and a 
HPC and across a rural context and an urban context. Projection models are 
used to take account of the dynamics between HIV/AIDS interventions and 
contexts. The effectiveness for patients using HIV/AIDS interventions are 
projected over the period 2007-2020. Annual average costs are applied to 
projected patient-years using interventions. The effectiveness of an HIV/AIDS 
intervention is estimated in terms of infections and deaths averted by that 
intervention. Section one describes the methods, section two presents the 
results while section three discusses the results.   
 
9.1 Methods  
 
The incremental cost-effectiveness ratio (ICER) of an HIV/AIDS intervention 
relative to usual care (absence of an intervention) is calculated in each context 
and the ICERs of that HIV/AIDS intervention are compared across contexts. In 
epidemiological contexts, the ICER of an HIV/AIDS intervention in an LPC is 
compared to the ICER of that intervention in a HPC.  In socio-economic contexts, 
the ICER of an HIV/AIDS intervention in a rural context is compared to the ICER 
of that intervention in an urban context. 
 
The total costs and total health outcomes of an HIV/AIDs intervention and 
USUAL CARE in each of these contexts form the basis of the calculation of the 
ICER. The total costs of an HIV/AIDS intervention in a context is the sum of the 
annual costs over the period 2007-2020, obtained by multiplying the annual 
number of patients by the average annual cost. It is assumed that in the 
absence of an HIV/AIDS intervention, patients use USUAL CARE. Consequently, 
the total cost of USUAL CARE in a context is obtained by multiplying the annual 
average cost of USUAL CARE by the annual number of patients using an 
HIV/AIDS intervention and summing up the results over the period 2007-2020.   
 
The annual number of patients in an LPC and a HPC from 2007 to 2020 are 





interventions. The projected numbers of patients for each HIV/AIDS intervention 
are also used for the intervention’s USUAL CARE. The ASSA2008 AIDS model 
was explained in detail in Chapter 6. 
 
The annual number of patients in a rural and an urban context over 2007-2020 
is projected by the Spectrum Policy Modelling system (SPMS) for each of the 
modelled HIV/AIDS interventions. SPMS also projects the annual number of 
patients in a rural context and an urban context in the case of USUAL CARE 
(absence of an HIV/AIDS intervention). The SPMS was explained in detail in 
Chapter 6. 
 
The evidence on the annual average costs of an HIV/AIDS intervention and 
USUAL CARE in a given context from the literature23 is applied to annual 
numbers of patients to provide annual costs of interventions which are summed 
up over the period 2007-2020 to give the total cost of an intervention (or USUAL 
CARE). All costs are estimated in 2007 constant US$ to control for inflation. The 
base-case comparison is conducted by taking into account the time preference 
with a discount rate of 3% as per the recommendation of an expert panel on 
cost-effectiveness analysis (Gold et al., 1996), a coverage rate of 97%, and 
mean values of cost estimates.  
 
Total health outcomes (total infections, deaths) of an intervention and total 
health outcomes of USUAL CARE in each context are obtained by summing up 
the projected annual health outcomes over the period 2007-2020. In 
epidemiological contexts (in an LPC and a HPC), annual health outcomes are 
produced by the ASSA2008 AIDS model projections while in socio-economic  
contexts (rural context and urban context) annual health outcomes are produced 
by SPMS projections.   
 
The incremental cost of an HIV/AIDS intervention in each context is obtained by 
subtracting the discounted total cost, projected over 2007-2020, of USUAL CARE 
from the total costs, projected over 2007-2020, of an HIV/AIDS intervention. 
                                       
23 The state of knowledge at the moment allows the use of costs from the literature in 





The incremental health outcomes (effectiveness) of an HIV/AIDS intervention in 
each context is obtained by subtracting the total health outcomes, projected 
over 2007-2020, of an HIV/AIDS intervention from the total health outcomes, 
projected over 2007-2020, of USUAL CARE. Since there are more infections and 
deaths in USUAL CARE than in an HIV/AIDS intervention, the effectiveness of the 
latter is expressed in terms of infections and deaths averted. The incremental 
costs and incremental effectiveness permitted the estimation of the ICER in each 
context for each intervention. The estimated ICERs were used to compare the CE 
of an intervention across contexts or to compare the CE across interventions.  
 
The comparison of the CE of an HIV/AIDS intervention across epidemiological 
contexts and socio-economic contexts distinguishes the base-case comparison 
and scenario comparisons.  The base-case comparison uses the evidence on the 
number of patients projected assuming a coverage rate of 97%, base-case 
values of annual cost estimates and a discount rate of 3%. In the first scenario, 
a decrease in the coverage rate is assumed. In the second scenario, the discount 
rate is changed to 0% and 7% following other literature in the country and the 
results are compared to the results of the base-case analysis. In the third 
scenario, upper and lower bound estimates of costs are used in the analysis and 
the results are compared to the results of the base- case analysis.  
 
The analysis of these scenarios is based on the requirements of CE analysis to 
check how sensitive the results of the base-case analysis are to the most likely 
events. The analysis of the effect of a drop in the coverage rate of the 
intervention was due to potential reduction in the adherence to HIV/AIDS 
interventions. Long-lasting and widespread antiretroviral use resulted in an 
increase in risky behaviours in other parts of the world (McGowan et al., 2004). 
With widespread antiretroviral therapy now available in South Africa, risky 
behaviours such as non-adherence to HIV/AIDS interventions, among others, 
are expected. The analysis of the effect of change in the discount rate is based 
on the recommendations by an expert panel on cost-effectiveness analysis (Gold 
et al., 1996). The analysis of the effect of change in the cost-estimates is due to 
the fact that these costs are expected to be lower in the future, that they are 






9.2 Results in epidemiological contexts  
 
This section presents the results in the epidemiological contexts. It presents the 
incremental cost, incremental effectiveness, and incremental cost-effectiveness.  
9.2.2 Incremental costs  
 
The incremental costs of HIV/AIDS interventions in a LPC and a HPC are 
presented in Table 9:1.  
 
Table 9:1 Comparison of incremental costs of HIV/AIDS interventions in epidemiological contexts 
(2007-2020) in US$ 
                                      Low HIV  prevalence areas 
Intervention  VCT STD PMTCT HAART 
Cost  GP 389,328,120 598070904 658914257 2,117,371,410 
Cost SP 475,845,480 755,497,409 733334410 2,758,929,249 
USUAL CARE GP 0 271,447,392 352,720,802 743,725,574 
USUAL CARE SP 0 318,126,185 418,126,185 802,024,941 
IC GP 389,328,120 326.623,512 306193455 1,373,645,836 























                                      High  HIV  prevalence areas 
Cost  GP 735,386,670 1,686,275,335 1,466,349,264 5,594,011,845 
Cost SP 742,128,040 1,874,097,366 1,525,891,975 5,932,044,036 
USUAL CARE GP 0 1,110,433,585 749,204,264 2,153,993,925 
USUAL CARE SP 0 1,289,139,491 799,823,225 2,301,299,316 
IC GP 735,386,670 575,841,750 717,145,000 3,440,017,920 























IC/100,000 in an 
LPC over IC per 
100,000 in 









Source: Author, based on the results of ASSA model projections and annual estimates of costs. Keys: IC: 
incremental costs, GP: Costs evaluated from the perspective of the government, SP: Costs evaluated from the 
societal perspective.   
 
 
Understandably, the extent of the cost of an HIV/AIDS intervention in each 





context. This implies that an HIV/AIDS intervention will incur more incremental 
costs in a HPC than it does in an LPC because there are more patients in a HPC. 
Table 9.1 shows that the results are as per expectation. For example, using the 
government perspective costs, the incremental costs of VCT over the period 
2007-2020 are US$389,328,120 in an LPC while they are US$585,702,432 in a 
HPC. Therefore, a plausible comparison of incremental costs of an HIV/AIDS 
intervention across an LPC and a HPC requires the control of the number of 
patients. Controlling for the size of the population of patients by comparing the 
incremental cost per 100,000 patients across contexts, the results show that the 
incremental costs are lower in a HPC. Per 100,000 patients, these costs are 
US$327,600 in a HPC while they are US$409500 in an LPC, using government 
perspective costs. The lower costs in an HPC are shown by the results in the last 
row of Table 9:1, which displays the incremental costs in an LPC as a percentage 
of the incremental costs in a HPC. The percentage is greater than 100%, 
indicating that incremental costs in an LPC per 100,000 patient-years are 
greater than corresponding costs in a HPC.  These results appear to concur with 
the evidence in the literature that the scale of the intervention results in lower 
costs (Dandona et al., 2008).   
 
 
9.2.1 Incremental effectiveness 
 
As discussed in the analysis of costs, it is not plausible to compare incremental 
effectiveness across an LPC and a HPC without controlling for the size of the 
population of patients because these contexts have a different number of 
patients. To control for the difference in the number of patients, the incremental 
effectiveness is analysed per 100,000 patient-years in each context. The 
incremental effectiveness results of each HIV/AIDS intervention modelled in an 


















Table 9:2 Comparison of incremental effectiveness (IE) of HIV/AIDS interventions in 
epidemiological contexts (2007-2020) 
 
Low HIV prevalence contexts 
Intervention  VCT STD PMTCT HAART 
Absence  


















Total infection  











IE (infections and  deaths  
averted)  
9,856 22,844 61,745 357,623 
IE (infections and deaths 














                                   High HIV prevalence contexts 
Intervention VCT STD PMTCT HAART 
Presence 












Total infection  













IE (infections and deaths  
averted)  
11,646 39,125 81,125 433,470 
 
IE (infections and deaths 














Infection averted per 
100,000 patients  in an LPC 
over infection averted per 
100,000 patients *100 
121% 116% 102% 115% 
Source: Author, based on the projections of ASSA2008 AIDS model. Note: the percentage under 
the IE figure in an LPC denotes that estimate as a percentage of the effectiveness of the same 
intervention in a HPC.  
 
This Table shows that the incremental effectiveness of each HIV/AIDS 
intervention in an LPC is greater than its incremental effectiveness in a HPC. For 
instance, the incremental effectiveness of VCT in terms of infections averted per 
100,000 patients is 189 in an LPC while the corresponding statistic in a HPC is 
156. In terms of relative comparison, the incremental effectiveness of VCT in an 
LPC is 121% of its incremental effectiveness in a HPC and this pattern of results 
applies to other modelled interventions. Since the incremental effectiveness is 
higher in an LPC for all modelled interventions, the latter are more effective in 





9.2.3  Cost-effectiveness  
This section compares joint cost and effectiveness across contexts for modelled 
interventions. These results are in Table 9:3.  
 
Table 9:3 Comparison of ICERs of HIV/AIDS interventions in epidemiological contexts (2007-
2020) 
Low HIV   prevalence areas 
Intervention  VCT STD PMTCT HAART 
cost  GP 389,328,120 598070904 658914257 2,117,371,410 
cost SP 475,845,480 755,497,409 733334410 2,758,929,249 
USUAL CARE GP 0 271,447,392 352,720,802 743,725,574 
USUAL CARE SP 0 318,126,185 418,126,185 802,024,941 
IC GP 389,328,120 326.623,512 306193455 1,373,645,836 
IC SP 475,845,480 437,371,224 315208225 1,956,904,308 
Incremental 
effectiveness  
9,856 22,844 61,745 257,623 
ICER GP 39,496 
 
14,298 4,959 5,332 
ICERSP 48,279 19,858 5,105 7,596 
                                     High HIV  prevalence areas 
cost  GP 735,386,670 1,686,275,335 1,466,349,264 5,594,011,845 
cost SP 742,128,040 1,874,097,366 1,525,891,975 5,932,044,036 
USUAL CARE GP 0 1,110,433,585 749,204,264 2,153,993,925 
USUAL CARE SP 0 1,289,139,491 799,823,225 2,301,299,316 
IC GP 735,386,670 575,841,750 717,145,000 3,440,017,920 
IC SP 742,128,040 584,957,875 726,068,750 3,630,744,720 
Incremental 
effectiveness  
11,646 39,125 81,125 433,470 
 
ICER GP 63,145 14,718 8,840 7,936 
ICER SP 63,723 14,951 8,950 8,375 
ICER 
LPC/ICERHPC*100 
62% 97% 56%  67% 
Source: Author, based on the results of ASSA2008 AIDS model projections. The percentage is the 
value of ICER in an LPC as a percentage of ICER in a HPC.  
 
Table 9:3 shows that the ICERs of all modelled HIV/AIDS interventions relative 
to their respective USUAL CARE are lower in an LPC than they are in a HPC.  For 
instance, the ICER of VCT is US$39,496 for each infection averted in an LPC 
while its ICER in a HPC is US$63,145. This pattern of ICER across an LPC and a 
HPC is also true for STD, PMTCT and HAART. This result shows that generally, 
modelled HIV/AIDS interventions are more cost-effective in an LPC than they are 
in a HPC.    
 
It should be noted, however, that, although the CE effectiveness of HIV/AIDS 
interventions is generally greater in an LPC than it is in a HPC, the extent of CE 






Table 9:4 Comparison of the extent of cost-effectiveness across HIV/AIDS interventions in 
epidemiological contexts (in US$/outcome) 
 
ICER LPC ICER HPC  ICER in an LPC as % of ICER in a 
HPC 
                                  VCT  
39,496 63,145 62 
                                 STD 
14,298 14,718 97 
                               PMTCT  
4,959 8,840 56 
                               HAART   
5,332 7,936 67 
Source: Author, based on the results of ASSA2008 AIDS model projections.  
 
To understand the comparison of the extent of CE across modelled HIV/AIDS 
interventions in Table 9:4, it is worth starting with a situation in which the 
extent of the CE of an HIV/AIDS intervention is the same across contexts.  An 
HIV/AIDS intervention is equally cost effective in an LPC and a HPC if Column 3 
of Table 9:4 is 100%, that is, the ICER of an HIV/AIDS intervention in an LPC is 
equal to the ICER of that HIV/AIDS intervention in a HPC. The farther the value 
in Column 3 is from 100%, the more the CE of an HIV/AIDS intervention in an 
LPC is unequal to the CE in a HPC.  In particular, if an intervention has a lower 
ICER in an LPC than it has in a HPC, it is more cost-effective in an LPC. Since the 
values in column 3 of Table 9:4 are less than 100%, each of the modelled 
HIV/AIDS interventions is more cost-effective in an LPC. However the extent of 
CE measured by how far the value is from 100%, suggests a different extent of 
CE across HIV/AIDS interventions. PMTCT for instance, emerges as the most 
cost-effective because the value in Column 3 for PMTCT is farthest from 100% 
and STD is the least cost-effective in an LPC because the value in Column 3 for 
STD is closest to 100%. 
 
These results are subjected to scenario analysis. In this analysis, the conclusion 
reached in the base-case analysis with 97% coverage rate is assessed against 
the assumption of a decrease in the coverage rate by 20%. Table 9:5 shows the 









Table 9:5 Effect of a decrease in coverage rate by 20%, government perspective.  
 
                 Decrease by 20% in an LPC, other parameters remaining  unchanged  
                                            VCT 
ICER LPC ICER HPC ICER in a HPC as % of ICER in 
an LPC 
Base-case        39,496 
Decrease         41,125 
Base-case    83,820 
Base-case    83,820 
47 
49 
       STD 
Base-case        14,298 
Decrease         14,595 
Base-case    14,718 
Base-case    14,718 
97 
99 
                                              PMTCT 
Base-case       13,052 
Decrease         13,512 
Base-case    14,498 
Base-case    14,498 
90 
68 
                                             HAART  
Base-case           5332 





                   Decrease by 20% in a HPC, other parameters remaining unchanged 
ICER LPC ICER HPC   
                                               VCT 
Base-case       39,496 
Base-case       39,496 
Decrease      83,820 
Base-case      83,650 
47 
49 
                                                STD  
Base-case       14,298 
Base-case       14,298 
Decrease      14,718 
Base-case      15,250 
97 
87 
                                               PMTCT  
Base-case       13,052 
Base-case       13,052 
Decrease      14,495 
Base-case      14,952 
90 
88 
                                               HAART   
Base-case         5,332 
Base-case         5,332 
Decrease         7936 
Base-case         8300 
67 
67 
Source: Author, based on the results ASSA2008 AIDS model projections and annual estimates of 
costs   
 
Table 9:5 shows that a decrease in the coverage of HIV/AIDS interventions by 
20% in an LPC increases their ICERs in this context. The Table also shows that a 
decrease in the coverage of HIV/AIDS interventions by 20% in a HPC increases 
their ICERs in that context. For example, the ICER of VCT in an LPC changes 
from US$39,496 in the base-case comparison to US$41,125 in the case of a 
decrease in the coverage of VCT by 20%. The Table shows further that the effect 
of a decrease in the coverage observed for VCT is true for other modelled 
interventions. Indeed an assumption of decrease in the coverage by 20% in an 
LPC or a HPC makes the ICER of all interventions increase. An implication of this 
result is that the effectiveness of the modelled HIV/AIDS interventions decreases 
more than the decrease in the cost as a result of reduction in the coverage by 
20%. It is however, worth noting that, despite the change in the ICER as a 
result of the reduction in the coverage of HIV/AIDS interventions, this change in 
ICER does not significantly affect the comparability of the CE of HIV/AIDS 





ICER of each intervention in an LPC is less than 100% of the ICER in a HPC, 
indicating no change in the patterns of cost-effectiveness of HIV/AIDS 
interventions from the patterns observed in the base-case comparison.  
 
The conclusion of the base-case comparison was also assessed against the 
change in the discount rate.  Table 9.6 shows the CE results under different 
discount rates.  
 
Table 9:6 Effect of using different discount rates, government perspective. 
                                                               VCT 
 LPC  HPC ICER in a HPC as % of ICER 
in an LPC 






















































Source: Author, based on the results of ASSA2008 AIDS model projections models. 
 
The Table shows, as expected, that the ICERs of modelled HIV/AIDS 
interventions decrease as the discount rates increase. The results show for 
example that with a discount rate of 3%, the ICER of VCT relative to USUAL 
CARE of US$ 39,496 in an LPC changes to 33,135 with a discount rate of 7%. 
The same patterns in the change of ICER are observed in a HPC as the discount 
rate increases from the base-case discount rate of 3% to a discount rate of 7%.  
While these changes are observed for all modelled HIV/AIDS interventions, they 
do not change the base-case conclusion that all modelled HIV/AIDS 
interventions are more cost-effective in an LPC than they are in a HPC.  
 
In contrast, using lower and upper bound cost-estimates reveals that the 
changes in the cost estimates affect the conclusions reached by the base-case 






Table 9:7  Effect of using lower and upper bound cost estimates  
 
ICER LPC ICER HPC  ICER HPC as % of ICER of an 
LPC 
                                                 VCT 
39,496 (mean cost)  
34,315 (lower cost) 







                                                   STD 
14,298 (mean cost) 
7,156 (lower limit) 







                                                 PMTCT 
13,052 (mean cost) 
11,125 (lower limit) 







                                                  HAART  
7704 (mean cost) 
5235 (lower limit) 








Source: Author, based on the results of epidemiological projection models, scenario analysis.  
The conclusions apply to the results when costs are evaluated from the societal perspective.  
 
As Table 9.7 shows, some interventions which are more cost-effective in an LPC 
become less cost-effective as a result of a change in the cost estimates.  For 
instance VCT and STD, which are more cost-effective in an LPC when the base-
case estimates of costs are used, become less cost-effective in that context 
when the lower bound estimates of costs are used. The results show, for 
example that VCT is more cost-effective in an LPC than it is in a HPC, with ICERs 
in these contexts being US$39,496 and US$ 83,820, respectively. This result 
arises when the median costs of the base-case comparison are used. When the 
lower bound cost estimates are used however, VCT becomes less cost effective 
in an LPC than it is in a HPC. The data in Table 9.7 show that in the case of 
lower bound cost-estimates, the ICER of VCT relative to USUAL CARE in an LPC 
is US$34,315 while the similar statistic in a HPC is US$33,453. The discussion 
about the change in the CE of VCT across an LPC and a HPC as a result of a 
change in cost estimates applies to STD. In sum, a change in the cost affects the 
conclusion of the base-case comparison.  
9.3 Results in socio-economic contexts  
 
This section presents the results in socio-economic contexts. The costs, the 






9.3.1 Costs  
 
The cost results are presented in Table 9:8. These costs are obtained by 
applying the average annual cost per patient to the number of patient-years 
using interventions over the period of analysis, as projected by SPMS.   
 
Table 9:8 Comparison of incremental costs of HIV/AIDS interventions in socio-economic contexts 
(2007-2020) 
 
                                                          Rural context 
Intervention PMTCT HAART FOR ADULTS  HAART FOR CHILDREN  
Total cost USUAL CARE GP 459,054,600 892,784,873 105,911,427 
Total cost USUAL CARE SP 463,149,140 982,063,361 116,502,569 
Total cost of intervention GP 618,810,422 1,205,259,579 185,344,996 
Total cost of intervention SP 692,676,440 1,249,898,823 195,936,139 
ICER GP per 100,000 patients  159,755,822 1,300,420,072 245,913,118 
ICER SP per 100,000 patients 229,527,300 267,835,462 79,433,570 
                                                      Urban context 
Total cost USUAL CARE GP 437,165,992 3,190,138,899 212,427,251 
Total cost USUAL CARE SP 453,748,675 3,312,836,549 155,043,316 
Total cost of intervention GP 675,607,516 3,987,673,624 298,971,687 
Total cost of intervention SP 575,553,200 4,294,417,749 314,707,039 
IC GP per 100,000 patients 238,441,525 2,483,740,496 379,740,496 
IC SP per 100,000 patients 251,804,525 592,202,559 102,279,788 
IC per 100,000 patients  GP 








Source: Author, based on the results of SPMS projections. Key: GP: government perspective; SP: 
societal perspective. The percentage reflects the value of the incremental costs of an HIV/AIDS 
intervention in a rural context as a percentage of the incremental costs of that intervention in an 
urban context for 100,000 patient-years.  
 
 
As the Table shows, the incremental cost per 100,000 patients is generally 
higher in a rural context than it is in an urban context for HAART FOR ADULTS 
and HAART FOR CHILDREN. For PMTCT however, the incremental cost is lower in 
the rural context than it is in an urban context. Table 9:8 shows, for example, 
that, using government perspective costs, PMTCT results in an incremental cost 
of US$159,755,822 in a rural context while the incremental costs in an urban 





interventions in a rural context can be attributed to reduced economies of scale 
although other factors such as seeking treatment too late may also play a role.   
 
9.3.2 Effectiveness  
 
After comparing the costs across a rural and an urban context, it is useful to 
compare the effectiveness of HIV/AIDS interventions across these contexts. The 
effectiveness measures used in this comparison are infections and deaths 
averted by an HIV/AIDS intervention relative to USUAL CARE. Table 9:9 shows 
the results.  
 
Table 9:9 Comparison of incremental effectiveness of HIV/AIDS interventions in socio-economic 
contexts (2007-2020)  
 
Intervention                Effectiveness 
Rural context Urban context  
No intervention at all 
Cumulative paediatric infections  
Cumulative adult deaths  










Total infections with PMTCT  
Paediatric infections averted by PMTCT   
 
 
HAART FOR ADULTS  
Total adult deaths with HAART FOR ADULTS  
Total adult deaths averted by HAART FOR ADULTS  
 
HAART FOR CHILDREN  
 
Total child deaths with HAART FOR CHILDREN   































Source: Author, based on the results of SPMS projections.  
  
Table 9:9 shows that for each HIV/AIDS intervention, the number of infections 
(deaths) averted by an HIV/AIDS intervention relative to USUAL CARE is greater 
in an urban context than it in a rural context. For instance, PMTCT averts 
198,398 infections over the period 2007-2020 in a rural context while it averts 
314,986 infections in the urban context over the same period. However, this 





contexts. The fact that there are more patients in an HIV/AIDS intervention in 
an urban context might lead to greater effectiveness in this context.  
 
 The effectiveness of an HIV/AIDS intervention across a rural and an urban 
context is better grasped if the difference in the number of patients across these 
contexts is controlled for. To control for the number of patients, estimates of 
effectiveness are reported per 100,000 patients in each context. Table 9:10 
shows the results.    
 
 
Table 9:10 Comparison of incremental effectiveness of HIV/AIDS Interventions in socio-economic 
contexts per 100,000 patient-years (2007-2020)  
 
 
HIV outcomes  
Rural context  
 
PMTCT HAARTA HAARTC  
 
A1. Total patient-years  
B1. Total infections averted   
C1. Averted infections per 100,000 patient-years 
 
A1. Total patient-years  
B1. Total adult deaths averted by HAARTA 
C1. Averted infections per 100,000 patient-years 
 
A1. Total patient-years  
B1. Total child deaths averted by HAARTC 
C1. Averted infections per 100,000 children-years 
 
893,972 



























HIV outcomes  
Urban context  
 
PMTCT HAARTA HAARTC  
 
A2. Total patient-years  
B2. Total infections averted   
C2. Averted infections per 100,000 patient-years 
 
 
A2. Total patient-years  
B2. Total adult deaths averted by HAARTA 
C2. Averted infections per 100,000 patient-years 
 
A2. Total patient-years 
B2.Total child deaths averted by HAARTC  

































C1/C2*100 91% 65% 80% 
Source: Author, based on SPMS projections. Key: HAARTA: HAART FOR ADULTS, HAARTC: HAART 
FOR CHILDREN. 
 
As Table 9:10 indicates, modelled HIV/AIDS interventions are less effective in a 
rural context than they are in an urban context. The Table shows that per 
100,000 patient-years, PMTCT prevent less HIV infections in the rural context 





infections in a rural context while it prevents 88,700 infections in the urban 
context.  
 
Similarly, HAART FOR ADULTS and HAART FOR CHILDREN prevent fewer deaths 
in the rural context. Per 100,000 patient-years, HAART for ADULTS prevents 
68,700 HIV/AIDS deaths in the rural context while it prevents about 71,600 
HIV/AIDS deaths in the urban context. Corresponding statistics of HIV/AIDS 
deaths averted by HAART FOR CHILDREN in a rural context and an urban 
context are 58,500 and 61,500. Because less HIV infections and HIV/AIDS 
deaths are averted in the rural context, the incremental effectiveness in a rural 
context expressed as percentage of the incremental effectiveness in an urban 
context is less than 100%. The last row of Table 9.10 shows that this percentage 
ranges from 65% to 91% for all modelled HIV/AIDS interventions.    
 
9.3.3 Cost-effectiveness  
 
In CE analysis, it is important to analyse the additional costs that induce 
additional benefits. To take account of the full effect of contexts on the cost and 
effectiveness of HIV/AIDS interventions, the ICER of an HIV/AIDS intervention 
relative to USUAL CARE is reported and the ICERs of the same intervention are 


























Table 9:11 Comparisons of ICERs of HIV/AIDS interventions in socio-economic contexts (2007-
2020)   
 
                                                Rural context  
Description  PMTCT HAARTA HAARTC 
Total cost USUAL CARE GP 162,570,017 892,784,873 105,911,427 
Total cost USUAL CARE  SP 177,349,110 982,063,361 116,502,569 
Total cost of intervention  GP 221,686,387 1,205,259,579 185,344,996 
Total cost of intervention   SP 243,855,026 1,249,898,823 195,936,139 
Incremental cost of intervention GP 159,755,822 1,300,420,072 245,913,118 
Incremental cost of intervention  SP 66,505,916 267,835,462 79,433,570 
ICER GP 1,367 2,456 2,266 
ICER SP 1,456 2,512 2,302 
                                                 Urban context 
Total cost USUAL CARE GP 73,895,462 3,190,138,899 212,427,251 
Total cost USUAL CARE SP 88,674,555 3,312,836,549 155,043,316 
Total cost of intervention  GP 466,705,815 3,987,673,624 298,971,687 
Total cost of intervention  SP 484,889,158 4,294,417,749 314,707,039 
Incremental cost of intervention  GP 387,830,916 2,483,740,496 379,740,496 
Incremental cost of intervention  SP 396,214,603 592,202,559 102,279,788 
ICER GP 2,034 1,712 2,070 
ICER SP  2,185 1,912 2,149 
ICER  rural GP/ICER urban GP *100 67% 143% 109% 
Source: Author, based on the results of SPMS projections. Key: GP: government perspective, SP: 
societal perspective. HAARTA: HAART FOR ADULTS, HAARTC: HAART FOR CHILDREN. The 
percentage in the last row of Table 9.11 reflects the value of the ICER in a rural context as a 
percentage of the ICER in an urban context for a given HIV/AIDS intervention.  
 
The results in Table 9:11 indicate that PMTCT is relatively more cost-effective in 
a rural context than it is in an urban context. The ICER for PMTCT in the rural 
context is US$1,367 per infection averted in the rural context while its ICER in 
the urban context is US$2,034 per infection averted.  In terms of relative cost-
effectiveness, the ICER of PMTCT in the rural context is 67% of its ICER in the 
urban context. Therefore, PMTCT is relatively more cost-effective in the rural 
context. As noted earlier, this could be the result of complex factors, mainly 
pertaining to costs in the rural areas, where lower costs are due to the fact that 
PMTCT is linked to antenatal care provided by rural clinics.  
 
HAART FOR ADULTS and HAART FOR CHILDREN are more cost-effective in the 
urban context than they are in a rural context. Their ICERs are US$2,456 and 
US$2,266, respectively per death averted in the rural context while these ICERs 
are US$1,712 and US$2,070 per death averted in the urban context. In terms of 
relative cost-effectiveness, the ICERs of HAART FOR ADULTS and HAART FOR 
CHILDREN in the rural context are 143% and 109% of their respective ICERs in 
the urban context. These results show that HAART FOR ADULTS and HAART FOR 





expected since the effectiveness of these interventions is expected to be lower in 
the rural context and the costs are expected to be lower in the urban context 
because of timely use of care. 
 
Furthermore, the results in Table 9:11 show that, the extent of CE varies across 
HIV/AIDS interventions. The extent of effectiveness in any context is measured 
by how close the ICER of an HIV/AIDS intervention in one context expressed as 
a percentage of the ICER of that intervention in another context is to 100%.  
Table 9:11 shows that the ICER of HAART FOR ADULTS in the rural context as a 
percentage of the ICER of HAART in the urban context is the farthest from 
100%. This implies that HAART has the greatest extent of cost-effectiveness in 
the urban context. The different extent to which the ICERs of modelled HIV/AIDS 
interventions are close to 100% in Column 3 of Table 9.12 indicates the different 
extent of cost-effectiveness across the modelled HIV/AIDS interventions.  
 
Table 9:12 Comparison of the extent of cost-effectiveness across HIV/AIDS interventions in socio-
economic contexts (in US$/outcome) 
 
ICER rural  ICER urban  ICER in a rural context as % of the 
ICER in an urban context 
                               PMTCT 
1367 2034 54 
                       HAART FOR ADULTS 
2456 1712 151 
                     HAART FOR CHILDREN 
2266 2070 109 
Source: Author, based on the results of SPMS projections 
 
 
Briefly, the results in Table 9.12 illustrate that the CE of HIV/AIDS interventions 
has no specific trend across a rural context and an urban context as some 
HIV/AIDS interventions are more cost-effective in the rural areas, while for 
others the opposite is true. The results also show that the extent of CE is 
different across interventions.  
 
These results are subjected to sensitivity analysis. One of the key issues likely to 
affect the effectiveness of HIV/AIDS interventions requiring lifelong therapy, 
HAART, is a decrease in treatment adherence. As this would affect the coverage 





coverage (due to a possible decrease in adherence) on the results of the base-
case comparison. The results are presented in Table 9:13.  
 
Table 9:13 Effect of a decrease in coverage rate by 20%, government’s perspective. 
                                    
                                   Adherence drop by 20% in rural context 
 
                                           Rural context 
  PMTCT HAART A HAARTC 
Base-case ICER GP 1367 576 2,281 
Drop 20% ICER GP 1417 494 2,632 
                                           Urban context 
Base-case ICER GP 2034 550 2,067 
Drop 20% ICER GP 2034 550 2,067 
                                   
                                    Adherence drop by 20% in urban context 
 
                                          Rural context  
  PMTCT HAART A HAART C 
Base-case ICER GP 1367 2452 2,266 
Drop 20% ICER SP 1367 2452 2,266 
                                          Urban context 
Base-case  1,914 540 2,044 
Drop 20%  1,923 665 2,215 
Source: Author, based on the results of SPMS projections. GP: government perspective costs, SP: 
societal perspective costs, HAARTA: HAART FOR ADULTS, HAART C: HAART FOR CHILDREN.  
 
It is observed that a 20% decrease in adherence in one context does not affect 
the result of the base-case estimates in another context but only the estimates 
in the context in which the decrease takes place. For instance, a 20% decrease 
in adherence in the rural context does not affect the ICER of PMTCT in the urban 
context. The ICER of PMTCT remains equal to the ICER of the base-case 
comparison, that is, US$2,034.  When there is 20% decrease in adherence in the 
rural context, the ICER of HIV/AIDS interventions in the rural context increases. 
For instance, the ICER of PMTCT increases from US$1,367 to US$1,417. This 
result implies that the effectiveness of modelled HIV/AIDS interventions 
decreases more than the decrease in the cost as a result of a 20% reduction in 
coverage. 
 
Similarly, a 20% decrease in adherence in the urban context does not affect the 
results of the base-case comparison in the rural context. However, this decrease 
in adherence increases the ICER of HIV/AIDS interventions in an urban context. 
Table 9.13 shows that the ICER of PMTCT in an urban context, for instance, 
increases from US$1,914 to US$1,923. Again, this signifies that, as a result of 





more than the decrease in costs. However, even though a decrease in adherence 
affects the CE of an intervention in the context in which the decrease takes 
place, it does not affect the comparability of the CE of HIV/AIDS interventions 
across contexts. Therefore the results of the base-case comparison are robust to 
the change in adherence.  
 
The discount rates used have been considered as factors influencing the CE 
results. Consequently, it was recommended (Gold et al., 1996) that studies 
examine how the conclusions of the base-case comparison change with different 
discount rates. To this end, the CE results of the base-case comparison were 
reproduced using different discount rates. Table 9:14 shows the ICER of HIV 
interventions under alternative discount rates.  
 
Table 9:14 Effect of using different discount rates 
Discount 
rate  
 Rural area Urban areas  
  PMTCT HAART HAARTC PMTCT HAART HAARTC 
0% ICER GP 1654 645 2,830 2,472 701 2,595 
 ICER SP 1805 753 3,266 2,494 863 2,812 
3% ICER GP 1367 590 2,266 2034 550 2,067 
 ICER SP 1492 606 2,605 2051 667 2,239 
7% ICER GP 1089 438 1,714 1,609 408 1,567 
 ICER SP 1188 984 1,815 1,623 502 1,697 
        
Source: Author, based on the results of SPMS projections. ICER is measured as costs per infection 
averted for PMTCT, per death averted for HAART interventions. Key: GP: government perspective costs, SP: 
societal perspective costs.  
 
As expected, the Table shows that the ICERs of HIV/AIDS interventions decrease 
as the discount rates increases. The results show for example, that with a 
discount rate of 3%, the ICER of PMTCT of US$1,367 (measured from the 
government perspective) in a rural context changes to US$1,089 with a discount 
rate of 7%. The same patterns in the change of ICER are observed in an urban 
context. While these changes are observed for all modelled interventions, they 
do not change the base-case conclusion that all modelled HIV/AIDS 
interventions are more cost-effective in an LPC than they are in a HPC.  
 
Finally, the insufficiency of cost data evidence required a scenario analysis of 
what would happen to the base-case conclusions when the lower and upper 






Table 9:15 Effect of using lower and upper bound cost estimates   
 
Lower bound estimates  
 
 
         Rural context 
 
ICER/ Intervention  PMTCT HAART HAARTC 
ICER GP 685 632 735 
ICER SP 752 759 750 
                                    
                                            Urban context 
   
ICER/Intervention  PMTCT HAART HAARTC 
ICER GP 1,050 803 656 
ICER SP 1,115 830 690 
                               
                                   Upper bound estimates 
                                            
                                            Rural context 
 
ICER/Intervention  PMTCT HAART HAARTC 
ICER GP 2300 1265 2150 
ICER SP 2548 1560 2250 
                                            
                                         Urban  context 
 
ICER/Intervention PMTCT HAART HAARTC 
ICER GP 1,850 1315 2400 
ICER SP 2,836 1395 2420 
Source: Author, based on the results of SPMS projections.  Key:  GP: government perspective costs, 
SP: societal perspective costs.  
 
The results in Table 9:15 show that the use of lower and upper bound cost 
estimates changes some of the conclusions in the base-case analysis.  For 
instance, in the base-case comparison, PMTCT was more cost-effective in the 
rural context.  While the intervention remains more cost-effective with the use of 
lower-bound cost estimates, the opposite is true when upper bound cost-
estimates are used.  Table 9:15 shows that with upper bound estimates of costs, 
the ICER of PMTCT in a rural context becomes US$2,300 per infection averted 
while it is US$1,850 per infection averted in an urban context. This result makes 
PMTCT more cost-effective in the urban context; this conclusion is different from 
the conclusion in the base-case comparison. The change in the cost-
effectiveness comparability of PMTCT across a rural context and an urban 
context as a result of a change in cost estimates applies to other modelled 
interventions. HAART FOR ADULTS, which was more cost-effective in the urban 





as shown in Table 9:15. As the results in Table 9:15 change many of the 
conclusions reached by the base-case comparison, the results are not robust to 
change in estimates of cost.    
 
9.4 Discussion of the results  
 
One of the research questions in this thesis was whether or not the CE of an 
HIV/AIDS intervention depends on contexts. In epidemiological contexts, the 
results presented above show that the ICER of each intervention in an LPC as a 
percentage of its ICER in a HPC is less than 100%. 
 
While the ICER of each HIV/AIDS intervention in an LPC is consistently lower 
than the ICER of that intervention in a HPC, this is not the case in socio-
economic contexts. The ICER of PMTCT in the rural context as a percentage of its 
ICER in the urban context is 67%. In contrast, the ICERs of HAART FOR ADULTS 
and HAART FOR CHILDREN in rural contexts are 151% and 109%, respectively 
of the ICERs in the urban context.  
 
Bearing in mind that the ICER of an intervention is the additional costs per 
additional health outcomes of an intervention as compared to USUAL CARE, the 
lower the ICER, the more cost-effective the intervention. Linking this information 
to the results above, it is clear that an HIV/AIDS intervention is not equally cost-
effective across epidemiological contexts and across socio-economic contexts. If 
an intervention was equally cost-effective across contexts, its ICER in one 
context as a percentage of its ICER in another context would be 100%.  
 
Although there is a difference in the CE of an intervention from one context to 
another, the CE trends depend on whether the contexts are epidemiological or 
socio-economic. In epidemiological contexts, the CE of each HIV/AIDS 
intervention is consistently higher in an LPC than in a HPC, while in socio-
economic contexts, how the CE of an HIV/AIDS intervention in a rural context 
compares with its CE in an urban context depends on the intervention.  For 
instance, PMTCT is more cost-effective in rural contexts while HAART for ADULTS 






The results have also shown that the extent of CE is different across 
interventions in both epidemiological contexts and socio-economic contexts.  For 
instance in epidemiological contexts, although all interventions are more cost-
effective in an LPC than they are in a HPC, PMTCT is comparably the most cost-
effective, achieving a relative ICER of 56% in an LPC, while STD is comparably 
the least cost-effective, achieving an ICER of 97% in an LPC.  In socio-economic 
contexts, not only do the CE trends depend on the intervention, the extent of CE 
is also different across interventions. For instance, the results indicate that 
HAART FOR ADULTS has the greatest extent of CE in the context in which it is 
more cost effective (ICER 151%).  
 
The results in this chapter have shown that the CE of HIV/AIDS interventions is 
different across epidemiological contexts (an LPC and a HPC) and socio-
economic contexts (a rural and an urban context). These results have provided 
ample evidence that the CE of HIV/AIDS interventions depends on the context, 
answering our research question on whether or not the CE of an HIV/AIDS 
intervention depends on the context and if so, to what extent. The results have 
indicated that CE and its extent indeed depend on the context and on the type of 
HIV/AIDS intervention.  
 
Interpreting the meaning of these results requires reverting back to the 
methodology used in this analysis. The design of the analysis was such that 
there were different sizes of patient cohorts in different contexts, but the results 
presented were controlled for such differences. After controlling for the 
difference in the sizes in projections, the CE results would have been the same 
across contexts.   
 
The fact that the results were not the same can be explained by the influence of 
the interaction between HIV/AIDS interventions and contextual and individual 
factors on the CE of HIV/AIDS interventions on the results.  Theory has indicated 
that individual risk behaviours can be shaped by the context in which people 
live. Since these factors prevail to a different extent in different contexts and 
HIV/AIDS interventions do not necessarily target these factors, the outcomes of 






On the basis of the above discussion, it can be concluded that CE depends on 
contexts and on the type of intervention. This conclusion implies that policy 
makers in South Africa need to consider how efficient HIV/AIDS interventions 
are in contexts in order to achieve more outcomes per health intervention.  
 
Policy makers have been implementing HIV/AIDS interventions on the basis of 
factors other than contexts. This may have been due to the lack of evidence in 
this respect. CE studies conducted in South Africa compared CE across provinces 
and were conducted in the early 2000s. The most recent studies comparing CE 
in contexts were aimed at international policy makers. While the effects of 
context on the performance of interventions have been noted in the literature, 
they have not received sufficient attention in South Africa.   Consequently, this 
analysis contributes to the literature on the CE of HIV/AIDS interventions in 
South Africa.  
 
Although the findings of this study appear to be significant with respect to policy 
making in resource allocation, they need to be understood in the context of the 
evidence used in the analysis. While scenario analysis on the discount rates and 
the coverage of interventions did not seem to reveal a change in the conclusions 
of the base-case analysis, the conclusions were very sensitive to the cost 
assumptions.  Given that the sources of estimates of the cost of the different 
interventions compared were inadequate, it is likely that the results might not be 
accurate. This calls for more studies on the cost analysis of health care 
interventions in general and HIV/AIDS interventions in particular, if policy on 
HIV/AIDS interventions is to be founded on solid evidence. Previous studies have 




This chapter compared the CE of HIV/AIDS interventions in epidemiological and 
socio-economic contexts in South Africa. In epidemiological contexts, it was 
found that the effectiveness of HIV/AIDS interventions was greater in an LPC 
than in a HPC, while in socio-economic contexts, it was found that the 
effectiveness was lower in rural contexts than in urban contexts. The costs and 





findings suggest that policy makers in South Africa need to consider 
implementing HIV/AIDS interventions in line with the CE of such interventions in 




































Chapter 10 :  Summary, conclusions and 
recommendations   
 
This chapter briefly recapitulates the work carried out in this study. Section one  
provides a summary of the research process, section two presents the main 
results and section three highlights the major conclusions of the study, while 
section four offers policy recommendations and suggests  areas for further 
study.      
 
10.1 Summary  
 
This section summarises the research process. It recapitulates the objectives 
and rationale of the study as well as the research methods. The results and 
recommendations are presented in subsequent sections.  
   
 10.1.1 Objectives and rationale  
 
This study set out to compare the CE of several HIV/AIDS interventions in 
epidemiological and socio-economic contexts in South Africa. In epidemiological 
settings, the study estimated and compared the CE of each of the modelled 
HIV/AIDS interventions in an LPC and in a HPC, while in socio-economic settings 
a similar comparison was done in a rural context and an urban context.     
 
The comparison exercise was motivated by the multitude of factors influencing 
the impact of HIV/AIDS, assumed to exist to a different extent in each context.  
Since HIV/AIDS interventions do not necessarily target all these factors, the 
influence of these interventions on the impact of HIV/AIDS (effectiveness) was 
expected to be different from one context to another. Furthermore, the costs of 
HIV/AIDS interventions were expected to depend on contexts as the intensity 
and patterns of the interventions’ activities and hence the resource 
requirements, were expected to follow the patterns and the extent of the impact 
of HIV/AIDS. A differentiated impact of HIV/AIDS in South Africa in the contexts 
of interest to this study (an LPC, a HPC, a rural context and an urban context) 
also motivated this research. Finally, the literature showing that the 





dependence should be considered by policy makers in implementing HIV/AIDS 
interventions (Grassly et al., 2001; Vickerman et al., 2006) was also inspiring.  
 
A review of the literature revealed that only a few studies have compared the CE 
of HIV/AIDS interventions in contexts. Some studies have compared the CE of 
HIV/AIDS interventions across continents (Hogan et al., 2005) or made 
comparisons between South Africa and other countries (Verguet & Walsh, 2010; 
Dowdy et al., 2006).  In South Africa, related but old evidence (Wilkinson et al. 
2000) compared the CE of PMTCT across the country’s nine provinces. Another 
South African study (Vickerman et al., 2006) produced estimates on how to treat 
STD in patients with high risk behaviours and patients with low risk behaviours.  
 
While related evidence has been available, it has mainly been of interest to 
international policy makers. Where it was directed at South African policy 
makers, it did not provide CE evidence in epidemiological and socio-economic 
contexts (areas) using a methodology that takes the interaction between 
interventions and contexts into account.  By taking the gaps in the CE evidence 
for South Africa into account, this study has made a contribution to the body of 
knowledge in the area of the CE of HIV/AIDS interventions.       
 
10.1.2 Methods  
 
Three types of analysis were conducted. The first compared HIV/AIDS 
interventions across an LPC and a HPC using Markov modelling. The second 
compared the CE of HIV/AIDS interventions in a rural context and an urban 
context using Markov modelling. The third, using epidemiological projection 
models, compared the CE of HIV/AIDS interventions in an LPC and a HPC and 
then in a rural and an urban context.   
 
The analysis in Chapter 7 compared the CE of an HIV/AIDS intervention across 
an LPC and a HPC without considering the CE of USUAL CARE for patients using 
that intervention. Markov states transition models as well as multidimensional 
measures of effectiveness (QALYs) were used. The size of the hypothetical 
cohort of patients (100,000 patients) was the same in each context and changed 





was conducted in each HIV/AIDS state across contexts for each HIV/AIDS 
intervention. The overall cost and effectiveness of an HIV/AIDS intervention was 
also compared across contexts. The analysis was conducted over the lifetime of 
the patients in the cohort.  
 
The analysis in Chapter 8 compared the CE of an HIV/AIDS intervention across a 
rural context and an urban context. The analysis took the cost and effectiveness 
of USUAL CARE for patients into account, using that intervention to capture the 
full effect of the interaction between contexts and HIV/AIDS interventions. 
Markov states transition models were used and the effectiveness was measured 
in terms of quality-adjusted life-years (QALYs). As in Chapter 7, a hypothetical 
cohort of the same size, 100,000 patients, was modelled in each context and for 
each intervention and the size of the cohort changed over time due to deaths. 
The ICER of each intervention relative to USUAL CARE was estimated in each 
context and the ICERs of a given intervention were compared in two contexts.   
 
The analysis in Chapter 9 consisted of comparing the CE of HIV/AIDS 
interventions using a different modelling approach, epidemiological projection 
models, over the period 2007-2020.  The ASSA2008 AIDS model (ASSA, 2011) 
and Spectrum Policy Modelling System (Stover, 2009) was used to estimate the 
effectiveness of an HIV/AIDS intervention in each context. These projections 
also enabled estimation of the costs of an HIV/AIDS intervention in each context 
on the basis of the projected or estimated number of annual patients for that 
intervention. As in Chapter 8, the estimation of the CE of an HIV/AIDS 
intervention took the cost and effectiveness of USUAL CARE into account in each 
context. Thus, the ICER of each intervention relative to USUAL CARE was 
estimated in each context and the ICERs of a given HIV/AIDS intervention were 
compared across two contexts. However, unlike in chapter 8, the sizes of 
patients modelled were assumed to be different across the contexts. These sizes 










10.2 Results  
 
This section summarises the results of the study.  It presents the results in 
epidemiological contexts first and then in socio-economic contexts. In each set 
of contexts, the comparison of costs, effectiveness and CE results are 
distinguished.  
 
10.2.1 Results in epidemiological contexts  
 
Mixed patterns of the costs of HIV/AIDS interventions were obtained in 
epidemiological contexts. In an LPC, the average costs of STD and PMTCT were 
greater than they were in a HPC. In contrast, the average costs of VCT and 
HAART were less in an LPC than they were in a HPC (see Table 7:5). These 
mixed patterns of the costs across an LPC and a HPC were obtained when 
HIV/AIDS interventions were modelled with Markov models. When modelled with 
epidemiological projection models however, the incremental costs of each of the 
modelled HIV/AIDS interventions were greater in an LPC than they were in a 
HPC (see Table 9:1). The fact that the patterns of costs depended on the models 
used indicates the absence of a common pattern of costs of HIV/AIDS 
interventions across an LPC and a HPC.  
   
Furthermore, the extent of the costs of a given HIV/AIDS intervention differed 
depending on the type of modelling and the type of interventions.  Using Markov 
modelling, STD and PMTCT were more costly in an LPC than they were in a HPC. 
The average lifetime cost of STD and PMTCT in an LPC were 122% and 185% of 
their costs in a HPC, respectively. Using the same model however, the cost of 
VCT and HAART in a LPPC was lower than their cost in a HPC. These costs in an 
LPC were 76% and 14% of their costs in a HPC (see Table 7:5). Using 
epidemiological projection models however, the incremental costs per 100,000 
patient-years of STD and PMTCT in an LPC were not relatively as high as in 
Markov modelling. These costs were 104% and 125% of their costs in a HPC 
(see Table 9:1). Using the same projection models, the incremental costs per 
100,000 patient-years of VCT and HAART in an LPC were, in contrast to their 
costs with Markov modelling, greater than their costs in a HPC.  These costs 





show that the extent of the costs of modelled HIV/AIDS intervention not only 
depended on the context, but also on the modelling approach used and on the 
type of HIV/AIDS intervention. Hence, the need to pitch the modelling 
approaches against each other to establish which has greater value or credibility 
to facilitate choice. 
 
While HIV/AIDS interventions did not display any pattern of costs across an LPC 
and a HPC, these interventions were consistently more effective in an LPC than 
they were in a HPC and this result prevailed regardless of whether Markov 
modelling or epidemiological projection models were used. However, even if 
HIV/AIDS interventions were more effective in an LPC than they were in a HPC, 
the extent of effectiveness differed across modelling approaches and across 
HIV/AIDS interventions.   
 
To measure the extent of the effectiveness of an HIV/AIDS intervention in an 
LPC, the effectiveness in an LPC and in a HPC were compared. Specifically, the 
effectiveness of an HIV/AIDS intervention in an LPC was expressed as a 
percentage of its effectiveness in a HPC. A percentage of 100% implied that an 
HIV/AIDS intervention was equally effective across an LPC and a HPC, while a 
percentage above 100% meant that HIV/AIDS intervention was more effective in 
an LPC. This measure showed that the extent of effectiveness of these 
interventions varied across contexts. 
 
The comparison of effectiveness of HIV/AIDS interventions across an LPC and a 
HPC revealed that the effectiveness of each HIV/AIDS intervention in an LPC, as 
a percentage of its effectiveness in a HPC, was greater than 100% (see Tables 
7:6 and 9:2), regardless of the modelling approach used. Using Markov 
modelling, the incremental effectiveness of HIV/AIDS interventions in an LPC as 
a percentage of the effectiveness of HIV/AIDS interventions in a HPC ranged 
from 125% to 300% (see Table 7:6). Using epidemiological projection models, it 
ranged from 102% to 121% (see Table 9:2). Although a greater extent of 
effectiveness of HIV/AIDS interventions in an LPC was observed in Markov 
modelling, the pattern of effectiveness of HIV/AIDS interventions was such that 





HIV/AIDS interventions modelled was more effective in an LPC than it was in a 
HPC.  
 
The CE results which combined the results on costs and effectiveness showed 
that the CE of HIV/AIDS interventions was greater in an LPC.  Having defined CE 
as the cost per health outcome and a more cost-effective intervention as one 
with lower costs per health outcome, the results of this study showed that each 
of the modelled HIV/AIDS interventions was more cost-effective in an LPC than 
it was in a HPC, regardless of the modelling approach (see Tables 7:7 & Table 
9:3). These results suggested that the CE of HIV/AIDS interventions depended 
on the context.  
 
Another observed result was the extent of difference in CE across HIV/AIDS 
interventions. Some HIV/AIDS interventions were most cost-effective than 
others in a given context. For instance,  PMTCT was the most cost-effective in an 
LPC (on the basis that the CE of this intervention in an LPC as a percentage of its 
CE in a HPC is farthest from 100% regardless of the modelling approach), while 
STD was the least cost-effective in an LPC (see Table 7:8 & Table 9:4). 
10.2.2 Results in socio-economic contexts  
 
As in epidemiological contexts, mixed results with respect to the pattern of costs 
of modelled HIVAIDS interventions were obtained in socio-economic contexts. 
HAART FOR ADULTS and HAART FOR CHILDREN were more costly in the rural 
context than they were in the urban context. Using Markov modelling, the 
incremental cost per 100,000 patient-years in a rural context for HAART FOR 
ADULTS and HAART FOR CHILDREN  were 107% and 179%, respectively, of 
their  incremental costs in the urban context (Table 8:5). When modelled with 
projection models the incremental costs per 100,000 patient-years in a rural 
context as a percentage of the incremental costs in an urban context were 143% 
and 103% (see Table 9:8). These results showed an absence of common 
patterns of costs across an LPC and a HPC for modelled interventions in socio-
economic contexts.  





Furthermore, the modelling revealed no common pattern of the extent of the 
costs of a given intervention. It was found that there was greater variation in 
costs across a rural and an urban context with Markov models than with 
projection models. The costs of HIV/AIDS interventions from any socio-economic 
context to another ranged from 29% to 179% with Markov models (see Table 
8:5) and from 67% to 143% with projection models (see Table 9:8)24.  
 
While the costs of HIV/AIDS showed no common pattern across a rural context 
and an urban context, modelled HIV/AIDS interventions were consistently  less 
effective in a rural context than they were in an urban context; this was 
consistent regardless of whether Markov modelling or epidemiological projection 
models were used (see Tables 8:4 and 9:10). However, as observed in 
epidemiological contexts, the extent of effectiveness differed across modelling 
approaches and across HIV/AIDS interventions.   
 
HIV/AIDS interventions were more effective with Markov modelling than they 
were with epidemiological projection models. Using Markov modelling, the 
incremental effectiveness of HIV/AIDS interventions in a rural context as a 
percentage of the effectiveness of HIV/AIDS interventions in an urban context 
ranged from 53% to 86% (see Table 8:5). Using epidemiological projection 
models, it ranged from 65% to 91% (see Table 9:10). These results suggested 
that although the extent of effectiveness of HIV/AIDS interventions in a rural 
context was lower with Markov models compared with epidemiological models, 
the modelled HIV/AIDS interventions were generally less effective in a rural 
context than they were in an urban context regardless of the modelling approach 
used.  
   
Taking into consideration cost and effectiveness, the results were such that 
there was no specific trend in the CE of HIV/AIDS interventions across a rural 
and an urban context. PMTCT was more cost-effective in the rural context than it 
was in the urban context while HAART FOR ADULTS and HAART FOR CHILDREN 
were more cost-effective in the urban context than they were in the rural 
                                       
24 Relative numbers (percentages) are used rather than absolute numbers to emphasize 
the relative comparability of HIV/AIDS interventions across contexts. This summary 





context. These results remained true regardless of the modelling approach used 
(see Table 8:4 & Table 9:11). The results showed that the CE of HIV/AIDS 
interventions depended on the context.  
 
In addition to the absence of specific trends of CE across contexts, there was 
also a different extent of CE across HIV/AIDS interventions. Some HIV/AIDS 
interventions were most cost-effective in some contexts, whilst others were least 
cost-effective. PMTCT was the most cost-effective in a rural context (the ICER of 
PMTCT in a rural context as a percentage of its ICER in an urban context was 
farther away from 100%), while HAART FOR ADULTS was the least cost-effective 
in a rural context (see Table 9:12). 
 
10.3 Conclusion and recommendations  
 
This section provides the conclusion reached by this research study and 
responds to the research problem. It also makes some recommendations. It 
starts with the conclusion on the comparability of the costs, effectiveness and 
cost-effectiveness of modelled HIV/AIDS interventions and proceeds to provide 
recommendations.  
10.3.1 Conclusion  
 
This study aimed to determine whether or not the CE of HIV/AIDS interventions 
depends on the contexts of their implementation. On the basis of the results 
presented above, it is concluded that the CE of modelled HIV/AIDS interventions 
depends on the epidemiological contexts and socio-economic contexts where 
they are implemented.  It is further concluded that the extent of CE is different 
across HIV/AIDS interventions. These results remained consistent regardless of 
the modelling approach used, although Markov modelling tended to increase the 
extent of the relative CE across HIV/AIDS interventions.   
10.3.1.1  Conclusion for epidemiological  contexts  
 
In epidemiological contexts, after controlling for the size of the patient 
population, modelled HIV/AIDS interventions in South Africa were generally 





costs depended on the type of modelling used and on the type of HIV/AIDS 
intervention. 
 
In epidemiological contexts, modelled HIV/AIDS interventions were generally 
more effective in an LPC than they were in a HPC although the extent of such 
effectiveness was different across HIV/AIDS interventions and depended on the 
type of modelling. Markov modelling made HIV/AIDS interventions more 
effective in an LPC than the results of projection models. 
 
In epidemiological contexts, modelled HIV/AIDS interventions were generally 
more cost-effective in an LPC than they were in a HPC.  
 
10.3.1.1  Conclusion for socio-economic contexts  
 
In socio-economic contexts, there was no trend in the costs of HIV/AIDS 
interventions. The costs of some modelled HIV/AIDS interventions were greater 
in the urban context while the cost of other modelled HIV/AIDS interventions 
were lower in the urban context than they were in the rural context.  
 
In socio-economic contexts, modelled HIV/AIDS interventions were generally 
more effective in urban contexts. In these contexts, the extent of effectiveness 
also differed across interventions and depended on the type of modelling used. 
Markov modelling made HIV/AIDS interventions more effective in an urban 
context than projection model results.  
 
In socio-economic contexts, the pattern in the CE of HIV/AIDS interventions 
across a rural and an urban context was not specific and depended on the type 
of intervention. Of the modelled HIV/AIDS interventions, PMTCT was the most 
cost-effective in the rural context while HAART interventions were generally the 
most cost-effective in the urban context.  
 
These results provided some evidence on which to base the overall conclusion of 
the study. It is concluded that the CE of modelled HIV/AIDS interventions in 







10.3.2 Recommendations  
 
In light of the above conclusion on the dependence of the CE of HIV/AIDS 
interventions on contexts, policy makers can achieve more health outcomes by 
allocating resources according to the CE of HIV/AIDS interventions in different 
contexts. This recommendation is based purely on efficiency criteria. Since policy 
makers make decisions on the basis of many criteria, including ethics and equity 
considerations, taking this aspect into consideration could be very significant 
towards the improvement of HIV/AIDS outcomes in South Africa. The 
reallocation of resources to achieve efficiency would not aim to completely 
remove any HIV/AIDS intervention in any specific context, thus abiding by 
equity and ethical considerations.   
 
 Because resources are allocated on the basis of cost-effectiveness, the evidence 
provided in this study would help policy makers achieve better health outcomes 
with the available budget. In allocating resources to HIV/AIDS interventions, 
policy makers should take epidemiological and socio-economic contexts into 
consideration in line with the findings of this study. 
 
This study was restricted to the CE of HIV/AIDS interventions in an LPC and a 
HPC and in rural and urban contexts. Other comparisons which could have been 
considered include the CE of HIV/AIDS interventions across a rural context and 
an LPC, for example. Time and space constraints did not allow for such 
comparisons, which could be the subject of future research. Future research is 
also needed to improve the quantity and quality of data for studies of this kind. 
This study mixed modelled data and some data collected in the literature. Such 
data cannot be expected to be accurate and more research, particularly on data 
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Appendix 1:  A typical Markov cycle tree structure for an HIV/AIDS prevention 





infected with no AIDS
0.06
infected with no AIDS
infected with AIDS
#












Init Eff: effnoninfinit/(1.03^_stag e)





infected with no AIDS
0.85
infected with no AIDS
infected with AIDS
#






infected with no AIDS
0
--- Markov Information
Init Cost: Cinfmore200init/(1.03^_stag e)








infected with no AIDS
#
infected with no AIDS
infected with AIDS
0.91










Incr Cost: Cinfless200incr/(1.03^_stag e)







Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: 0
Init Eff: effdeathinit/(1.03^_stag e)






















Term : _stage>10 & _stage>100|  _stage_eff<(0.0001)
 
Note: data in this model structure changes with  the type of intervention (VCT, STD, or PMTCT) 















Appendix 2: A typical Markov cycle tree structure for a HAART intervention in a given 
HIV prevalence context  
 
 
infected with no AIDS
0.960
infected with no AIDS
infected with AIIDS  
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infected with no AIDS
0
--- Markov Information
Init Cost: Cinfmore200init/(1.03^_stag e)





     infected with no AIDS
#
infected with no AIDS
    infected with AIDS 
0.920






infected with AIDS 
1
--- Markov Information
Init Cost: Cinfless200init/(1.03^_stag e)
Incr Cost: Cinfless200incr/(1.03^_stag e)







Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)




















Term : _stage>10 & _stage>100|_stag e_eff<(0.0001)
 
Note: data in this model structure changes with  the type of intervention (VCT, STD, or PMTCT) 























Appendix 3:  A typical Markov cycle tree structure for PMTCT in a rural context (base-










































Init Cost:  Cinfected_init 
Incr Cost: Cinfected_incr

























































































Appendix 4: A typical Markov cycle tree for USUAL CARE related to PMTCT in a rural 












































Init Cost:  Cinfected_init 
Incr Cost: Cinfected_incr
































































































































Init Cost:  Cinfected_init 
Incr Cost: Cinfected_incr
































































































































Init Cost:  Cinfected_init 
Incr Cost: Cinfected_incr






































































































Init Cost: Cnon_AIDSinit/(1.03^_stag e)





     non-aids
0.15
non-AIDS













Init Cost: CAIDSinit/(1.03^_stag e)
Incr Cost: CAIDSincr/(1.03^_stag e)
Final Cost: 0 






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)

























Term : _stage>10 &(_stag e>100|_stag e_eff<0.0001)
 
 
Note: data in this structure changes with type of population of patients (children or adults) and the 
type of intervention (HAART or USUAL CARE) and the type of context (rural or uban)  but 



























Appendix 8: A typical Markov cycle tree structure for USUAL CARE  related to  HAART 
















Init Cost: Cinfmore200init/(1.03^_stag e)
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0
non-AIDS













Init Cost: Cinfless200init/(1.03^_stag e)
Incr Cost: Cinfless200incr/(1.03^_stag e)







Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)
Incr Eff: effdeathincr/(1.03^_stag e)
Final Eff: 0










































































Init Cost: Cinfmore200init/(1.03^_stag e)





     non-aids
0.15
non-AIDS













Init Cost: Cinfless200init/(1.03^_stag e)
Incr Cost: Cinfless200incr/(1.03^_stag e)







Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)
Incr Eff: effdeathincr/(1.03^_stag e)
Final Eff: 0


























































Appendix 10: A typical Markov cycle tree structure for USUAL CARE  related to  HAART 
















Init Cost: Cinfmore200init/(1.03^_stag e)





     non-aids
0
non-AIDS













Init Cost: Cinfless200init/(1.03^_stag e)
Incr Cost: Cinfless200incr/(1.03^_stag e)







Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)
Incr Eff: effdeathincr/(1.03^_stag e)
Final Eff: 0

























































Appendix 11: A typical Markov cycle tree structure for a HAART FOR CHILDREN  in a 

















Init Cost: Cnon_AIDSinit/(1.03^_stag e)





     non-aids
0.06
non-AIDS













Init Cost: CAIDSinit/(1.03^_stag e)
Incr Cost: CAIDSincr/(1.03^_stag e)
Final Cost: 0 






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)
Incr Eff: effdeathincr/(1.03^_stag e)
Final Eff: 0
























































Appendix 12: A typical Markov cycle tree structure for USUAL CARE related to  HAART 
















Init Cost: Cnon_AIDSinit/(1.03^_stag e)
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0
non-AIDS













Init Cost: CAIDSinit/(1.03^_stag e)
Incr Cost: CAIDSincr/(1.03^_stag e)
Final Cost: 0 






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)
Incr Eff: effdeathincr/(1.03^_stag e)
Final Eff: 0
























































Appendix 13: A typical Markov cycle tree structure for a HAART FOR CHILDREN in an 


















Init Cost: Cnon_AIDSinit/(1.03^_stag e)
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0.08
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Init Cost: CAIDSinit/(1.03^_stag e)
Incr Cost: CAIDSincr/(1.03^_stag e)
Final Cost: 0 






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)
Incr Eff: effdeathincr/(1.03^_stag e)
Final Eff: 0






















































Appendix 14: A typical Markov cycle tree structure for USUAL CARE related to HAART 
















Init Cost: Cnon_AIDSinit/(1.03^_stag e)





     non-aids
0
non-AIDS













Init Cost: CAIDSinit/(1.03^_stag e)
Incr Cost: CAIDSincr/(1.03^_stag e)
Final Cost: 0 






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)
Incr Eff: effdeathincr/(1.03^_stag e)
Final Eff: 0













































Appendix 15: explanation of how progression in subsequent states was pegged on ASSA 
2008 AIDS model projections.  
 
A simple way of evalauating the cost and effectiveness using Markov model is to 
assume the same transition probability matrix in all successive periods.  The use 
of the same transition probability matrix assumes  that the epidemic is constant. 
In the case of South Africa, the epidemic has not been constant since 
2007.There has been decrease in new infections and mortality.  
 
To take into account the decreasing HIV infections rates and HIV-related  
mortality rates, the study used the Table option in Markov. The Table option 
allows the application of decreasing infection rate and mortality rate on patients 
in an  “infected” state and “death” state as per SPMS projections in each  Markov 
period.  
 
The Table option in TreeAge Pro consists of defining the variable’s infection and 
mortality such that in the evaluation of the costs, the estimation  is based on the 
patients in that state which in turn is determined by value in the Table reflecting 
the trend in the epidemic. The variables for which Tables were created in 
TreeAge pro were infected but not yet in need of treatment (effinfmoreinc 200) 
and deaths (effdeathincr) nas shown in the model structure for HAART in 




















Init Cost: Cinfmore200init/(1.03^_stag e)
Incr Cost: Cinfmore200incr/(1.03^_stag e)
Final Cost: 0
Init Eff: effinfmore200init/(1.03^_stag e)
Incr Eff: effinfmore200incr/(1.03^_stag e)
Final Eff: 0
     infected 200+
#
inf 200+











Init Cost: Cinfless200init/(1.03^_stag e)
Incr Cost: Cinfless200incr/(1.03^_stag e)
Final Cost: 0 
Init Eff: effinfless200init/(1.03^_stag e)






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)




















Term : _stage>10 &(_stage>100|_stag e_eff<0.0001)
 
 
Since the cohort must be fully distributed in all HIV/AIDS states. Pegging 
transition probabilities to infections rates and deaths required adjustment of 
transition probabilities in the intermediates HIV/AIDS states.  
 
To determine the proportion of infected and deaths  in each Markov period in 
TreeAge Pro Table, annual estimates of average infection rate in each  context, 
the LPC and the HPC, were obtained from the ASSA2008 AIDS model. ASSA2008 
is an excel model developed by the Actarial Society of South Africa.  These 
annual infection rates were then transformed into 3-month transition infection 
rates. The %  decrease in the rate of infection  or mortality  from a three-month 
period  to another  was then  applied to the  previous  period transition 
probability  to dtermine the value to be recorded in the Table. The values in a 
treeAge pro Table for successive Markov periods will be picked up in the model 








Appendix 16: explanation of how data were transferred  from TreeAge Pro Software to 
excell for graphical and numerical analysis  
 
Running Markov model in TreeAge pro allowed the transfer of data in excel for 
graphical nummemrical analysis. Below is an example of results of Markov 
models as they would appear in an excel spreadsheet for grahical analysis and 










200+) P(infect200<) P(death) 
0 95.58348 0.125 95.58348 0.125 0 1 0 
1 84.88408 0.114284 180.4676 0.239284 0.0378 0.9072 0.055 
2 75.67432 0.104739 256.1419 0.344024 0.069188 0.825841 0.10497 
3 67.72495 0.096212 323.8668 0.440236 0.09509 0.754382 0.150528 
4 60.84343 0.088573 384.7103 0.528809 0.116301 0.691493 0.192206 
5 54.86792 0.081708 439.5782 0.610517 0.133504 0.636028 0.230468 
6 49.66235 0.075522 489.2405 0.686039 0.14729 0.586998 0.265712 
7 45.11219 0.069931 534.3527 0.75597 0.158164 0.543549 0.298287 
8 41.12105 0.064865 575.4738 0.820835 0.166559 0.504947 0.328494 
9 37.60765 0.060261 613.0814 0.881096 0.172851 0.470555 0.356594 
10 34.50345 0.056066 647.5849 0.937162 0.177359 0.439826 0.382815 
11 31.75059 0.052267 679.3355 0.989429 0.180359 0.412286 0.407355 
12 29.30013 0.04879 708.6356 1.038219 0.182088 0.387526 0.430386 
13 27.11069 0.0456 735.7463 1.083819 0.182748 0.365193 0.452059 
14 25.14717 0.042666 760.8934 1.126485 0.182513 0.344982 0.472504 
15 23.37981 0.039963 784.2733 1.166448 0.181533 0.32663 0.491838 
16 21.78329 0.037465 806.0565 1.203913 0.179933 0.309906 0.51016 
17 20.33606 0.035153 826.3926 1.239066 0.177825 0.294616 0.527559 
18 19.01974 0.03301 845.4123 1.272076 0.175301 0.280586 0.544114 
19 17.81861 0.031019 863.2309 1.303096 0.17244 0.267669 0.559891 
20 16.71921 0.029167 879.9502 1.332263 0.16931 0.255737 0.574953 
21 15.70996 0.027479 895.6601 1.359742 0.16597 0.244678 0.589352 
22 14.78092 0.025904 910.441 1.385646 0.162469 0.234395 0.603136 
23 13.92348 0.024431 924.3645 1.410077 0.158848 0.224804 0.616348 
24 13.13019 0.023054 937.4947 1.433131 0.155142 0.215833 0.629025 
25 12.39461 0.021763 949.8893 1.454894 0.151383 0.207416 0.641201 
26 11.71108 0.020553 961.6004 1.475447 0.147593 0.199499 0.652908 
27 11.0747 0.019417 972.6751 1.494864 0.143796 0.192033 0.664171 
28 10.48115 0.01835 983.1563 1.513214 0.140008 0.184976 0.675016 
29 9.926618 0.017346 993.0829 1.53056 0.136244 0.17829 0.685465 
30 9.40776 0.016402 1002.491 1.546961 0.132517 0.171943 0.69554 
31 8.9216 0.015512 1011.412 1.562474 0.128836 0.165906 0.705258 
32 8.465493 0.014674 1019.878 1.577148 0.12521 0.160154 0.714636 
33 8.037078 0.013952 1027.915 1.5911 0.121645 0.154664 0.723691 





35 7.255077 0.012628 1042.804 1.617 0.114718 0.144394 0.740888 
36 6.897874 0.012021 1049.702 1.62902 0.111363 0.139581 0.749056 
37 6.561078 0.011446 1056.263 1.640466 0.108084 0.134964 0.756952 
38 6.24328 0.010903 1062.506 1.651369 0.104882 0.130529 0.764588 
39 5.943195 0.010388 1068.45 1.661757 0.101759 0.126267 0.771974 
40 5.659652 0.009901 1074.109 1.671659 0.098715 0.122166 0.779119 
41 5.391575 0.00944 1079.501 1.681099 0.095749 0.118218 0.786033 
42 5.137979 0.009003 1084.639 1.690102 0.092862 0.114415 0.792723 
43 4.897955 0.008589 1089.537 1.698691 0.090053 0.110748 0.799199 
44 4.670666 0.008196 1094.207 1.706887 0.087321 0.107211 0.805468 
45 4.455336 0.007824 1098.663 1.714711 0.084666 0.103798 0.811536 
46 4.251247 0.00747 1102.914 1.722181 0.082085 0.100503 0.817412 
47 4.057734 0.007134 1106.972 1.729315 0.079578 0.097321 0.823101 
48 3.874176 0.006816 1110.846 1.736131 0.077143 0.094246 0.828611 
49 3.699997 0.006513 1114.546 1.742644 0.07478 0.091274 0.833946 
50 3.534658 0.006225 1118.081 1.748869 0.072485 0.088401 0.839114 
51 3.377657 0.005952 1121.458 1.754822 0.070258 0.085623 0.844118 
52 3.228524 0.005692 1124.687 1.760514 0.068097 0.082937 0.848966 
53 3.086819 0.005445 1127.774 1.765959 0.066001 0.080337 0.853662 
54 2.952132 0.00521 1130.726 1.77117 0.063967 0.077822 0.85821 
55 2.824074 0.004987 1133.55 1.776157 0.061995 0.075389 0.862617 
56 2.702285 0.004774 1136.252 1.780931 0.060082 0.073033 0.866885 
57 2.586423 0.004572 1138.838 1.785502 0.058227 0.070753 0.87102 
58 2.476169 0.004379 1141.315 1.789881 0.056428 0.068545 0.875026 
59 2.371222 0.004195 1143.686 1.794076 0.054684 0.066408 0.878908 
60 2.271298 0.00402 1145.957 1.798096 0.052994 0.064339 0.882668 
61 2.176132 0.003853 1148.133 1.80195 0.051355 0.062335 0.886311 
62 2.085472 0.003695 1150.219 1.805644 0.049766 0.060394 0.88984 
63 1.999082 0.003543 1152.218 1.809187 0.048225 0.058515 0.89326 
64 1.916738 0.003399 1154.135 1.812586 0.046732 0.056694 0.896573 
65 1.838231 0.003261 1155.973 1.815847 0.045285 0.054931 0.899784 
66 1.763362 0.003129 1157.736 1.818976 0.043883 0.053223 0.902894 
67 1.691943 0.003004 1159.428 1.82198 0.042524 0.051569 0.905908 
68 1.623798 0.002884 1161.052 1.824864 0.041206 0.049966 0.908828 
69 1.55876 0.00277 1162.611 1.827633 0.039929 0.048414 0.911657 
70 1.496671 0.00266 1164.107 1.830294 0.038692 0.04691 0.914398 
71 1.437383 0.002556 1165.545 1.83285 0.037493 0.045453 0.917055 
72 1.380754 0.002456 1166.925 1.835306 0.03633 0.044041 0.919628 
73 1.326651 0.002361 1168.252 1.837667 0.035204 0.042673 0.922122 
74 1.274948 0.00227 1169.527 1.839937 0.034113 0.041348 0.924539 
75 1.225527 0.002183 1170.753 1.842119 0.033055 0.040065 0.92688 
76 1.178274 0.002099 1171.931 1.844218 0.03203 0.038821 0.929149 
77 1.133084 0.002019 1173.064 1.846238 0.031037 0.037616 0.931347 
78 1.089855 0.001943 1174.154 1.848181 0.030075 0.036448 0.933477 
79 1.048491 0.00187 1175.202 1.850051 0.029142 0.035317 0.935541 





81 0.971004 0.001733 1177.182 1.853584 0.027362 0.033159 0.939479 
82 0.934714 0.001669 1178.117 1.855253 0.026514 0.03213 0.941356 
83 0.899956 0.001607 1179.017 1.85686 0.025691 0.031133 0.943176 
84 0.866657 0.001548 1179.884 1.858409 0.024895 0.030167 0.944939 
85 0.834748 0.001492 1180.718 1.8599 0.024122 0.029231 0.946647 
86 0.804164 0.001438 1181.522 1.861338 0.023374 0.028324 0.948302 
87 0.774842 0.001386 1182.297 1.862724 0.022649 0.027445 0.949906 
88 0.746724 0.001336 1183.044 1.864059 0.021947 0.026593 0.95146 
89 0.719753 0.001288 1183.764 1.865347 0.021266 0.025768 0.952966 
90 0.693878 0.001242 1184.458 1.866589 0.020606 0.024969 0.954425 
91 0.669047 0.001198 1185.127 1.867787 0.019967 0.024194 0.955839 
92 0.645214 0.001156 1185.772 1.868943 0.019348 0.023443 0.957209 
93 0.622332 0.001115 1186.394 1.870057 0.018748 0.022716 0.958536 
94 0.600359 0.001076 1186.995 1.871133 0.018166 0.022011 0.959823 
95 0.579254 0.001038 1187.574 1.872171 0.017602 0.021328 0.961069 
96 0.558978 0.001002 1188.133 1.873174 0.017056 0.020667 0.962277 
97 0.539494 0.000967 1188.672 1.874141 0.016527 0.020026 0.963447 
98 0.520768 0.000934 1189.193 1.875075 0.016015 0.019404 0.964581 
99 0.502765 0.000902 1189.696 1.875977 0.015518 0.018802 0.96568 
100 0.485455 0.000871 1190.181 1.876849 0.015036 0.018219 0.966745 
101 7.480096 0 1197.661 1.876849 0.01457 0.017654 0.967776 
 
These results were then used to graph how the effectiveness  and the cost of 
each intervention compare in LPC and high Prevalence context. TreeAge pro 
provides a limited option for graphical analysis of the results. So, I had to export 
data from TreeAge pro to excel to  conduct graphical analysis  relevant to the 


















Appendix 17: Markov model structure for HAART intervention with distributions of 
parameters for probabilistic sensitivity analysis.  
 
To asses the uncertianty of the results, probabilistic sensitivity analysis has to be 
conducted. This necessiated  defining  paramter values as distribution rather 
than variables. With variables transformed into distribution, the evalauation is 
done thousand times each time picking up a vlaue in the distribution and 
averaging the 1000 estimates of costs and effectiveness obtained. The figure 
below shows the strcuture which include the distribution of paramters for the 
















Init Cost: Cinfmore200init/(1.03^_stag e)
Incr Cost: Cinfmore200incr/(1.03^_stag e)
Final Cost: 0
Init Eff: effinfmore200init/(1.03^_stag e)
Incr Eff: effinfmore200incr/(1.03^_stag e)
Final Eff: 0
     infected 200+
#
inf 200+











Init Cost: Cinfless200init/(1.03^_stag e)
Incr Cost: Cinfless200incr/(1.03^_stag e)
Final Cost: 0 
Init Eff: effinfless200init/(1.03^_stag e)






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)








































Appendix 18: explanation of how a societal perspective was analysed  
 
To analyses the societal perspctive, the costs each HIV intervention model was 
modified to  include patients costs. Patients costs consisted of estimates of 
transport costs to and from facility, waiting time to receive the intervention and 
funeral costs. these costs are not usually incurred by the government. An 
example of Markov model structure  for HAART intervention in a HPC which 

















Init Cost: Cinfmore200init/(1.03^_stag e)
Incr Cost: Cinfmore200incr/(1.03^_stag e)
Final Cost: 0
Init Eff: effinfmore200init/(1.03^_stag e)
Incr Eff: effinfmore200incr/(1.03^_stag e)
Final Eff: 0
     infected 200+
#
inf 200+











Init Cost: Cinfless200init/(1.03^_stag e)
Incr Cost: Cinfless200incr/(1.03^_stag e)
Final Cost: 0 
Init Eff: effinfless200init/(1.03^_stag e)






Init Cost: cdeathinit/(1.03^_stag e)
Incr Cost: cdeathincr/(1.03^_stag e)
Final Cost: cdeathfin
Init Eff: effdeathinit/(1.03^_stag e)


























Markov model applies, in each period in an HIV/AIDS state, the cost of the state 
to patients in that state. In the case of “dead” state, Markov model would apply 
the cost in the “dead”  state to patients in that state. Since, the cost in the 
“dead” state is once-off cost, and applying the cost at each period implies 
counting many time the costs  in “dead” state for the same patients, the cost in 
death  was adjusted manually in excel. The cost in “dead” state in one period 
was the cumulative cost in that period minus the cumulative cost in “dead” state 






Appendix 19: example of how the number of patients using VCT was estimated.  
 






% target tested  
Eastern Cape 6,884,482 2,737,815 1,267,394 46 
Free State  2,972,983 1,479,942 405,399 27 
Gauten  9,853,543 5,308,415 1,668,087 31 
KZn 10,027,620 4,578,031 2,268,963 50 
LM 5,357,949 2,275,491 1,350,641 59 
MP 3,646,123 1,660,038 739,226 45 
NW 3,229,078 1,537,093 1,109,242 72 
NC 1,108,599 485,391 282,211 58 
WC 4,945,732 2,203,620 1,481,729 67 
Source: SANAC Secretariat (2010) 
Estimated the number of patients in each province and found that this number 
was:  




Annual number  % target tested  
Eastern Cape 6,884,482 2,737,815 253,479 0.09 
Free State  2,972,983 1,479,942 67,579 0.05 
Gauten  9,853,543 5,308,415 278,015 0.05 
KZn 10,027,620 4,578,031 378,161 0.08 
LM 5,357,949 2,275,491 225,107 0.09 
MP 3,646,123 1,660,038 123,204 0.07 
NW 3,229,078 1,537,093 184,874 0.12 
NC 1,108,599 485,391 47,035 0.10 
WC 4,945,732 2,203,620 246,955 0.11 
 




























Appendix 20: How QALYs in rural context were estimated  
 
 
The estimation of QALYs required the estimation of quality of life in each Markov 
states. The study used measure of quality of life from three studies. The Quality 
of life in AIDS state was assumed to be 0.7 based on the evidence from other 
studies (Jelsma et al., 2006, O’keefe & Wood (1996), and Louwagie et al. 
(2007). Improvement to Non-aids State was assumed to have 0.84 again based 
on the values in non-AIDS state in these studies. The study assumed quality of 
life of 0.90 for non-infected and 0 for the HIV/AIDS “dead” state. The average in 
O’Keefe was 0.79 for white female and 0.62 for black so 0.62/0.79 was 
multiplied to get Quality of life to get a value a rural context and 0.79/0.62 to 
get the score in an urban context. 
In AIDS in rural context the score was calculated as follows: 62/79*0.7=0.55. 
The corresponding score in the urban context is 79/63*0.7=0.87. In the non-
AIDS we used 62/79*0.84=0.67. In the absence of usual care, we assumed a 
decrease in the quality of life by 20%. This was a simplistic assumption  but 
probabilistic sensitivity analysis dealt with the potential bias it would bring in the 
results.    
 

